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ABSTRACT 
 
Ovarian cancer is known as one of the dreaded diseases due to its low five years’ 
survival, acquired drug resistance and recurrence. It is treated mainly by platinum 
drugs given alone or in combination with paclitaxel. However, problems of drug 
resistance that is often acquired still remain. While resistance to platinum drugs at the 
molecular level can be due to overexpression of nuclear factor kappa B (NF-κB) and 
protein kinase B (AKT/PKB) pathways, it is believed that phytochemicals and other 
natural compounds can inhibit expression of NF-κB and AKT/PKB. This study aimed 
to apply binary combinations of platinum drugs cisplatin and oxaliplatin with natural 
compounds mycophenolic acid, honokiol, cholecalciferol and 6-shogaol to four 
ovarian cancer cell lines: A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 towards 
overcoming drug resistance. IC50 values of compounds were first determined before 
the combination studies. Studies on DNA damage, cellular platinum accumulation and 
platinumDNA binding were carried out. Proteomic study has been performed aiming 
to determine key proteins associated with drug resistance. Mycophenolic acid (IC50: 
1.34-7.83 μM) and 6-shogaol (IC50: 6.79-10.20 μM) showed significant activity 
against ovarian cancer cell lines compared to cisplatin (IC50: 1.18-9.02 μM). 6-
shogaol showed synergism in combination with cisplatin and oxaliplatin when 
administered as a bolus 0/0h and with 0/4 h sequence against A2780, A2780
cisR
 and 
A2780
ZD0473R
 cell lines. Honokiol alone and in combination with cisplatin caused 
significant DNA damage in the parent A2780 cell line whereas cholecalciferol did the 
same to cisplatin-resistant A2780
cisR
 cell line. Concurrent administration of cisplatin 
and 6-shogaol produced higher cellular platinum accumulation and three times greater 
platinumDNA binding than cisplatin in the parent ovarian A2780 cell line.  
 XII 
Although (0/0 h) combination of honokiol and cisplatin produced a lower cellular 
accumulation of platinum, it resulted in greater platinumDNA binding. 
Cholecalciferol and 6-shogaol in combination with cisplatin also produced increased 
platinumDNA binding in the A2780cisR cell line. Proteomic studies have been 
performed to explore the proteins involved with drug-resistance in cisplatin-resistant 
A2780
cisR
 and picoplatin-resistant A2780
ZD0473R
 cell lines. Nineteen proteins were 
found to be significantly expressed in 23 different spots in untreated A2780
cisR
 and 
A2780
ZD0473R
 cell lines compared to the expression level observed in the untreated 
parent A2780 cell line. Selected synergistic combinations of platinum drugs and 
natural compounds were associated with reduced expression of anti-apoptotic proteins 
and heightened expression of the pro-apoptotic proteins towards overcoming 
chemoresistance. 6-shogaol in combination with cisplatin and oxaliplatin had the 
ability to combat platinum chemoresistance by downregulating the expression of the 
anti-apoptotic proteins and increasing the expression of the pro-apoptotic proteins in 
ovarian A2780
cisR
 and A2780
ZD0473R
 cell lines. In summary, ginger derived 
phytochemical, 6-shogaol alone and in combination with cisplatin and oxaliplatin 
showed significant cytotoxicity against ovarian cancer tumour models. Therefore, 6-
shogaol could be a prospective candidate for combination therapy to manage ovarian 
cancer in future.  
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1 Introduction 
1.1 Preamble 
Cancer appears to be one of the most feared diseases of our time in all parts of the 
globe. It develops when cells acquire the ability to undergo uncontrolled division and 
spread beyond its point of origin (Ferlay, Soerjomataram et al. 2015). This research is 
centered on ovarian cancer and its treatment using chemotherapeutics. In particular, 
the thesis considers employment of binary combinations of platinum drugs and 
compounds from natural sources to overcome drug resistance and reduce side effects 
in ovarian cancer as attempts are also made to explore mechanisms of action.  
In this chapter, a brief introduction to cancer would be given with a special focus on 
ovarian cancer, types, risk factors, management, chemo-resistance mechanisms and 
strategies to overcome drug-resistance. The objective and justification of the present 
study will be provided at the end of this chapter.  
1.2 Cancer  
Cancer is abnormal growth of malignant cells with the ability to spread away from the 
point of origin (Ferlay, Soerjomataram et al. 2015). This ability of cancer cells is 
called metastasis. Currently, over 277 different types of diseases are termed as cancer 
(Hassanpour and Dehghani 2017). The common sign and symptoms of cancer include 
anxiety, fatigue, pain (Nainis, Paice et al. 2006) nausea, sudden loss of body weight 
and loss of appetite (Teunissen, Wesker et al. 2007).  
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1.3 Types of cancer  
Cancers are commonly classified based on their ability to metastasize and the point of 
origin. These are described as follows. 
Based on ability to metastasize, cancer can be divided into two types namely 
adenomas or benign tumours and adenocarcinomas or malignant tumours.  
Based on the point of origin, cancer could be classified into four different types 
namely carcinoma, sarcoma, lymphoma and leukemia.  
a) Carcinoma: Cancer originated from surface epithelium and almost 90 % 
cancers are carcinomas, for example ovarian, colon and skin cancer    
b) Sarcoma: Cancer originated in connective tissues (cartilage, muscle, fibrous 
and bone tissue) are the point of organ and this type of cancer accounts for 
about 2%  
c) Lymphoma: Uncontrolled growth of lymphocytes originated from the immune 
system and blood-forming cells 
d) Leukemia: Abnormal growth of leukocytes from bone marrow and the sum of 
the lymphoma and leukemia is about 8% among all cancers (Ravindran, 
Prasad et al. 2009). 
1.4 Global burden of cancer 
Cancer is the most feared disease in the modern era. It is the second most common 
reason for mortality after ischemic heart disease globally (Hassanpour and Dehghani 
2017). According to US National Centre for Health Statistics, there assumed to be 
1,688,780 new cases of cancer and the death toll estimated to be 600,920 cases during 
2017 in the United States. Though the higher number of men assumed to be diagnosed 
with cancer, more women supposed to die than man (Siegel, Miller et al. 2017).  
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134174 people diagnosed with cancer and among them, 47753 patients presumed to 
die in Australia at the calendar year 2017. Mortality in men higher in this region than 
women (AIHW 2017). Globally cancer costs roughly 2.5 trillion US dollars per year 
to the patients and their families (Lopes 2015). It has been proposed that preventive 
measures, early diagnosis and proper treatment could reduce the cost of cancer 
management.  
1.5 Hallmarks of cancer 
Cancer cells can be differentiated from normal cells by six unique characteristics. 
These are a) Persistent growth signaling by triggering H-Ras oncogene; mitogenic 
growth signal is not required for cell division and proliferation of cancer cell,  
b) Resistant to tumour suppressor by losing retinoblastoma protein; retinoblastoma 
protein suppresses neoplasm progression, thus in absence of this protein tumour 
continuously grow,  
c) Escape programmed cell death (apoptosis) by producing insulin-like growth factors 
(IGFs); IGFs facilitate cell multiplication and inhibit natural cell death to become 
immortal in nature which leads increase number of cells in the body,  
d) The infinite ability of replication by stimulating terminal transferase (telomerase) 
activity which provides cancer cells the ability to grow and replicate spontaneously,  
e) Constant blood vessel formation by stimulating vascular endothelial growth factor 
(VEGF); new blood vessel supplies nutrients and favourable factors for continuous 
cell division,  
f) Invade into normal cells and metastasis by deactivating epithelial cadherin gene 
(cadherin-1); inter-cellular bond strength depends on the activity of cadherin-1, loss of 
its activity causes intrusion of cancer cells and metastasis (Hanahan and Weinberg 
2000).  
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Recently, deregulations of cellular metabolism and avoiding immune destruction have 
emerged as hallmarks of cancer (Hanahan and Weinberg 2011).  
1.6 Ovarian cancer 
Ovarian cancer is considered as one of the most dreaded gynecologic neoplasms 
around the globe. It may be defined as cancer associated with spontaneous and 
uncontrolled growth in one or both ovaries (Woodhouse and Edmondson 2017). 
Oncologists view ovarian cancer as being “insidious” and “a silent killer” (Jasen 
2009) due to its subtle nature (Seagle, Butler et al. 2017) and patients are often 
diagnosed when the disease would have metastasized beyond the point of origin. The 
common sign and symptoms of ovarian cancer include abdominal discomfort, 
abdominal pain and blotting, lower back pain, constipation or diarrhea, anorexia and 
tiredness (Anderson 2009, Ebell, Culp et al. 2016) which are often misunderstood as 
usual menstrual symptoms by women.  
1.7 Current scenario of ovarian cancer  
In women, ovarian cancer is found to cause significant mortality in developed 
countries including USA and Australia. Australian Institute of Health and Welfare 
2017 reported that 1,394 patients were newly diagnosed with ovarian cancer and 974 
patients died during 2014 (AIHW 2017). However, it is anticipated to be the eighth 
most diagnosed cancer (1580 cases) for females in Australia during 2017 and would 
cause highest mortality (1047 deaths) among gynecological carcinomas (AIHW 
2017). Five years survival rate remains low (44.4 % during the period of 2009 to 2013 
in Australia (AIHW 2017)). In the United States, ovarian cancer was the highest killer 
among gynecological cancers in 2014 and estimated to be the second highest 
diagnosed gynecological cancer after uterine corpus cancer among women during 
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2017 but will remain a prime cause of death (14080 deaths) among females (Siegel, 
Miller et al. 2017). In 2012, worldwide 239,000 new cases of ovarian cancer were 
reported resulting in 152,000 deaths, being the fifth most common cause of death 
among women.  Women from developed countries such as Europe, North America 
and Australia were at high risk of having this cancer than developing and less 
developed regions (Ferlay, Soerjomataram et al. 2015, Webb and Jordan 2017).  
1.8 Types and stages of ovarian cancer  
Ovary consists of surface epithelial cells, germ cells (produce egg or ovum) and 
stromal cells (secret estrogen and progesterone hormones). The common origin of the 
ovarian cancer is surface epithelial cells (90%); germ (4%) and stromal ovarian 
cancers are rare (Jayson, Kohn et al. 2014). There are two types of epithelial ovarian 
cancer. Type I (benign) and Type II (malignant) epithelial ovarian cancers. Clinically 
at early stage or type I it is indolent in nature which consists mucinous, clear cell, 
low-grade serous and low-grade endometrioid benign tumours but become aggressive 
at type II containing high-grade endometrioid, high-grade serous and 
indistinguishable malignant cancers (Kim, Ueda et al. 2012).  Depending on the 
nature of progression International Federation of Gynaecology and Obstetrics (FIGO), 
classified ovarian cancer into four stages namely Stage I- IV. 
Stage I: One or both ovaries are affected by abnormal growth 
Stage II: One or both ovaries along with pelvic organs are affected with carcinomas 
Stage III: Metastasis of ovarian carcinoma beyond pelvic organs such as 
retroperitoneal organs or peritoneum or inguinal lymph nodes 
Stage IV: Ovarian carcinoma metastasizes further into distant organs such as liver or 
lungs. (Heintz, Odicino et al. 2006, Prat and Oncology 2014). 
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1.9 Epidemiology of ovarian cancer 
The major risk factors linked with ovarian cancer are a family history of breast or 
ovarian carcinoma, age over 50, nulliparity, menopause at an older age, hormone 
replacement therapy after menopause, history of endometriosis, smoking, high body 
mass index (Webb and Jordan 2017). Dermatomyositis (Field and Goff 2017),  
abnormalities in BRCA 1 and BRCA 2 genes often lead to ovarian cancer (Weigelt, 
Comino-Méndez et al. 2017). Also, early menarche, diabetes mellitus and use of 
talcum powder around genital areas could induce ovarian cancer. Other reasons for 
ovarian cancer are a high intake of alcohol and animal fat, use of fertility drugs, 
polycystic ovarian syndrome, ovarian cysts and lack of physical activity. In contrast, 
one or more full-term pregnancy, surgical contraceptive i.e. tubal ligation and long-
term use of oral contraceptives reduce the risk of an ovarian tumour (Koushik, 
Grundy et al. 2017). Positive correlations with the prevention of ovarian cancer and 
use of low dose aspirin, breastfeeding, vitamin D, regular exercise and vegetable 
intake have been reported (Webb and Jordan 2017). Intake of healthy diet and 
adhering to the dietary guidelines have been demonstrated to reduce the chance of 
ovarian cancer among African American women (Qin, Moorman et al. 2017). 
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1.10 Genes involved in ovarian cancer  
Tumour suppressor genes are the distinctive type of genes which protect cells from 
cancer. Mutation or alteration and deficiency of tumour suppressor genes could lead 
to induce cancer (Weinberg 2013). There are different types of tumour suppressor 
genes such as RB1, TP53, CDKN2A, BRCA APC, WT1, WT2, NF1, NF2 and VHL 
etc. reported to be associated with cancer (Chial 2008). Among them, BRCA and 
TP53 genes were highly linked with ovarian carcinoma.  
BRCA (breast cancer type 1 susceptibility protein) genes namely BRCA1 and BRCA2 
are well-known tumour suppressor genes, which play a major role to repair damaged 
DNA. In contrast, the BRCA1 and BRCA2 genes also facilitate apoptosis when DNA 
seems to be unrepairable (Friedenson 2007). However, inherited anomalies in those 
genes significantly increase the risk of ovarian cancer (Riaz, Blecua et al. 2017). For 
instance, 14% of patients diagnosed with epithelial ovarian carcinoma have been 
associated with altered BRCA1 and BRCA2 gene (Andrews and Mutch 2017). 
Tumour protein p53 (TP53) gene is considered as “guardian of the genome” because 
it safeguards genome from mutation. It also maintains stability within the genome. 
TP53 prevents cancer by inducing apoptosis or programmed cell death (Surget, 
Khoury et al. 2014). However, mutation in TP53 gene can cause cancer i.e. alteration 
in TP53 is highly predisposed to Li-Fraumeni syndrome, which can contribute to the 
development of ovarian cancer (Toss, Tomasello et al. 2015). Cell migration and 
invasion in ovarian cancer have also been associated with mutation in TP53 (Ahn, 
Kim et al. 2017).  
The genes acting on DNA repair pathways play a crucial role to protect the cell from 
cancer or abnormal growth. But alteration or mutation in DNA repair pathways gene 
could highly increase the risk of cancer malformation (Qian, Zhang et al. 2011).  
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Familial history of mutant DNA mismatch repair genes associated with lynch 
syndrome such as MSH2 and MLH1 (Lynch, Casey et al. 2009). Altered double-
strand breaks repair genes i.e. PALB2, RAD51, CHEK2 and BRIP1 (Toss, Tomasello 
et al. 2015) are also reported to cause ovarian cancer. 
MYC genes are involved with transcription pathways such as cell cycle, survival, cell 
adhesion, cytoskeleton and metabolism, expression of mRNA and protein synthesis 
during cellular development and multiplication (Dang, O’Donnell et al. 2006). 
Conversely, overexpression of c-MYC genes triggers the development of solid 
cancers (Knoepfler 2007, Dang 2012) especially ovarian cancer (Baker, Borst et al. 
1990).  
1.11 Diagnosis of ovarian cancer 
Three out of four ovarian cancer patients are diagnosed with malignancy either in 
stage III or stage IV (Ozols 2006). American cancer society reported that early 
diagnosis of ovarian cancer could increase five-year survival rate up to 94 percent. 
However, researchers are yet to discover a proven test for the diagnosis of ovarian 
cancer at early stage.  
CA 125 (Cancer antigen 125, a transmembrane protein) biomarker level in serum is 
commonly used to diagnose ovarian cancer (Glasgow, Pacheco-Rodriguez et al. 
2017); more than 35 U/mL in blood is regarded as abnormalities in the ovary (Skates 
2012). Post-menopausal women having raised the level of CA 125 often diagnosed 
with ovarian cancer than pre-menopausal women (Anderson 2009). This is because of 
CA 125 serum level increases during adenomyosis, menstrual and gestational periods 
(Russell, D'Amato et al. 2017). Recently, screening a pool of biomarkers level namely 
CA 125, lecithin-cholesterol acyltransferase (LCAT) and insulin-like growth factor-
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binding protein 2 (IGFBP2) showed a more accurate diagnosis of ovarian cancer than 
CA 125 alone (Russell, Graham et al. 2017).  
Transvaginal sonography (TVS) is another commonly preferred diagnostic technique 
for the detection of ovarian cancer. Uncontrolled proliferation of ovaries can be 
detected through TVS but the actual stage of ovarian cancer cannot be defined (van 
Nagell and Hoff 2014). Therefore, the combination of CA 125 and TVS  is the ideal 
choice among the clinicians to diagnose ovarian cancer (Anderson 2009). Despite 
women having a family history of ovarian or breast carcinoma and or mutation in 
BRCA1/2 gene, diagnosis of early-stage ovarian cancer is possible by monitoring the 
CA 125 serum profile and transvaginal ultrasonography (Skates, Greene et al. 2017).  
1.12 Management of ovarian cancer 
Ovarian tumours are mainly managed by surgery, radiotherapy, and chemotherapy. 
According to the level and stages of cancer, clinicians choose any of the above-
mentioned treatment methods or combinations. 
Surgical debulking is the preferable method to treat ovarian cancer at early or 
advanced stage since the 1970s (Schorge, McCann et al. 2010). Epithelial ovarian 
tumour at stage I and IIA could be managed by surgical removal of affected areas 
(Trimbos 2017). Oncologist often prefers to do debulking surgery before 
administration of chemotherapy to treat malignant ovarian cancers (Gyparaki and 
Papavassiliou 2017).  
The usefulness of radiation therapy remains questionable to treat early stages of 
ovarian cancer. Nevertheless, this method of treatment could be a better option to treat 
recurrent epithelial ovarian carcinoma (Lee, Park et al. 2015), which improves the 
quality of life with fewer adverse symptoms during palliative care (Eifel 2017).  
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About 75 % of ovarian cancer patients are diagnosed at stage III and IV due to its 
poor prognosis (Pignata, Cannella et al. 2011, Vargas 2014). Approximately 70% of 
them give a positive response to chemotherapy based on a combination of platinum 
with taxane after debulking surgery and this combination is the popular 
chemotherapeutic regimen to manage ovarian cancer from the early 90s to till to date 
(Bast Jr, Hennessy et al. 2009, Desale, Soni et al. 2015). Chemotherapy is usually 
given between 21 to 35 days after surgical removal of an ovarian tumour to achieve 
highest possible survival (Seagle, Butler et al. 2017). Figure 1.1 gives a pictorial 
representation of ovarian cancer treatment plan for last 50 years.  
 
 
Figure 1.1: Ovarian cancer treatment plan for last 50 years (Vaughan, Coward et al. 
2011) 
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1.12.1 Platinum-based anti-cancer therapy 
Platinum drugs are the primary drug of choice to manage solid neoplasms after the 
serendipitous innovation of cisplatin by Barnett Rosenberg in 1965. Ovarian cancer is 
mainly treated with platinum drugs such as cisplatin, carboplatin and oxaliplatin 
(Rosenberg, Vancamp et al. 1969, Monneret 2011, Nessa, Beale et al. 2011).  
1.12.1.1 Cisplatin 
Cisplatin is the first generation platinum drug chemically known as cis-
diamminedichloroplatinum (II) (CDDP), extensively used to treat solid tumours such 
as ovarian, testicular, head and neck, bladder, breast, brain, lung and cervical 
neoplasms (Dasari and Tchounwou 2014). Although cisplatin delivers substantial 
activity against solid tumours, it also exhibits some serious side effects for example 
myelosuppression (bone marrow suppression), nephrotoxicity (kidney damage), 
neurotoxicity or ototoxicity (hearing loss), alopecia (hair loss) and vertigo (Astolfi, 
Ghiselli et al. 2013). However, cisplatin is a small molecule having a molecular 
weight of 300.1 but poorly soluble in water (2.53 g/L at 25° C). Therefore, force 
hydration is mandatory prior to intravenous administration and saline diuresis is 
essential after treatment to reduce nephrotoxicity.  
Tumours especially heterogeneous types such as ovarian cancer often develop 
resistance against cisplatin leading to treatment failure and cancer recurrence (dos 
Santos Guimarães, Ladislau-Magescky et al. 2017). Hence searches are made for new 
cisplatin analogues would be able to overcome cisplatin resistance, reduced or no side 
effects and preferably soluble in water. 
1.12.1.2 Carboplatin 
Carboplatin is a second generation platinum drug, approved by Food and Drug 
Administration (FDA) in 1989 due to its reduced side effects. It is better tolerated by 
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the patients than cisplatin due to the absence of nausea and vomiting, and less 
nephrotoxicity during treatment (Monneret 2011). It exhibits similar activity 
compared to cisplatin against ovarian and lung malignancies (Sebastião, da Silva 
Rocha et al. 2016). A combination of carboplatin with paclitaxel/docetaxel is being 
used to treat ovarian cancer (Liu, Liu et al. 2015) (Yazawa, Hiraiwa et al. 2017). 
Carboplatin in combination with liposomal doxorubicin has been found to be active 
against recurrent epithelial ovarian cancer (Grenader, Rosengarten et al. 2012).   
1.12.1.3 Oxaliplatin 
Oxaliplatin also known as oxalate (trans-l-1,2-diaminocyclohexane) platinum (II) ] is 
a third generation platinum drug that is used alone and in combination to treat 
epithelial ovarian cancer due to its potent activity, fewer side effects and well 
tolerated by patients (Fu, Kavanagh et al. 2006). Bulky diaminocyclohexane-DNA 
adduct which is hydrophobic in nature formed by oxaliplatin makes it less prone to 
drug-resistance and hypersensitive reactions than cisplatin and carboplatin (Taylor, 
Beck et al. 2014). About 75 % of patients showed a positive response to oxaliplatin 
treatment where 50% of them previously received either cisplatin or carboplatin 
therapy. Thus, oxaliplatin has emerged as the drug of choice to treat recurrent and 
cisplatin/carboplatin resistant ovarian cancer nowadays (Bogliolo, Cassani et al. 
2015).  
1.13 Mechanism of action of cisplatin 
Cisplatin exhibits its antitumour action by forming a covalent bond with purine bases 
of genomic deoxyribonucleic acid (gDNA) in cancer cells. Hence it resists DNA 
transcription and replication which leads to programmed cell death (apoptosis) of 
cancer cells (Dasari and Bernard Tchounwou 2014). However, a series of stages are 
involved with the mechanism of action of cisplatin such as cellular accumulation of 
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drug, activation of cisplatin, the formation of inter and intra-strand cisplatin-DNA 
adducts, signal transduction from cisplatin-induced DNA damage and oxidative stress 
by the glutathione-cisplatin complex. These are described as follows:  
1.13.1 Cellular accumulation of cisplatin 
Cisplatin is administered intravenously to the patient, and blood carries the drug 
throughout the body. After reaching into the circulatory system, about 90% of the 
drugs are bound to plasma protein and becomes inactive. Only free cisplatin is entered 
into the cell by passive diffusion (Victoria, Miguel et al. 2007), pinocytosis, 
endocytosis and macrocytosis (Shen, Pouliot et al. 2012). Copper transporter CTR1 
facilitates active transport of cisplatin into the cells (Ishida, Lee et al. 2002). Cellular 
accumulation and sensitivity of cisplatin had been increased with elevated CTR1 
expression (Howell, Safaei et al. 2010).  
1.13.2 Activation of cisplatin 
Cisplatin remains unchanged in the blood due to higher extracellular chlorine (100 
mM) concentration. In contrast, intracellular fluids contain low chlorine (3-20 mM) 
concentration with an abundant amount of water molecules. Once neutral cisplatin 
enters into the cell, it undergoes hydrolysis in presence of water and replaces one or 
both chlorine molecule with water molecules. Subsequently, cisplatin is converted 
into mono [Pt(H2O)Cl(NH3)2]
+
 and diaquo  [Pt(H2O)2(NH3)2]2
+
 cations.  
These cations are extremely reactive towards negatively charged DNA, glutathione, 
and metallothioneins (Victoria, Miguel et al. 2007). The following figure 1.2 
summarizes steps in the entry into the cell, activation of cisplatin and its binding to 
DNA. 
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Figure 1.2: Activation of cisplatin and its binding to DNA (Bugarčić, Bogojeski et al. 
2012) 
1.13.3 Oxidative stress by cisplatin-glutathione 
complex  
Glutathione is a vital antioxidant which prevents the cell from oxidative stress-related 
damages to biomolecules including DNA by neutralizing reactive oxygen species 
such as peroxidase, free radicals etc. (Pompella, Visvikis et al. 2003). Highly reactive 
mono [Pt(H2O)Cl(NH3)2]
+
 and diaquo  [Pt(H2O)2(NH3)2]
2+
 cations are attracted by 
glutathione to form a cisplatin-glutathione complex (Cadoni, Valletta et al. 2017) 
which result in less number of free glutathione available inside the cells to prevent 
oxidative stress. Thus, it causes oxidative stress-related cell apoptosis (Dasari and 
Bernard Tchounwou 2014).  
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1.13.4 Formation of cisplatin-DNA intra-strand 
and inter-strand adducts 
Cisplatin binds to the nucleophilic N7 reactive centers on adenine and guanine to form 
1, 2-intrastrand DNA (GpG) adducts and 1, 2-intrastrand DNA (ApG) adducts (Figure 
1.3). Most of the adducts are 1, 2-intrastrand DNA (GpG) 90% whereas about 10% of 
the adducts are 1, 2-intrastrand DNA (ApG) (Dasari and Bernard Tchounwou 2014). 
These adducts inhibit DNA transcription and replication. Hence, it causes damage to 
the DNA and programmed cell death (Victoria, Miguel et al. 2007).  
 
Figure 1.3: A) 1,2-intrastrand cisplatin-DNA adduct, B) 1,2-interstrand cisplatin-DNA 
adduct,  C) monofunctional adduct, D) DNA-protein adduct (Victoria, Miguel et al. 
2007) 
1.13.5 Cell death by apoptosis 
As stated earlier, cisplatin mainly forms 1,2-intrastrand adducts with DNA. These 
adducts are shielded by high mobility group (HMGB) proteins principally HMGB1 
and HMGB2 from NER (nuclear excision repair) and MMR (mismatch repair) 
proteins (Victoria, Miguel et al. 2007). Subsequently, cisplatin causes significant 
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DNA damage which activates a series of signal transduction pathways generally p53, 
p38, AKT, MAPK, c-ABL, MAPK, JNK, ERK, MKP1/CL100, telomere shortening 
and ubiquitination pathways, hence it initiated programmed cell death  (Victoria, 
Miguel et al. 2007). The following figure 1.4 summarizes signal transduction 
pathways induced by cisplatin-DNA adducts. 
 
Figure 1.4: Signal transduction pathways induced by cisplatin-DNA adducts (Siddik 
2003) 
1.13.6 Cell cycle arrest  
Cisplatin also exerts cytotoxicity through cell cycle arrest usually in S phase and 
occasionally in G1 phase (Qu, Lin et al. 2013). Cisplatin inhibits Cdc2-cyclin A or B 
kinase, which prolongs G2/M phase and ultimately induce apoptotic cell death (Siddik 
2003).  
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1.14 Mechanism of cisplatin 
resistance 
The ultimate objective of the chemotherapy is to facilitate cancer cells towards 
apoptotic cell death. Complications arise as tumour cells would acquire resistance 
towards chemotherapeutic agents by continuous exposure and or alter intrinsic 
mechanisms to avoid programmed cell death (Siddik 2003). As mentioned earlier, 
cisplatin exerts ts its antitumour action by accumulating inside the cell, followed by 
formation of cisplatin-DNA adducts. It causes DNA damage and cisplatin-DNA 
adducts activate a series of signal transduction pathway which leads to apoptotic 
cancer cell death (Siddik 2003). Nevertheless, alteration of any of the earlier 
discussed pathways could lead to resistance to cisplatin (Siddik 2003). It may be 
noted that resistance to cisplatin could be classified into four types namely pre-target, 
on-target, post-target and off-target (Galluzzi, Vitale et al. 2014). These are as 
follows: 
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1.14.1 Mechanism of pre-target cisplatin resistance 
There are two possible mechanisms of pre-target cisplatin resistance. Those are 
decreased cellular accumulation and neutralization of cisplatin before binding with 
DNA (Galluzzi, Senovilla et al. 2011). 
1.14.1.1 Decreased cellular accumulation  
The intracellular concentration of cisplatin could be decreased by either reduced 
uptake or increased efflux. A reduction (20-70 %) of intracellular drug concentration 
could contribute to drug resistance (Siddik 2003). As discussed earlier, cisplatin enters 
into the cell by passive diffusion (Victoria, Miguel et al. 2007) and actively transport 
by the CRT1 transporter (Ishida, Lee et al. 2002, Galluzzi, Vitale et al. 2014).  And 
the higher expression of CTR1 transporter significantly increases cell uptake and 
sensitivity of cisplatin (Howell, Safaei et al. 2010). In contrast, prompt degradation of 
the CRT1 transporter is caused by cisplatin. As a result, cisplatin cellular influx is 
decreased and hence it acquires drug resistance (Holzer, Samimi et al. 2004) (Kilari, 
Guancial et al. 2016). Increased expression of copper-extruding P-type ATPase 
ATP7B protein (Moinuddin, Shinsato et al. 2016) and multidrug-resistance (MRP2) 
protein (Wen, Buckley et al. 2014) are significantly contribute towards cisplatin-
resistance by mediating cisplatin efflux from the cell.  
1.14.1.2 Deactivation of cisplatin 
Highly reactive mono and diaquo cisplatin cations are appealed by nucleophilic 
glutathione (GSH) (Cadoni, Valletta et al. 2017). However, overexpression of γ-
glutamylcysteine synthase (γ-GCS) catalyzes increased intracellular glutathione 
concentration  (Chen and Kuo 2010). Hence, extra GSH neutralizes more than the 
usual amount of cisplatin and aggravates cisplatin-resistance in ovarian cancer 
(Galluzzi, Senovilla et al. 2011).  
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1.14.2 Mechanism of on-target cisplatin resistance 
As discussed earlier, cisplatin exerts its mechanism of action by binding with DNA to 
form cisplatin-DNA intra and interstrand adduct followed by DNA damage. In 
contrast, increased DNA damage repair significantly contributes towards cisplatin 
resistance. The prime mechanisms of on-target cisplatin resistance are as follows: a) 
hyperactive nucleotide excision repair system, b) higher activity of mismatch repair 
system and c) mutation in homologous recombination repair system (Ferreira, Peixoto 
et al. 2016). The steps are pictorially given in the following figure. 
 
 
Figure 1.5: Mechanism of on-target cisplatin resistance (Ferreira, Peixoto et al. 2016) 
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1.14.2.1 Overactivity of nucleotide excision repair (NER) 
system 
Nucleotide excision repair (NER) system consists of twenty different types of 
proteins. The main protein contributing to NER system is ERCC1 (excision repair 
cross-complementation group 1) endonuclease. ERCC1 forms a strong dimer with 
XPF (Xeroderma pigmentosum complementation group F) and ERCC1-XPF complex 
removes the cisplatin-DNA adducts from the DNA (Galluzzi, Senovilla et al. 2011).  
The overactivity of ERCC1-XPF endonuclease is considerably contributing towards 
cisplatin resistance (Ferreira, Peixoto et al. 2016), especially in ovarian cancer 
resistant cell lines (Ferry, Hamilton et al. 2000, Shen, Pouliot et al. 2012). 
1.14.2.2 Mutation in mismatch repair (MMR) system 
Mismatch repair proteins such as MLH1 (Galluzzi, Vitale et al. 2014), MSH2 and 
MSH3  recognize the mismatch base pairs of DNA and induce apoptosis towards 
programmed cell death (Ferreira, Peixoto et al. 2016). Down-regulation of mismatch 
repair genes and or up-regulation of the mutant mismatch repair genes significantly 
increases cisplatin resistance (Ferreira, Peixoto et al. 2016).  
1.14.2.3 Hyperactive homologous recombination repair 
(HR) system  
Breast cancer susceptibility proteins namely BRCA1 and BRCA2 are an integral part 
of homologous recombination DNA repair (HR) system. The main function of these 
proteins is to facilitate DNA repair. However, patients having deficient BRCA1 and 
BRCA2 genes showed a noticeable response to cisplatin treatment against ovarian and 
breast cancers (Ferreira, Peixoto et al. 2016). Restoration of BRCA1 and BRCA2 
genes expression by secondary mutation could contribute to cisplatin resistance 
against ovarian neoplasms (Shen, Pouliot et al. 2012, Galluzzi, Vitale et al. 2014).  
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1.14.3 Mechanism of post-target cisplatin 
resistance 
The post-target cisplatin resistance is mainly related to apoptosis. Down-regulation or 
mutation of pro-apoptotic genes and/or up-regulation of anti-apoptotic genes prevent 
the cisplatin-treated cancer cells from natural cell death. Hence it causes cell survival 
and resistant to cisplatin. The factors involved with post-target cisplatin resistance are 
described as follows: 
1.14.3.1 Abnormalities in TP53 pathways 
Tumour Protein (TP53) is a tumor suppressor gene, mainly recognizes damage or 
mutation in DNA and induce apoptotic cell death. For this reason, it is regarded as the 
guardian of the genome. Likewise, the optimal function of TP53 is mandatory for 
cisplatin-induced DNA damage which contributed to cell kill. In contrast, down-
regulation and mutations in TP53 gene substantially increase cisplatin-resistant and 
tolerance (Siddik 2003). Alteration in TP53 expression is greatly contributing towards 
platinum drug resistance in ovarian cancer cell line (Reles, Wen et al. 2001). 
1.14.3.2 PI3-K/mTOR/AKT pathway  
Phosphatidylinositol 3-OH kinase pathway is reported to be contributing factor for 
cell survival by avoiding apoptosis and cancer progression (King, Yeomanson et al. 
2015).  AKT induces the activity of survivin which leads inactivation of caspase-
dependent apoptosis in ovarian cancer (Jiang, Luo et al. 2013). Thus, up-regulation of 
the PI3-K pathway has been extensively associated with cisplatin-resistance (Galluzzi, 
Senovilla et al. 2011). 
1.14.3.3 BCL-2 like proteins 
BCL-2 proteins are either proapoptotic or anti-apoptotic in nature. However, 
overexpression of anti-apoptotic proteins namely BCL-XL,  BCL-2 and MCL-1 are 
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highly linked with cisplatin resistance (Michaud, Nichols et al. 2009, Galluzzi, Vitale 
et al. 2014). Conversely, down-regulation of pro-apoptotic proteins i.e. Bax and Bak 
also prominently increase cisplatin resistance (Ferreira, Peixoto et al. 2016). 
1.14.3.4 Nuclear factor kappa beta (NF-κB) pathway 
Nuclear Factor-kappa B (NF-κB) is a protein complex consists of five proteins 
namely p50, p52, p65, RelB, and c-Rel. NF-κB proteins facilitate cell proliferation 
and cancer progression by protecting the cell from apoptosis (Godwin, Baird et al. 
2013). Likewise, NF-κB inhibits TP53 protein expression to prevent cell death 
(Meylan, Dooley et al. 2009). Up-regulation of NF-κB is an indicator of poor patient 
prognosis in ovarian cancer (Annunziata, Stavnes et al. 2010). NF-κB is a key factors 
for producing cisplatin resistance (Godwin, Baird et al. 2013). Because elevated NF-
κB expression in cancer cells is reported as a significant contributor to cisplatin 
resistance (Godwin, Baird et al. 2013). Higher expression of NF-κB decreases cancer 
cell sensitivity towards chemotherapy (Chuang, Yeh et al. 2002). Instead, inhibition of 
NF-κB transduction pathways shows an improved response to anti-cancer treatment 
(Li, Ahmed et al. 2005, Meylan, Dooley et al. 2009, Godwin, Baird et al. 2013). The 
following figure provides a summary of inhibition of apoptotic pathways.  
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Figure 1.6: Inhibition of apoptotic pathways (Siddik 2003). 
1.14.4 Mechanism of off-target cisplatin resistance  
Cisplatin resistance could also be acquired by the factors which are not directly linked 
with cisplatin.  For example: up-regulation of autophagy, protooncogene ERBB2 
(NEU), conserved kinase DYRK1B, chaperone HSPs and transmembrane protein 
TMEM205 in cancer cells have been reported as being interconnected with cisplatin 
resistance in different types of cancers especially ovarian cancer (Peracchio, Alabiso 
et al. 2012, English, Roque et al. 2013, Galluzzi, Vitale et al. 2014).  
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Conversely, knockdown of autophagy could highly improve the outcome of cisplatin 
treatment in ovarian cancer (Wang and Wu 2014, Pagotto, Pilotto et al. 2017). The 
following figure provides a summary of cisplatin including off-target resistance. 
 
 
Figure 1.7: Cisplatin resistance mechanism (Galluzzi, Vitale et al. 2014) 
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1.15 Current approaches for 
overcoming platinum resistance in 
ovarian cancer   
Due to the heterogeneous nature of ovarian cancer, cisplatin resistance and recurrence 
is more common. Currently, clinicians and researchers are mainly following four 
major tactics to overcome cisplatin resistance (Figure 1.8). These are:  
i) Synthesis of platinum analogues having fewer side effects and superior 
activity than cisplatin, 
ii) Improved drug delivery to achieve better bioavailability in tumour site,  
iii) Concurrent administration of platinum and molecularly targeted anti-
cancer agents,  
iv) Combination of the platinum drug with a tumour active compounds from 
other sources having the ability to act on the platinum-resistance 
mechanism.  
 
Figure 1.8: Current strategies to combat platinum resistance in ovarian cancer 
(Kelland 2007) 
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With the view of widening the spectrum of activity and reducing the side effects of 
platinum drugs, thousands of cisplatin analogues have been synthesized. Among 
these, carboplatin, oxaliplatin, satraplatin, nedaplatin, lobaplatin, picoplatin, prolindac 
and aroplatin were found to be prominent drugs which exhibit significant activity 
against different types of cancer. Amongst thousands of cisplatin analogues, 
carboplatin showed comparable activity against ovarian cancer with fewer side effects 
and better tolerance by the patient (Kelland 2007, Raja, Chopra et al. 2012). 
Intraperitoneal administration of cisplatin showed improved efficacy and treatment 
outcome to manage ovarian cancer (Armstrong , Bundy  et al. 2006). Liposomal 
doxorubicin and paclitaxel along with platinum also exhibit superior capability to treat 
recurrent ovarian cancer (Kelland 2007, Cronin, Robison et al. 2013, Lawrie, Bryant 
et al. 2013).  
Molecularly targeted anticancer drugs such as bevacizumab, trastuzumab, imatinib 
and sunitinib have recently emerged as a drug of choice along with platinums to treat 
different types of cancers. Unfortunately, combination therapy based on platinum and 
targeted agents is still far behind the success rate of carboplatin and paclitaxel 
combination against ovarian cancer (Kelland 2007, Coward, Middleton et al. 2015).  
Currently, the most popular technique to overcome platinum drug resistance is to use 
a combination of platinum with other tumour active compounds having a different 
kind of mechanism of action. For example, a combination of paclitaxel with 
carboplatin is the main dosage regimen to treat ovarian cancer for last few decades 
(Coward, Middleton et al. 2015).  Treatment outcome has been dramatically improved 
by using a combination of carboplatin with paclitaxel. Since paclitaxel has a different 
mechanism of action than platinum, drug-resistance and recurrence are less common 
than monotherapy (Luvero, Milani et al. 2014).  
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However, a combination of carboplatin with liposomal doxorubicin is preferred to 
treat recurrent ovarian cancer due to its lesser side effects than carboplatin-paclitaxel 
regimen nowadays (Pujade-Lauraine, Wagner et al. 2010).  
1.16 Compounds from natural 
sources 
Tumour active compounds from natural sources having different mechanisms of 
action than platinum drugs could provide key compounds for combination with 
platinums to overcome drug resistance and reduce side effects. The current study is 
centered on the combination of the platinum drug with a tumour active compound 
from natural resources to overcome drug resistance in ovarian cancer. The following 
natural compounds have been combined with platinum drugs. 
1.16.1 Mycophenolic acid 
Mycophenolic acid (Figure 1.9) is a weak acid and secondary metabolite from marine 
fungi Penicillium brevicompactum (Rovirosa, Diaz-Marrero et al. 2006). The prodrug 
of mycophenolic acid namely mycophenolate mofetil has been used as an immune-
suppressant drug during kidney transplantation for the prevention of organ rejection 
(Silverman Kitchin, Pomeranz et al. 1997, Bentley 2000).  Mycophenolic acid has 
also found to be active against viral, bacterial, fungal diseases and psoriasis 
(Silverman Kitchin, Pomeranz et al. 1997, Rovirosa, Diaz-Marrero et al. 2006).   
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Figure 1.9: Chemical structure of mycophenolic acid 
Mycophenolic acid is a powerful suppressor of inosine monophosphate 
dehydrogenase (IMPDH), the rate-limiting enzyme in the de-novo synthesis of 
guanosine nucleotides (Allison and Eugui 2000), which inhibits synthesis of T cells 
such as interleukin-17, Interferon-γ and tumour necrosis factor-α (He, Smeets et al. 
2011). Thus mycophenolic acid can prevent DNA replication. It induces the activity 
of pro-apoptotic p53 protein to accelerate apoptosis (Sun, Dai et al. 2008) and inhibits 
new blood vessel formation by preventing vascular endothelial growth factor alpha 
(VEGF-α) secretion (Monguilhott Dalmarco, Mendes de Córdova et al. 2011). It also 
blocks protein kinase B (AKT/mTOR) and nuclear factor kappa B (NF-κB) pathways 
(He, Smeets et al. 2011). Hence it exhibits significant anti-activity against prostate 
cancer (Morales, Agrapart et al. 2008) and breast cancer (Zheng, Yang et al. 2011). 
Besides, mycophenolate mofetil profoundly decreases cisplatin-induced renal 
dysfunction (Saad, Arafah et al. 2007). Therefore, it can be used in combination with 
cisplatin to treat cancer.  
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1.16.2 6-shogaol 
6-shogaol chemically known as [1-(4-hydroxy-methoxyphenyl)-4-decen-one] is 
derived from Zingiber officinale Roscoe (ginger) (Ok and Jeong 2012).  
 
Figure 1.10: Chemical structure of 6-shogaol 
6-shogaol exhibits potent anti-bacterial and anti-fungal activity (Rahmani, shabrmi et 
al. 2014). It also shown to has neuroprotective activity in parkinsonism disease (Park, 
Kim et al. 2013). 6-shogaol triggers autophagy to prevent breast and colorectal 
cancers progression (Ray, Vasudevan et al. 2015, Li and Chiang 2017). 6-shogaol is 
found tosubstantially down-regulate NF-κB genes such as c-MYC, cyclin D1 and 
survivin to inhibit prostate cancer (Saha, Blando et al. 2014) and metastasis in breast 
cancer (Ling, Yang et al. 2010). It blocks G2/M phase in the cell cycle to prevent 
colorectal carcinoma (Li and Chiang 2017). 6-shogaol has been associated with 
triggering caspase-dependent programmed cell death in leukemic cancer (Liu, Peng et 
al. 2013),  and up-regulate pro-apoptotic factors such as interleukin-7, BAX and p27 
to induce apoptosis in prostate cancer (Saha, Blando et al. 2014). It also blocks the 
invasion of lung cancer by resisting CC-Chemokine Ligand 2 secretion (Hsu, Hung et 
al. 2015). 
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1.16.3 Honokiol 
Honokiol is mainly isolated from bark/leaf/seed of magnolia tree (Magnolia virginia) 
(Fried and Arbiser 2009). Chemically it is derived from polyphenol group and also 
known as 2-(4-hydroxy-3-prop-2-enyl-phenyl)- 4-prop-2-enyl-phenol. It has a 
molecular weight of 266.3 and poorly soluble in water. However, it is used as a 
Chinese herbal medicine to combat various types of diseases such as bacterial, viral, 
fungal infections, anxiety, pain and cancer (Arora, Singh et al. 2012).    
  
Figure 1.11: Chemical structure of honokiol 
Honokiol act as a neuroprotective agent used to prevent nervousness, pain and 
epilepsy (Woodbury, Yu et al. 2013). It suppresses inflammatory mediators to give 
anti-inflammatory effects and has been reported as an anti-oxidant which prevents the 
formation of reactive oxygen species (Fried and Arbiser 2009). Honokiol is a potent 
anti-coagulant which induces prostacyclin activity to inhibit platelet aggregation (Hu, 
Zhang et al. 2005). Honokiol has been reported as an anti-viral compound which 
suppresses dengue virus and HIV-virus replication (Arora, Singh et al. 2012, Fang, 
Chen et al. 2015). Honokiol has been associated with down-regulation of NF-κB, 
mTOR, STAT3 and EFGR pathways to exhibit anticancer activity against ovarian, 
prostate, skin and gastrointestinal cancers (Arora, Singh et al. 2012).  
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Also, it triggers caspase-dependent programmed cell death and inhibits formation of 
new blood vessel by blocking VEGF expression to show anti-neoplastic activity 
against chronic lymphocytic leukemia, myeloma and leukemia (Fried and Arbiser 
2009). Honokiol suppresses cancer cell proliferation and triggers programmed cell 
death in lung and colon carcinomas. It also inhibits expression of human epidermal 
growth receptor 2 to prevent breast cancer cell multiplication (Liu, Zang et al. 2008). 
Honokiol blocks G1 phase in the cell cycle, induce the activity of pro-apoptotic 
protein Bax and attenuate expression of NF-κB to show anti-cancer activity against 
pancreatic cancer (Arora, Bhardwaj et al. 2011).  
1.16.4 Cholecalciferol 
Cholecalciferol is commonly known as vitamin D3 and mammalian skin synthesizes 
cholecalciferol in presence of sunlight (Norman 2008). A minute amount of 
cholecalciferol is derived from dietary resources such as fatty fish, liver, eggs and 
dairy products. The major role of cholecalciferol is maintaining plasma calcium 
concentration and bone health (Chang, Schlussel et al. 2015).  
 
Figure 1.12: Chemical structure of cholecalciferol 
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Inactive cholecalciferol is converted into calcifediol in liver followed by another 
hydroxylation in the kidney to form calcitriol. Calcitriol plays a key role in the 
synthesis of different types of the enzymes (Norman 2008). The vitamin-D3 deficiency 
could increase the risk of breast, colon and prostate cancers (Fleet, DeSmet et al. 
2012). Maintaining an optimum level of vitamin-D3 could decrease the risk of ovarian 
cancer (Ong, Cuellar-Partida et al. 2016). Also, it prevents ovarian cancer progression 
in combination with celecoxib (Thill, Woeste et al. 2015).  Vitamin-D3 has the ability 
to suppress the expression of NF-κB and interferon-gamma to trigger autophagy (Wu 
and Sun 2011). Vitamin-D3 is found to be associated with lowering the expression of 
anti-apoptotic cyclin D1, Bcl-2  proteins and potentiate expression of pro-apoptotic 
BAX protein (Yang, Lamprecht et al. 2008). Also, vitamin-D3 prevents cancer 
progression and induces apoptotic cell death (Fleet, DeSmet et al. 2012). Therefore, 
cholecalciferol could significantly inhibit breast, colon, colorectal, prostate cancer cell 
multiplication and progression (Tokar and Webber 2005, Giammanco, Di Majo et al. 
2015).  
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1.16.5 Kaempferol 
Kaempferol is a flavanol which can be isolated from different fruits and plants, for 
example, apple, tomato, broccoli, grapes and green tea (Kim and Choi 2013).   
  
Figure 1.13: Chemical structure of kaempferol 
 Kaempferol reduces oxidative stress by increasing amount of glutathione, vitamin c 
and vitamin E. It also was shown to has anti-diabetic activity by increasing secretion 
of insulin (Al-Numair, Chandramohan et al. 2015). Kaempferol is reported to inhibit 
viral and fungal infections, suppress inflammatory mediators and provide pain relief 
(Calderon-Montano, Burgos-Moron et al. 2011). Kaempferol substantially down-
regulates expression of VEGF biomarker to inhibit new blood vessel formation. It 
prevents G2/M phase transition in the cell cycle by blocking cyclin-dependent kinase 
1 and cyclin B. Kaempferol inhibits ERKp38- JNK and AP-1 signaling pathways to 
block the invasion of the cancer cell. It suppresses the expression of NF-κB and anti-
apoptotic proteins such as Bcl-2 and Bcl-xL. Besides, kaempferol highly increases 
expression of pro-apoptotic p53, BAX and BAD proteins. Hence it exhibited anti-
cancer activity against ovarian, skin, breast, osteosarcoma and colon carcinoma (Kim 
and Choi 2013).   
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1.17 Role of natural compounds to 
overcome platinum resistance 
Platinum drugs remain the standard first-line therapy to treat ovarian cancer. But 
monotherapy by platinum would meet chemo-resistance in ovarian cancer which 
increases relapse and mortality (Parmar 2003). At the molecular level, platinum 
resistance is believed to be associated with higher expression of transcriptional factors 
(NF-κB, STAT3), angiogenic and invasive factors (VEGF, IL-8), cell cycle proteins 
(cyclin D1, cyclin E), protein kinases (AKT, JNK), cell proliferation factors (TNF, 
IGF, IFN-γ, IL-6) and anti-apoptotic factors (Bcl-2, Bcl-xL, survivin). Likewise, 
lower expression of transcriptional factor p53 and pro-apoptotic proteins (Caspase-3, 
Caspase-7, Caspase-9, BAX) also play a significant role in platinum chemo-resistance 
(Agarwal and Kaye 2003, Aggarwal and Shishodia 2006). In contrast, compounds 
from natural sources have the enormous potential to act on resistance pathways of 
platinum drugs. Natural compounds inhibit the expression of NF-κB, VEGF, AKT, 
anti-apoptotic proteins. Compounds from the natural sources found to be associated 
with up-regulation of pro-apoptotic proteins such as caspase, p53, BAD and BAX 
proteins  (Aggarwal and Shishodia 2006, Nessa, Beale et al. 2012, Huq, Yu et al. 
2014).  
The following figure summaries mechanism of action of phytochemicals. It can be 
assumed that tumour active phytochemicals and indeed other natural compounds 
could be effective candidates for combination with platinum drugs to overcome 
platinum drug-resistance in ovarian cancer.  
 35 
 
Figure 1.14: Mechanism of action of phytochemicals (Aggarwal and Shishodia 2006) 
1.18 The rationale of the present 
study  
Ovarian cancer causes the highest number of mortality among the gynecological 
neoplasms. Recurrence due to treatment failure is the main reason for such amount of 
death caused by ovarian cancer. However, platinum chemoresistance is believed to be 
the key factor involved in ovarian cancer relapse (Chan and Fong 2007, Nessa, Beale 
et al. 2011).  
One of the popular strategies to overcome cancer drug-resistance is to use the 
combination of anticancer drugs instead of a monotherapy (Kelland 2007). Currently, 
clinicians use two anti-cancer drugs having two different modes of action with the 
view to overcoming chemoresistance as well as to get synergistic action (Li, Ahmed 
et al. 2005).  
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As discussed above, natural compounds have the ability to combat platinum resistance 
mechanism. Hence tumour-active natural compound could be the potential candidates 
to be used in combination with the platinum drug for overpowering drug-resistance. 
The compounds from the natural resources in combination with cisplatin or 
oxaliplatin exhibit substantial synergism against ovarian cancer cell lines especially 
resistant cell lines (Mazumder, Beale et al. 2012, Nessa, Beale et al. 2012, Huq, Yu et 
al. 2014).  
Platinum drugs have serious side effects such as ototoxicity, myelosuppression, 
alopecia, nephrotoxicity and toxicity of platinum is dose-dependent (Gregg, Molepo 
et al. 1992, Jaishankar, Tseten et al. 2014). As the reduced amount of dose would be 
required when drugs act synergistically in combination therapy, platinum toxicity 
would be minimized (Li, Ahmed et al. 2005).  
The mortality caused by ovarian cancer remains high even though patient receives 
best available treatment. For this reason, continuous research is warranted to improve 
treatment regimen for getting better survival rate.  
1.19 The aim of the study 
The aims of the present study are to explore the cytotoxic potential of compounds 
from the natural resources against ovarian cancer cell lines and in particular, 
a) Apply a binary combination of platinum drug and natural compound against 
ovarian tumour models to attain a synergistic outcome. 
b) Explore mechanistic insight of selected platinum drug and natural compound 
combinations at cellular and DNA levels.  
c) Discover major proteins involved in platinum-resistant and changes in 
expression with the combination. 
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2 Materials and 
Methods 
2.1 Preamble 
In this study, three platinum drugs: cisplatin (CS), oxaliplatin (OX) and carboplatin 
(CB) and five compounds from natural sources: mycophenolic acid (MA), 6-shogaol 
(6-SG), honokiol (HK), cholecalciferol (CC) and kaempferol (KF) were applied alone 
and in binary combination to four ovarian tumour models: A2780 (parent), A2780
cisR
 
(cisplatin-resistant), A2780
ZD0473R
 (picoplatin-resistant) and SKOV-3 (p53 null) with 
the aim of overcoming drug resistance. First, the IC50 values of the compounds were 
determined. Kaempferol was not considered for combination study because of its low 
activity.  
DNA damage study along with studies on cellular accumulation and level of 
platinumDNA binding were carried out for a number of combinations (nine) as 
applied to the parent and cisplatin-resistant ovarian cancer cell lines, with the aim of 
providing insight on the mechanism of drug action.  Proteomic studies were also 
carried out to provide mechanistic insight on drug resistance and programmed cell 
death, for which nine synergistic combinations were selected. The study involved 2D-
gel electrophoresis followed by the characterization of the selected protein spots 
(namely 23) by mass spectrometry with the aim to provide insight into the mechanism 
of drug action. 
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2.2 Platinum drugs and compounds 
from natural sources 
Cisplatin was synthesized in the host laboratory following the method described by 
Dhara (Dhara 1970). Oxaliplatin and carboplatin were purchased from Sigma Aldrich.  
Five natural compounds: mycophenolic acid (AdooQ Bioscience) and 6-shogaol 
(Toronto Research Chemicals), honokiol (LKT Laboratories), cholecalciferol (LKT 
Laboratories), kaempferol (LKT Laboratories) were supplied by Sapphire Bioscience, 
NSW, Australia.  
2.3 Synthesis of cisplatin 
2.3.1 Materials 
Potassium tetrachloroplatinate (II), K2[PtCl]4 was obtained from Sigma Aldrich, USA 
and potassium iodide (KI) purchased from UniveR, Australia, 28% ammonia solution 
and potassium chloride (KCl) were obtained from BDH Chemicals, Australia. Silver 
Nitrate (AgNO3) was procured from Merck, Australia.  
2.3.2 Synthesis procedure of cisplatin 
Cisplatin is the most common drug used to treat ovarian cancer worldwide. For this 
reason, it was used as a reference drug in the study. As stated earlier, it was 
synthesized according to Dhara method starting with potassium tetrachloroplatinate 
(Dhara 1970) following the standard operating procedure developed in the laboratory. 
Briefly, it involved treating K2PtCl4 in solution with potassium iodide (KI) resulting 
in the formation of K2PtI4. Addition of ammonia resulted in the formation of cis-
Pt(NH3)2I2 which was reacted with AgNO3 to produce cis-Pt(NH3)2(NO3)2. Addition 
of KCl to cis-Pt(NH3)2(NO3)2 resulted in the formation of cis-Pt(NH3)2Cl2. 
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2.4 Ovarian cancer cell lines 
Four human epithelial ovarian cancer cell lines used in the study were provided by 
Associate Professor Philip Beale, Clinical Director of Cancer Services, Concord 
Repatriation General Hospital, NSW Australia. These are A2780 (parent), A2780
cisR
 
(cisplatin-resistant), A2780
ZD0473R
 (picoplatin-resistant) and SKOV-3 (p53 null) 
ovarian cancer cell lines.  
The parent ovarian cancer epithelial cell was first developed from an untreated patient 
suffering from ovarian endometrioid adenocarcinoma by Dr. T H Ward, Cell Culture 
Unit, Patterson Laboratories, Christies Hospital, Manchester UK. As A2780 cell was 
found to have potential to grow as monolayer cells in tissue culture medium. Since 
then, A2780 cell line is widely used as a reference cell line in ovarian cancer research. 
The A2780 cell line was persistently treated with higher concentration of cisplatin to 
develop cisplatin-resistant (A2780
cisR
) cell line (Behrens, Hamilton et al. 1987). And 
picoplatin-resistant ovarian A2780
ZD0473R
 cell line has been developed by following 
the similar method (Holford, Beale et al. 2000). And SKOV-3 cell line was collected 
from a Caucasian women’s ovarian adenocarcinoma.  
  
 40 
2.5 Cell culture and MTT reduction 
assay  
2.5.1 Materials 
10 heat-inactivated fetal bovine serum (FBS) was supplied by Bovogen, Australia. 
Roswell Park Memorial Institute (RPMI) 1640 medium, 200mM L-glutamine and 
5.6% (w/v) sodium bicarbonate was procured from Thermo Trace Pty Ltd, Australia. 
Trypsin, Hepes, Dulbecco’s phosphate buffered saline powder (DPBS), Dimethyl 
sulfoxide (DMSO) and Thiazolyl Blue Tetrazolium Blue / Methylthiazolyldiphenyl-
tetrazolium bromide (MTT) were purchased from Sigma Aldrich Pty Ltd, Australia. 
96 well flat bottom plates with lids were obtained from Edward Keller. 25 cm
2 
tissue 
culture flasks, the canted neck was provided by Crown Scientific, NSW, Australia. 
DISMIC-25cs filter (cellulose acetate, 0.22 µm hydrophilic, pressure limitation: 
0.51MPa) was supplied by ADVANTEC. iMark
TM 
Bio-Rad Microplate Reader 
Version 1.04.02E was purchased from BIO-RAD. And CO2 Incubator, 5% CO2 in air 
at 37ºC was procured from SANYO, Japan.  
2.5.2 Cell culture and subculture 
Ovarian cancer cells were grown in a cell culture medium as a monolayer cell 
(Freshney 2010). 1 mL of each ovarian cancer cell line was aseptically withdrawn 
from the cryogenic vial and cultured individually in 25 cm
2
 flat bottom cell culture 
flasks.  Then, 5 mL of Roswell Park Memorial Institute (RPMI) 1640 medium was 
added gently to each cell culture flask after which the cell culture flasks were 
incubated in an atmosphere consisting air (95% v/v) and carbon dioxide (5% v/v) at 
37ºC to maintain proper growth environment. After reaching an optimum 
concentration of cells in cell culture flask, subculture of the cells was performed to 
multiply the number of cells to do numerous amount of research work.  
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Subculture is the process of cell culture to generate a huge amount of cells from a few 
cells.  First, the old culture medium was drained from the cell culture flasks. Then, the 
monolayers were rinsed with phosphate buffer solution to remove the serum which 
could inhibit the action of trypsin. Then, 1 mL of 0.05% trypsin solution was added 
and allows the trypsin spread over the cell culture flask by gently rotating the flask. 
Subsequently, flasks were transferred to carbon dioxide incubator for 2-3 minutes at 
37ºC to allow the trypsinization means cells could detach from each other and act like an 
independent unit. Then, 9 mL of fresh 10% (w/v) fetal calf serum /RPMI 1640 medium 
was added aseptically with the flask to neutralize the action of trypsin and to achieve 
the desired concentration of cells per mL. Afterward, 1 mL of suspended cells and 9 
mL of fresh 10% FCS/RPMI 1640 medium were allocated to new 25 cm
2
 flat bottom 
cell culture flasks. Then the subculture flasks were transferred to the carbon dioxide 
incubator having an atmosphere with air (95% v/v) and carbon dioxide (5% v/v) at 
37ºC. Later, subculture was performed two times in a week to sustain the log or 
exponential phase of the cancer cells.  
2.5.3 Cell counting and seeding 
Cell concentration in subculture medium was determined by using TC 10 BIO-RAD 
automated cell counter to find out whether the suspended cell met the optimum 
concentration needed for cell viability (MTT reduction) assay. First, 15 µL of each 
trypan blue dye and cancer cell suspension were mixed gently in an Eppendorf tube. 
Then, 10 µL of mixed sample was applied to each chamber of the slide carefully. 
Finally, the slide was inserted into TC 10 BIO-RAD automated cell counter to get the 
cell concentration.  
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96 well flat bottom plates were used for MTT reduction assay. 100 µL of cell 
suspension seeded in each well with the desired concentration of the suspended cells 
about 4 х 104 cells per mL. Then, 96 well plates were kept in the carbon dioxide 
incubator comprising an atmosphere with air (95% v/v) and carbon dioxide (5% v/v) 
at 37ºC for 24 hours to form monolayer cell by settling at the bottom of the well.  
2.5.4 Storage of cells 
Ovarian cancer cells become healthy and free from contamination when it reaches its 
late exponential growth phase. However, 10% fetal bovine serum/RPMI 1640 and 
dimethyl sulfoxide (DMSO) were used as medium and cryoprotectants respectively 
for the storage of ovarian cancer cell lines. And DMSO is commonly used as 
cryoprotectants meaning it protects the ice formation in the cells during storage in a 
liquid nitrogen tank.  
Monolayer cancer cells at its late exponential growth phase with the quality of healthy 
and free from contamination were collected for final storage of the cells aiming to do 
future studies. 10% FBS/RPMI 1640 was used as a medium to make a cell 
concentration of 2 x10
6
 cells per mL. Then, 10 mL of 20 % DMSO (8 mL 10% 
FBS/RPMI + 2ml DMSO) and the same volume of cancer cells were mixed together 
to get final 10% DMSO concentration in the mixture. Afterward, 1 mL of the mixture 
(cancer cells and 10% DMSO) was transferred to a previously labeled cryogenic vial 
and place into a box sealed by cotton-wool for 24 hours at a -70ºC temperature and 
finally stored into liquid nitrogen tank.  
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2.5.5 Preparation of stock solution of platinum 
drugs and natural compounds 
Stock solutions of the platinum drugs and compounds from the natural sources were 
prepared by using suitable solvents. The procedure for the preparation of stock 
solution is as follows:  
Cisplatin was dissolved in dimethyl formamide (DMF) after that mQ water was added 
at a ratio of 1:4 to make 1 mM concentration. Carboplatin and oxaliplatin were 
dissolved in mQ water to attain 1 mM concentration of the stock solution. 
Mycophenolic acid, honokiol and kaempferol were dissolved in dimethyl sulfoxide 
(DMSO) to give 1mM, 10 mM and 10 mM stock solution respectively. Ethanol used 
as a solvent to get 10 mM stock solution of 6-shogaol and cholecalciferol.  
Filtration by using membrane filters (0.22 µm) was performed to sterilize the stock 
solution. After that, the filtrate was allocated to several 5 mL tubes and stored at -
20ºC. Then, serial dilution of the stock solution was performed to get a final 
concentration of (0.08-350) µM for drug adding. Fetal bovine serum-free Roswell 
Park Memorial Institute (RPMI) 1640 was used as a medium during serial dilutions. 
Each concentration of drug solution had a final volume of 2-3 mL.   
2.5.6 Cell treatments 
First, 100 μL cell suspension of each cell line containing 4000 to 6000 cells were 
seeded in each well of 96 well flat bottom plates. Then, the plates were kept in carbon 
dioxide incubator for 24 hours at 37ºC to grow and form monolayer cell. After that, 
the cancer cells were treated with drugs consisting different concentration as 
discussed in the previous section and for each concentration, the treatment of the drug 
was triplicated in the same plate to get an average result.  
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RPMI 1640 medium was applied to the control wells (untreated) to compare with the 
treated cells. Finally, the 96 well plates were transferred to the carbon dioxide 
incubator again for 72 hours.  
2.5.7 MTT reduction assay 
MTT reduction assay is a quantitative colorimetric method widely used to determine 
cell proliferation and cytotoxicity. The key feature of the method is that a smaller 
number of cells can produce the expected result. No washing step is needed and there 
is no need to use any radioisotopes.  MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl 
tetrazolium bromide) a yellow tetrazole enter into the cells and in presence of viable 
cell’s mitochondrial succinate dehydrogenase, it is converted into insoluble and dark 
purple coloured formazan. Then, dimethyl sulfoxide (DMSO) allows formazan to 
solubilize in it and form dark purple coloured solution MTT (Mosmann 1983). 
Afterward, the absorbance of formazan was determined by using iMark
TM 
Bio-Rad 
Microplate Reader Version 1.04.02E. Finally, the concentration of cells has been 
calculated by plotting absorbance of viable cancer cells against applied concentration.  
500 mg of MTT power was dissolved in 500 ml of FBS free RPMI 1600 medium. 
Then, the solution was sterilized by 0.45 µM membrane filter to get rid of unwanted 
particles and microorganism. After that, 500ml MTT solution was allocated into 
several 50 mL tubes and stored at 4ºC temperature.  
MTT reduction assay was performed after 72 hours of incubation to determine the 
viable cell concentration. The old RPMI 1600 medium was discarded from the 96 
well plates and 50 µL of MTT solution applied on each well. Then 96 well plates 
were transferred to carbon dioxide incubator for 4 hours to allow MTT for the 
formation of formazan. After four hours, MTT solution was drained from 96 flat 
bottom well plates; viable cells were still stuck to the bottom of the plates.  
 45 
150 µL of dimethyl sulfoxide (DMSO) was applied in each well to solubilize the 
insoluble formazan to get the dark purple colour of living (viable) cells. Then, 
iMark
TM 
Bio-Rad Microplate Reader Version 1.04.02E was used to determine the 
optical density of viable cells at 595 nm.  
Cell survival fractions were calculated using following equation:  
The optical density of the sample  – The optical density of DMSO 
The optical density of control – The optical density of DMSO 
2.5.8 Calculation of IC50 and resistant factor (RF) 
Dose-response curve i.e. plot cell survival fraction against drug concentration was 
used to get IC50 values (meaning the drug concentration needed to kill 50% cells) of 
each platinum drugs and natural drugs. Three or more sets of standard experiments for 
each concentration applied to A2780 (parent), A2780
cisR
 (cisplatin-resistant), 
A2780
ZD0473R
 (picoplatin-resistant) and SKOV-3 (p53 null) were done to get an 
average cell survival fraction. IC50 values were used to calculate corresponding 
resistant factor (ratio of the IC50 value in the resistant cell line over that in the parent 
cell line) of each compound applying to A2780
cisR
 (cisplatin-resistant), A2780
ZD0473R
 
(picoplatin-resistant) and SKOV-3 (p53 null) cell lines. Less than 1 resistant factor 
value reflects that the drug is more active against resistant cell line than parent cell 
line and greater than 1 RF value is the converse. A resistant factor was calculated by 
the following equation: 
IC50 value in resistant cell line 
IC50 value in parent cell line 
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2.6 Combined studies 
2.6.1 Activity of drugs in combination 
Binary combinations of platinum drugs and natural compounds using 0/0 h, 0/4 h and 
4/0 h sequences of administration were administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines towards synergistic outcomes. 0/0 h stands for 
concurrent administration of both platinum drug and natural compound, 0/4 h 
indicates the platinum drug was added first followed by natural compound added 4 
hours later and 4/0 h meant the converse. 
Studies on drug combination were carried out by treating ovarian cancer cells at three 
different concentrations of compounds alone and in combination with 1:1 ratio of 
their IC50 values in parent, cisplatin-resistant, picoplatin-resistant and p53 null cell 
lines as illustrates in Table 2.1. 
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Table 2.1: Molar ratio between platinum drugs (CS, OX and CB) and compounds 
from natural sources (6-SG, MA, HK and CC) added in combination to A2780, 
A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Combination 
Molar ratio 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
CS + 6-SG 1:8.44 1:1.65 1:1.65 1:1.33 
OX + 6-SG 1:37.8 1:15.0 1:32.5 1:0.50 
CS + MA 1:1.67 1:0.275 1:0.275 1:0.86 
OX + MA 1:7.50 1:3.67 1:3.67 1:0.18 
CB + MA 1:0.10 1:0.03 1:0.03 1:0.11 
CS + HK 1:20.83 1:5.50 1:4.12 1:4.44 
OX + HK 1:88.5 1:48.67 1:78.67 1:0.90 
CB + HK 1:1.13 1:0.44 1:0.55 1:0.57 
CS + CC 1:14.63 1:5.50 1:2.13 1:5.55 
OX + CC 1:70.20 1:44.0 1:33.13 1:1.67 
Table 2.2 provides drug treatment plan with the combination of cisplatin and honokiol 
using 0/0 h, 0/4 h and 4/0 h sequences of administration in 96 flat bottom well plate.  
Table 2.2: Drug treatment plan with the combination of cisplatin and honokiol using 
0/0 h, 0/4 h and 4/0 h sequences of administration in 96 flat bottom well plate. 
 1         2         3 4         5          6 7         8          9 10     11      12  
A Cisplatin-1 6-Shogaol-1 Honokiol-1 CS + HK (4/0)-3 A 
B Cisplatin-2 6-Shogaol-2 Honokiol-2 CS + HK (4/0)-2 B 
C Cisplatin-3 6-Shogaol-3 Honokiol-3 CS + HK (4/0)-1 C 
D CS + 6-SG (0/4)-3 CS + 6-SG (0/0)-3 CS + HK (0/0)-3 CS + HK (0/4)-3 D 
E CS + 6-SG (0/4)-2 CS + 6-SG (0/0)-2 CS + HK (0/0)-2 CS + HK (0/4)-2 E 
F CS + 6-SG (0/4)-1 CS + 6-SG (0/0)-1 CS + HK (0/0)-1 CS + HK (0/4)-1 F 
G CS + 6-SG (4/0)-3 CS + 6-SG (4/0)-1 Blank G 
H CS + 6-SG (4/0)-2 Blank H 
 1         2         3 4         5          6 7         8          9 10     11      12  
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100 µL of cell suspension was added to each well of 96 flat bottom cell culture plate 
and then placed in the incubator for 24 h to grow and attach to the plate. Then, the 
plates were taken out and 100 µL of drugs (as per the concentrations mentioned in 
Table) were added to each well during cytotoxicity study of single compounds. While 
in the combination study, 50 µL of each drug was added to each well to make a final 
volume of 100 µL. In addition, 100 µL of FBS free RPMI 1600 medium was added in 
each well marked as blank. Then, 96 flat bottom cell culture plate was transferred to 
carbon dioxide incubator again for 72 h. Afterward, MTT reduction assay was 
performed according to the previously described procedure to know inhibition of cell 
growth caused by a platinum drug or the compounds from natural sources alone and 
in combination. After repeating an experiment for three or more times, pooled data 
were used to obtain combination index (CI) values and dose-response curve.  
2.6.2 Combination index analysis  
Combination index (CI) analysis is a quantitative method that reflects the synergistic 
or additive or antagonistic nature of combined drug action (Chou and Talalay 1984). 
The authors suggested a few simple equations for the calculation of combination 
index as described in Appendix I. CalcuSyn Version 2.0 (Biosoft, United Kingdom) 
was used to determine the CI values. CI value equal to 1 suggests the combination is 
additive, less than 1 meaning synergistic combination and more than 1 reflects the 
combination is antagonistic.  
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2.7 Cellular accumulation and 
Platinum-DNA binding 
Cellular accumulation of platinum and the level of platinumDNA binding were 
determined to obtain mechanistic insight on the combined drug action. 
2.7.1 Materials 
EZ-10 spin column genomic DNA minipreps KIT and RNase were purchased from 
Astral Scientific Pty Ltd., Australia. Kodak Gel Logic 100 imaging system was 
procured from Eastman Kodak Company, USA. SpectraMax-M3 multi-mode 
microplate reader, Molecular Devices was collected from Biostrategy, v3.0.22. 
Atomic absorption spectroscopy (AAS) with GTA-120 graphite furnace tube atomizer 
was provided by Varian SpectrAA 240. Triton-X was supplied by Sigma Aldrich Pty 
Ltd, NSW, Australia.  
Nine prominent synergistic combinations were selected for cellular accumulation and 
platinumDNA binding with aim of finding mechanistic insight into the combined 
drug action. Specifically, the aim was to determine whether the compounds from the 
natural sources had any influence on the cellular accumulation of platinum drugs and 
the level of platinumDNA binding.   
2.7.2 Method 
A2780 (parent) and A2780
cisR
 (cisplatin-resistant) cell lines were sub-cultured 
repeatedly aiming to gain sufficient cell concentration for cellular accumulation and 
platinum-DNA binding assay. After that, 4.75 mL of cell suspension contains half 
million cells per mL were seeded in 5 mL petri-dishes and placed in carbon dioxide 
incubator for 24 h. Then, the cell concentration reaches one million cells per mL after 
24 h and settle down to the bottom of the petri-dishes by forming monolayer cells.  
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One set of cell culture dishes was prepared for cellular accumulation study and 
another set of platinumDNA binding study.  
After 24 h, 250 µL of FBS free RPMI 1600 medium was added in petri dishes marked 
as blank (untreated) and the same volume of platinum drug solution added in 
“control” cell culture dishes. Then, 125 µL of each platinum drug and the natural 
compound solution was added in cell culture petri dishes by following their sequences 
of administration during combination studies. Then the cell culture petri dishes were 
transferred to incubator again for 24 hours. Afterward, cell scraper was used for 
detaching monolayer cells from petri dishes and collected in 10 mL centrifugal tubes. 
Then, 10 mL tubes were centrifuged at 3500 rpm for 2 minutes at 4ºC. After that, the 
medium was discarded from cell pellet and 2 mL of ice-cold PBS was added to it for 
suspending the cell pellet. Then, the pellet was centrifuged again and PBS was 
discarded from the cell pellet. Afterward, 1 mL of phosphate buffer solution was 
added again with cell pellet to re-suspend and transfer from 10 mL tubes to 1.5 mL 
Eppendorf tubes. Finally, Eppendorf tubes were centrifuged again and PBS was 
discarded from the cell pellet, followed by storage at - 20 ºC for further studies.  
2.7.3 Cellular accumulation 
Triton X-100 (Sigma, Australia) was dissolved in mQ water to make 1% Triton X-100 
solution. Then, 500 µL of 1% Triton X-100 solution was added to each cell pellet. 
Afterward, cell suspensions were sonicated in a Unisonoics sonicator held on ice for 
half an hour to facilitate cell lysis (Farrell, Kelland et al. 1992). After that, the lysed 
cells were spun at 14000 rpm for 3 minutes. At the end, 400 µL of each corresponding 
supernatant was collected and then intracellular platinum concentration was 
determined by Varian SpectrAA-240 atomic absorption spectrophotometer with GTA 
120 Graphite furnace tube atomizer.  
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2.7.4 PlatinumDNA binding 
It is believed that platinum drugs bind to DNA that may result in DNA damage. In 
order to carry out platinum-DNA binding assay, high molecular weight DNA was 
needed to extract from the cell pellet. The detailed DNA extraction procedure is given 
in Appendix II.  
After getting pure DNA from cell pellet, Varian Cary 1E UV-Visible with Varian 
Cary Temperature Controller (260 nm) was used to determine the DNA content of 
each sample. However, the ratios of A260 / A280 between 1.75 and 1.90 for all DNA 
samples reflect pureness of DNA  (Holford, Beale et al. 2000). The following 
equation was used to calculate the DNA concentration in each sample.  
DNA concentration (each sample) = Absorbance (260 nm) х 50 ng / µL 
The DNA bound platinum concentration was determined by Varian SpectrAA-240 
atomic absorption spectrophotometer with GTA 120 Graphite furnace tube atomizer.  
2.8 DNA damage study 
In the present study, cisplatin, oxaliplatin, mycophenolic acid, 6-shogaol, honokiol 
and cholecalciferol alone and in combination (nine combinations) were selected for 
DNA damage assay.  Platinum drugs are believed to be able to cause DNA damage 
while few compounds from the natural sources also could do the same although some 
others can provide protection against DNA damage. So the combination of platinum 
drugs and compounds from natural resources could cause greater or reduced damage 
to DNA. 
The methods for cell collection and treatment with drugs for DNA damage study were 
already described in cellular accumulation and platinumDNA binding studies. The 
detailed DNA extraction procedure for DNA damage study is described in Appendix 
II.  
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2.8.1 Materials 
EZ-10 spin column genomic DNA minipreps KIT and RNase were supplied by Astral 
Scientific Pty Ltd., Australia. Agarose was purchased from BIO-RAD, USA. 
Disodium salt of ethylene diamine tetraacetic acid, Boric acid, Acetic acid, Tris base, 
Tris-HCl, Ethidium bromide and Triton-X were provided by Sigma Aldrich Pty Ltd, 
NSW, Australia. Atomic absorption spectroscopy (AAS) with GTA-120 graphite 
furnace tube atomizer was obtained from Varian SpectrAA 240. Kodak Gel Logic 100 
imaging system was brought from Eastman Kodak Company, USA. And SpectraMax-
M3 multi-mode microplate reader, Molecular Devices was obtained from Biostrategy, 
v3.0.22.  
2.8.2 Agarose-DNA gel electrophoresis 
The preparation of 1% agarose gel solution and 1X TAE buffer (contains tris base, 
acetic acid and EDTA) are essential for agarose gel electrophoresis. First, 2M tris base 
(24.22g), 2M glacial acetic acid (5.71 mL), 50 mM EDTA (1.86g) and mQ water 
(94.3 mL) were mixed together to get 100 mL of 50X TAE buffer. Then, 40 mL of 
50X TAE buffer was mixed with 1960 mL mQ to make 1X TAE buffer. Secondly, 2 g 
agarose powder and 200 mL of 1X TAE buffer were added together then boiled in the 
microwave for 2 min. After that, the mixture was thoroughly mixed by spinning and 
again heated to boil for 5 minutes and left at room temperature. Afterward, ethidium 
bromide (125 mL) was added to the agarose gel solution (after cooling down to the 
room temperature) and thoroughly mixed with each other. Finally, the agarose 
solution was slowly poured into the gel tray with comb placed in certain position and 
solidified the gel at room temperature (Stellwagen 2009).  
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Electrophoresis chamber filled was with an optimum amount of 1X TAE buffer and 
250 µL of ethidium bromide was added to both sides of the chamber. Then, DNA 
samples were removed from the freezer and allow them to defrost. After that, 2 µL of 
marker dye consisting 40% (w/v) of sucrose and 0.25% (v/v) of bromophenol blue 
were mixed with each sample to detect sample movement during electrophoresis. 
Afterward, each well in agarose gel was loaded with one DNA sample in order to 
conduct electrophoresis at 120 V for 120 minutes. Then, Kodak Gel Logic 100 
imaging system was used to detect DNA bands under UV light followed by gel 
images were captured and then analyzed by Kodak molecular imaging software.  
2.9 Proteomics 
Proteomics studies were performed to provide mechanistic insight of combined drug 
action and the key proteins involved in drug resistance. Two dimensional (2D) gel 
electrophoresis would allow detection of more than a thousand protein at a time with 
the detection limit of less than 1 ng per spot (Gorg and Weiss 2004).  
The profiles of the protein derived from the untreated and treated A2780 (parent) and 
A2780
cisR
 (cisplatin-resistant) cell lines were compared and analyzed to be able to 
contemplate the key proteins involved with drug resistance.  Melanie 7.0 software was 
used to analyze the protein.  
2.9.1 Materials 
1,4-Dithiothreitol (DTT), Urea, Glycerol, Sodium dodecyl sulfate (SDS) and CHAPS 
(3[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate were 
supplied by MP Biomedicals, LLC., USA. Protease inhibitor cocktail tablets 
(Complete, Mini, EDTA-free) was obtained from Roche Diagnostics, Germany.  
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Protean® plus overlay agarose, Bovine serum albumin (BSA),  (1.44 mg/ml)10х 
tris/glycine buffer, 0.2% Carrier ampholytes, Bio-Rad protein assay standard II kit 
(500-0007), Iodoacetamide, Mineral oil, Gels for 1
st
 dimensional electrophoresis 
[ReadyStrip IPG strip of 11cm long, 3.3 mm wide, 3-10 NL (nonlinear) pH gradient 
and 0.5 mm thick gel], Sodium azide, Thiourea, Dye reagent concentrate (500-0006), 
BioSafe Coomassie G-250 Stain, Bromophenol Blue, Criterion TGX Precast gel, 
Wicks, ChemiDoc XRS system (Serial: 720BR1508), Phosphate buffered saline 
(PBS), Power Pac Universal, PROTEAN i12 IEF Cell, DeStreak reagent and Criterion 
Dodeca cell (Serial: 561BR 01908) were provided by Bio-Rad, USA. Melanie 
(Version 7.0) was collected from the Swiss Institute of Bioinformatics, Genebio, 
Switzerland. 
2.9.2 Methods 
The parent (A2780), cisplatin-resistant (A2780
cisR
) and picoplatin-resistant 
(A2780
ZD0473R
) cell lines were selected for proteomic assay. Ovarian cancer cells were 
sub-cultured in 150 cm
2
 cell culture flasks aiming to reach one million cells per flask. 
Then, RPMI 1600 medium was added to untreated (blank) cells and cells treated with 
drugs at their IC50 values. After that, the cell flasks were transferred to carbon dioxide 
incubator for 24 hours. Then, the rest of the procedure was performed according to the 
standard procedure adopted in our lab which is described in Appendix III.  
A flow diagram of entire proteomic study protocol is given in figure 2.1. 
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Figure 2.1: Proteomic study protocol 
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3 Chapter Three: 
Results 
3.1 Preamble 
Acquired drug resistance and adverse effects remain the biggest challenges in 
chemotherapy against ovarian cancer. Platinum drugs in combination with compounds 
from natural sources are considered to provide an advantage in chemotherapy to treat 
ovarian cancer. In this study, binary combinations of platinum drugs: cisplatin (CS), 
oxaliplatin (OX) and carboplatin (CB) and five compounds from plants and other 
natural sources, namely mycophenolic acid (MA), 6-shogaol (6-SG), honokiol (HK), 
kaempferol (KF) and cholecalciferol (CC) were applied to four ovarian cancer A2780, 
A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines aiming to achieve synergistic 
outcomes. First, the IC50 values of compounds meaning drug concentration required 
for 50% cell kill were determined using MTT reduction assay. Studies on damage to 
cellular DNA, drug accumulation and drug-DNA binding were also carried out. 
Proteomic studies were carried out to explore the key proteins responsible for drug 
resistance in ovarian cancer cell lines.  
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3.2 Anticancer activity of single drugs 
3.2.1 Parent ovarian cancer cell line (A2780) 
Figure 3.1 presents cell survival fraction against applied concentrations line graphs for 
platinum drugs: carboplatin (CB), cisplatin (CS), oxaliplatin (OX) and compounds 
from natural sources: mycophenolic acid (MA), 6-shogaol (6-SG), honokiol (HK), 
cholecalciferol (CC) and kaempferol (KF) as added to the ovarian parent A2780 cell 
line.  
 
Figure 3.1: Line graphs of cell survival versus applied concentrations of CB, CS, OX, 
MA, 6-SG, HK, CC and KF as added to the parent A2780 cell line 
Amongst the platinum drugs, oxaliplatin is the most active compound and carboplatin 
is the least active compound against parent ovarian cancer A2780 cell line. Among 
the compounds from natural resources, mycophenolic acid is the most active 
compound whereas kaempferol is the least active compound against same cell line. 
Overall, oxaliplatin is the most active compound against parent ovarian cancer A2780 
cell line. The order of activity against ovarian parent A2780 cell line is 
OX>CS>MA>6-SG>CC>CB>HK>KF. 
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3.2.2 Cisplatin-resistant ovarian cancer cell line 
(A2780
cisR
) 
Figure 3.2 shows cell survival fraction against applied concentrations line graphs for 
platinum drugs: carboplatin (CB), cisplatin (CS), oxaliplatin (OX) and compounds 
from natural sources: mycophenolic acid (MA), 6-shogaol (6-SG), honokiol (HK), 
cholecalciferol (CC) and kaempferol (KF) as added to the ovarian cisplatin-resistant 
A2780
cisR
 cell line.  
 
Figure 3.2: Line graphs of cell survival versus applied concentrations of CB, CS, OX, 
MA, 6-SG, HK, CC and KF as added to the cisplatin-resistant A2780
cisR
 cell line 
It is found that amongst the platinum drugs, oxaliplatin is the most active compound 
whereas carboplatin is the least active compound against cisplatin-resistant ovarian 
A2780
cisR
 cancer cell line. And among the compounds from natural sources, 
mycophenolic acid is the most active compound and honokiol is the least active 
compound against same cell line. Overall, oxaliplatin is the most active compound 
against cisplatin-resistant A2780
cisR
 ovarian cancer cell line. The order of activity 
against ovarian cisplatin-resistant A2780
cisR 
cell line is OX>MA>6-
SG>CS>CC>KF>HK>CB. 
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3.2.3 Picoplatin-resistant ovarian cancer cell line 
(A2780
ZD0473R
) 
Figure 3.3 displays cell survival fraction against applied concentrations line graphs for 
platinum drugs: carboplatin (CB), cisplatin (CS), oxaliplatin (OX) and compounds 
from natural sources: mycophenolic acid (MA), 6-shogaol (6-SG), honokiol (HK), 
cholecalciferol (CC) and kaempferol (KF) as added to the ovarian picoplatin-resistant 
A2780
ZD0473R
 cell line.  
 
Figure 3.3: Line graphs of cell survival versus applied concentrations of CB, CS, OX, 
MA, 6-SG, HK, CC and KF as added to the picoplatin-resistant A2780
ZD0473R
 cell line 
It is found that among the platinum drugs, oxaliplatin is the most active compound 
and carboplatin is the least active compound against picoplatin-resistant ovarian 
A2780
ZD0473R
 cancer cell line. And amongst the compounds from natural resources, 
mycophenolic acid is the most active compound and kaempferol is the least active 
compound against same cell line. Overall, oxaliplatin is the most active compound 
against picoplatin-resistant ovarian cancer A2780
ZD0473R
 cell line. The order of 
activity against ovarian picoplatin-resistant A2780
ZD0473R 
cell line is OX>MA>CS>6-
SG>CC> HK>CB>KF. 
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3.2.4 p53 null ovarian cancer cell line (SKOV-3) 
Figure 3.4 presents cell survival fraction against applied concentrations line graphs for 
platinum drugs: carboplatin (CB), cisplatin (CS), oxaliplatin (OX) and compounds 
from natural sources: mycophenolic acid (MA), 6-shogaol (6-SG), honokiol (HK), 
cholecalciferol (CC) and kaempferol (KF) as added to the ovarian p53 null SKOV-3 
cell line.  
 
Figure 3.4: Line graphs of cell survival versus applied concentrations of CB, CS, OX, 
MA, 6-SG, HK, CC and KF as added to the p53 null SKOV-3 cell line 
It is found that amongst the platinum drugs, cisplatin is the most active compound and 
carboplatin is the least active compound against p53 null SKOV-3 ovarian cancer cell 
line. And among the compounds from natural sources, 6-shogaol is the most active 
compound and kaempferol is the least active compound against same cell line. 
Overall, 6-shogaol is the most active compound against p53 null SKOV-3 ovarian 
cancer cell line. The order of activity against ovarian p53 null SKOV-3 cell line is 6-
SG>MA>CS>OX>CC> HK>KF >CB. 
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3.2.5 IC50 of single compounds at a glance 
The following table provides a summary of the IC50 values and the resistant factors 
(RFs) for drugs as applied to four ovarian cancer cell lines: A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3. The IC50 value or the median effective dose is defined as 
the drug concentration required for fifty percent (50%) cell death whereas the resistant 
factor (RF) is the ratio of the IC50 value in the resistant cell line over that in the parent 
cell line. 
Table 3.1: IC50 values (µM) and resistance factors (RF) for platinum drugs and 
compounds from natural resources as added to the four ovarian cancer cell lines: 
A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3.  
Drug 
A2780 
(µM) 
A2780
cisR 
(µM) 
RF 
A2780
ZD0473R 
(µM) 
RF 
SKOV-3 
(µM) 
RF 
CS 1.18±0.12 9.02±0.99 7.64 6.23±0.53 5.27 9.01±0.81 7.64 
OX 0.61±0.04 0.72±0.07 1.18 0.44±0.05 0.72 16.98±1.36 27.84 
CB 19.52±1.76 41.20±4.12 2.11 54.12±3.80 2.77 68.56±6.85 3.51 
MA 1.82±0.14 1.43±0.07 0.78 1.34±0.10 0.73 7.83±0.94 4.30 
6-SG 9.45±0.75 8.31±1.16 0.88 10.20±1.02 1.07 6.79±0.61 0.71 
CC 17.57±0.88 13.24±0.27 0.75 13.24±0.26 0.75 34.73±3.40 1.98 
HK 22.10±1.77 18.21±1.82 0.82 29.51±4.42 1.33 39.16±5.09 1.77 
KF 24.14±2.41 13.65±1.91 0.56 79.10±3.95 3.27 58.36±5.84 2.42 
 
It is found that oxaliplatin is more active than cisplatin against A2780, A2780
cisR
 and 
A2780
ZD0473R
 cell lines. However, against SKOV3 cell line the converse is true. 
Among the compounds from natural sources, the most active compound is 
mycophenolic acid. One of the phytochemicals, 6-shogaol, shows comparable activity 
with cisplatin against all the four ovarian cancer cell lines and is the most active 
compound against SKOV-3 cell line. It is also found that compounds from natural 
sources show greater activity against resistant cell lines than parent cell line, showing 
that at the level of their activity the compounds have been better able to overcome the 
mechanisms of resistance operating in the resistant cell lines. 
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3.3 Drug Combinations 
Combination studies were carried out with the aim of achieving synergistic outcomes. 
The IC50 values served as the starting point as drugs were mixed at constant ratios of 
the IC50 values. Dose-response curves and combination indices were used as measures 
of combined drug action. In the present study, binary combinations of platinum drugs 
and compounds from natural sources using 0/0 h, 0/4 h and 4/0 h sequence of 
administration were applied to the human epithelial ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines towards synergistic outcomes. 0/0 h stands for 
bolus administration of both platinum drug and natural compound, 0/4 h indicates the 
platinum drug is added first followed by natural compound added 4 hours later and 
4/0 h sequence is the converse. Combination index (CI) value provides a quantitative 
nature of degree of combined drug action as a form of antagonism, additiveness and 
synergism. A value greater than 1 indicates antagonism, a value equal to 1 indicates 
additiveness and a value less than 1 indicates synergism. 
3.3.1 Dose-response effects 
3.3.1.1 Dose-response of cisplatin (CS) with 6-shogaol (6-
SG) 
Table 3.2 presents the dose-response values (fa) at three different concentrations of CS 
and 6-SG administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-
resistant A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.5 displays the 
corresponding dose-effect logarithmic line graphs. 
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Table 3.2: Fractions of the affected cell (fa) at three different concentrations of CS and 
6-SG administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
CS (µM) Effect CS (µM) Effect CS (µM) Effect CS (µM) Effect 
0.09 0.16±0.00 0.40 0.12±0.01 0.50 0.12±0.01 0.72 0.03±0.00 
0.94 0.47±0.04 4.00 0.27±0.03 4.98 0.44±0.02 7.21 0.36±0.02 
9.44 0.81±0.10 40.00 0.61±0.06 49.84 0.88±0.04 72.08 0.92±0.05 
6-SG (µM) Effect 6-SG (µM) Effect 6-SG 
(µM) 
Effect 6-SG 
(µM) 
Effect 
0.76 0.13±0.01 0.66 0.10±0.01 0.82 0.21±0.04 0.96 0.01±0.00 
7.56 0.71±0.05 6.65 0.39±0.04 8.16 0.66±0.09 9.60 0.64±0.04 
75.60 0.91±0.07 66.48 0.92±0.09 81.60 0.89±0.09 96.00 0.91±0.09 
Drug concentrations (µM) treated in combination, effect means % cell death 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 CS 6-SG Effect Effect Effect 
0.05 0.38 0.21±0.02 0.19±0.02 0.12±0.01 
0.47 3.78 0.56±0.06 0.50±0.04 0.49±0.05 
4.72 37.80 0.92±0.09 0.91±0.08 0.90±0.04 
A2780
cisR
 CS 6-SG Effect Effect Effect 
0.20 0.33 0.17±0.02 0.07±0.01 0.09±0.00 
2.00 3.33 0.29±0.03 0.22±0.02 0.34±0.02 
20.00 33.24 0.93±0.08 0.92±0.06 0.92±0.09 
A2780
ZD0473R
 
 
CS 6-SG Effect Effect Effect 
0.25 0.41 0.38±0.02 0.11±0.01 0.09±0.01 
2.49 4.08 0.54±0.04 0.53±0.03 0.53±0.04 
24.92 40.80 0.90±0.12 0.90±0.07 0.89±0.08 
SKOV-3 CS 6-SG Effect Effect Effect 
0.36 0.48 0.01±0.00 0.01±0.00 0.03±0.00 
3.61 4.80 0.25±0.01 0.26±0.03 0.39±0.02 
36.04 48.00 0.92±0.11 0.93±0.01 0.91±0.11 
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a) A2780 
 
b) A2780
cisR
 
 
c) A2780
ZD0473R
 
 
d) SKOV-3 
 
Figure 3.5 Dose-response curves applying to CS and 6-SG alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between CS and 6-SG, it was found that the bolus 0/0 h 
combination showed highest number of cell kill compared to the two other sequences 
in the parent A2780 and cisplatin-resistant A2780
cisR
 ovarian cancer cell lines while 
4/0 h combination of CS and 6-SG showed the greatest number of cell kill against 
picoplatin-resistant A2780
ZD0473R
 and p53 null SKOV-3 tumour models.   
3.3.1.2 Dose-response of oxaliplatin (OX) with 6-shogaol 
(6-SG) 
Table 3.3 presents the dose-response values (fa) at three different concentrations of 
OX and 6-SG administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-
resistant A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.6 displays the 
corresponding dose-effect logarithmic line graphs. 
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Table 3.3: Fractions of the affected cell (fa) at three different concentrations of OX 
and 6-SG administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
OX (µM) Effect OX (µM) Effect OX (µM) Effect OX (µM) Effect 
0.05 0.20±0.01 0.10 0.35±0.03 0.08 0.23±0.02 6.00 0.19±0.01 
0.20 0.63±0.06 0.40 0.66±0.05 0.32 0.58±0.04 24.00 0.38±0.02 
0.80 0.73±0.08 1.60 0.75±0.04 1.28 0.70±0.06 96.00 0.79±0.01 
6-SG (µM) Effect 6-SG 
(µM) 
Effect 6-SG 
(µM) 
Effect 6-SG 
(µM) 
Effect 
1.89 0.15±0.01 1.50 0.34±0.03 2.60 0.27±0.01 3.00 0.01±0.00 
7.56 0.79±0.07 6.00 0.52±0.04 10.40 0.80±0.08 12.00 0.63±0.05 
30.24 0.93±0.01 24.00 0.91±0.09 41.60 0.94±0.04 48.00 0.94±0.06 
Drug concentrations (µM) treated in combination, effect means the percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 OX 6-SG Effect Effect Effect 
0.03 0.95 0.23±0.01 0.11±0.01 0.15±0.02 
0.10 3.78 0.58±0.04 0.51±0.05 0.68±0.05 
0.40 15.12 0.93±0.08 0.92±0.08 0.93±0.06 
A2780
cisR
 OX 6-SG Effect Effect Effect 
0.05 0.75 0.47±0.03 0.37±0.03 0.34±0.03 
0.20 3.00 0.52±0.04 0.56±0.06 0.55±0.03 
0.80 12.00 0.88±0.06 0.81±0.05 0.89±0.07 
A2780
ZD0473R
 
 
OX 6-SG Effect Effect Effect 
0.04 1.30 0.29±0.00 0.27±0.02 0.27±0.02 
0.16 5.20 0.64±0.05 0.59±0.05 0.67±0.06 
0.64 20.80 0.94±0.03 0.94±0.03 0.94±0.07 
SKOV-3 OX 6-SG Effect Effect Effect 
3.00 1.50 0.09±0.01 0.14±0.01 0.01±0.00 
12.00 6.00 0.53±0.04 0.60±0.06 0.62±0.05 
48.00 24.00 0.93±0.09 0.91±0.04 0.93±0.11 
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a) A2780 
 
b) A2780
cisR
 
 
c) A2780
ZD0473R
 
 
d) SKOV-3 
 
Figure 3.6: Dose-response curves applying to OX and 6-SG alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between OX and 6-SG, it was found that the 0/0 h 
combination (meaning 6-shogaol and oxaliplatin added at the same time) produced the 
highest number of cell kill (as compared to the two other sequences) against both the 
parent and cisplatin-resistant cell lines while 4/0 h combination (meaning 6-SG added 
first and OX four hours later) showed greatest number of cell kill against picoplatin-
resistant cell line and 0/4 h combination (meaning OX added first and 6-SG four 
hours later) produced the highest number of cell kill against p53 null ovarian cancer 
cell line. 
3.3.1.3 Dose-response of cisplatin (CS) with 
mycophenolic acid (MA) 
Table 3.4 presents the dose-response values (fa) at three different concentrations of CS 
and MA administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant 
A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.7 displays the corresponding 
dose-effect logarithmic line graphs. 
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Table 3.4: Fractions of the affected cell (fa) at three different concentrations of CS and 
MA administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
CS (µM) Effect CS (µM) Effect CS (µM) Effect CS (µM) Effect 
0.09 0.16±0.00 0.40 0.12±0.01 0.50 0.12±0.01 0.72 0.03±0.00 
0.94 0.47±0.04 4.00 0.27±0.03 4.98 0.44±0.02 7.21 0.36±0.02 
9.44 0.81±0.10 40.00 0.61±0.06 49.84 0.88±0.04 72.08 0.92±0.05 
MA (µM) Effect MA (µM) Effect MA (µM) Effect MA (µM) Effect 
0.15 0.10±0.00 0.11 0.13±0.01 0.11 0.32±0.02 0.62 0.18±0.02 
1.46 0.62±0.05 1.14 0.75±0.08 1.07 0.64±0.03 6.26 0.49±0.01 
14.56 0.77±0.07 11.44 0.81±0.10 10.72 0.80±0.09 62.64 0.92±0.07 
Drug concentrations (µM) treated in combination, effect means percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0h 0/4h 4/0h 
A2780 CS MA Effect Effect Effect 
0.05 0.075 0.06±0.00 0.05±0.00 0.13±0.01 
0.47 0.73 0.48±0.03 0.52±0.05 0.50±0.03 
4.72 7.28 0.75±0.06 0.75±0.04 0.72±0.06 
A2780
cisR
 CS MA Effect Effect Effect 
0.20 0.055 0.12±0.01 0.06±0.00 0.11±0.01 
2.00 0.57 0.70±0.06 0.45±0.02 0.65±0.04 
20.00 5.72 0.81±0.11 0.70±0.06 0.82±0.05 
A2780
ZD0473R
 
 
CS MA Effect Effect Effect 
0.25 0.055 0.07±0.00 0.08±0.01 0.11±0.01 
2.49 0.53 0.50±0.04 0.41±0.02 0.48±0.05 
24.92 5.36 0.80±0.05 0.84±0.07 0.77±0.04 
SKOV-3 CS MA Effect Effect Effect 
0.36 0.31 0.11±0.01 0.06±0.00 0.06±0.00 
3.61 3.13 0.45±0.05 0.59±0.04 0.49±0.03 
36.04 31.32 0.94±0.15 0.94±0.09 0.95±0.07 
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Figure 3.7: Dose-response curves applying to CS and MA alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between CS and MA, it was found that the 4/0 h 
combination (meaning mycophenolic acid added first then cisplatin four hours later) 
produced the highest number of cell kill in compare to the other sequences against 
ovarian A2780 parent and A2780
ZD0473R
 picoplatin-resistant cell lines. 0/0 h 
combination (meaning CS and MA added at the same time) showed the greatest 
number of cell kill against ovarian A2780
cisR
 cisplatin-resistant and SKOV-3 p53 null 
tumour models.  
3.3.1.4 Dose-response of oxaliplatin (OX) with 
mycophenolic acid (MA) 
Table 3.5 presents the dose-response values (fa) at three different concentrations of 
OX and MA administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-
resistant A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.8 displays the 
corresponding dose-effect logarithmic line graphs. 
  
 72 
Table 3.5: Fractions of the affected cell (fa) at three different concentrations of OX 
and MA administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
OX (µM) Effect OX (µM) Effect OX (µM) Effect OX (µM) Effect 
0.02 0.08±0.00 0.03 0.10±0.01 0.03 0.14±0.01 3.49 0.23±0.02 
0.16 0.35±0.02 0.29 0.45±0.04 0.33 0.48±0.04 34.88 0.62±0.02 
1.60 0.61±0.05 2.88 0.58±0.03 3.28 0.61±0.05 348.80 0.89±0.05 
MA (µM) Effect MA (µM) Effect MA (µM) Effect MA (µM) Effect 
0.15 0.06±0.00 0.11 0.08±0.01 0.11 0.03±0.00 0.63 0.30±0.01 
1.46 0.60±0.05 1.14 0.62±0.06 1.07 0.58±0.02 6.26 0.68±0.05 
14.56 0.67±0.04 11.44 0.66±0.04 10.72 0.67±0.01 62.64 0.88±0.02 
Drug concentrations (µM) treated in combination, effect means the percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 OX MA Effect Effect Effect 
0.01 0.075 0.01±0.00 0.04±0.00 0.03±0.00 
0.08 0.73 0.37±0.02 0.43±0.04 0.46±0.02 
0.80 7.28 0.67±0.01 0.66±0.04 0.69±0.03 
A2780
cisR
 OX MA Effect Effect Effect 
0.02 0.055 0.01±0.00 0.01±0.00 0.06±0.00 
0.15 0.57 0.44±0.02 0.41±0.03 0.44±0.04 
1.44 5.72 0.67±0.02 0.62±0.03 0.67±0.03 
A2780
ZD0473R
 
 
OX MA Effect Effect Effect 
0.02 0.055 0.01±0.00 0.08±0.00 0.07±0.00 
0.17 0.53 0.39±0.03 0.43±0.03 0.33±0.03 
1.64 5.36 0.70±0.05 0.68±0.05 0.72±0.06 
SKOV-3 OX MA Effect Effect Effect 
1.75 0.31 0.18±0.01 0.16±0.02 0.19±0.01 
17.44 3.13 0.50±0.05 0.57±0.05 0.61±0.04 
174.40 31.32 0.90±0.01 0.89±0.04 0.90±0.03 
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Figure 3.8: Dose-response curves applying to OX and MA alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between OX and MA, it was found that the 4/0 h 
combination (meaning mycophenolic acid added first followed by oxaliplatin four 
hours later) showed the highest number of cell kill (as compared to the other 
sequences) against A2780, A2780
cisR
 and SKOV-3 ovarian cancer cell lines. And 0/4 
h combination did the same against A2780
ZD0473R
 cell line. 
3.3.1.5 Dose-response of carboplatin (CB) with 
mycophenolic acid (MA) 
Table 3.6 presents the dose-response values (fa) at three different concentrations of 
CB and MA administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-
resistant A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.9 displays the 
corresponding dose-effect logarithmic line graphs. 
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Table 3.6: Fractions of the affected cell (fa) at three different concentrations of CB 
and MA administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) given alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
CB (µM) Effect CB (µM) Effect CB (µM) Effect CB (µM) Effect 
1.56 0.14± 0.01 3.30 0.12±0.01 4.33 0.16±0.02 5.48 0.17±0.01 
15.62 0.42±0.05 32.96 0.44±0.04 43.30 0.39±0.03 54.85 0.44±0.01 
156.16 0.86±0.06 329.60 0.84±0.08 432.96 0.80±0.05 548.48 0.89±0.06 
MA (µM) Effect MA (µM) Effect MA (µM) Effect MA (µM) Effect 
0.15 0.09±0.01 0.11 0.06±0.01 0.11 0.09±0.01 0.63 0.24±0.01 
1.46 0.62±0.06 1.14 0.52±0.05 1.07 0.56±0.04 6.26 0.45±0.04 
14.56 0.74±0.04 11.44 0.69±0.07 10.72 0.68±0.07 62.64 0.87±0.05 
Drug concentrations (µM) given in combination, effect means the percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 CB MA Effect Effect Effect 
0.78 0.075 0.11±0.01 0.13±0.01 0.05±0.01 
7.81 0.73 0.63±0.05 0.52±0.05 0.49±0.04 
78.08 7.28 0.85±0.09 0.79±0.10 0.84±0.06 
A2780
cisR
 CB MA Effect Effect Effect 
1.65 0.055 0.02±0.00 0.03±0.00 0.07±0.00 
16.48 0.57 0.52±0.04 0.48±0.04 0.48±0.01 
164.80 5.72 0.76±0.05 0.77±0.08 0.74±0.03 
A2780
ZD0473R
 
 
CB MA Effect Effect Effect 
2.17 0.055 0.01±0.00 0.01±0.00 0.06±0.00 
21.65 0.53 0.43±0.04 0.39±0.02 0.48±0.04 
216.48 5.36 0.81±0.06 0.81±0.05 0.82±0.06 
SKOV-3 CB MA Effect Effect Effect 
2.74 0.31 0.17±0.01 0.15±0.01 0.16±0.01 
27.43 3.13 0.50±0.03 0.50±0.04 0.48±0.03 
274.24 31.32 0.91±0.06 0.91±0.05 0.91±0.07 
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Figure 3.9: Dose-response curves applying to CB and MA alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between CB and MA, it was that the 4/0 h combination 
(meaning mycophenolic acid added first followed by carboplatin four hours later) that 
produced the highest cell kill as compared to the other sequences, against A2780 
parent and SKOV-3 p53 null cell lines. Bolus combination of MA and CB (meaning 
both drugs added at the same time) showed the greatest cell kill against A2780
cisR
 and 
A2780
ZD0473R
 ovarian cancer cell lines. 
3.3.1.6 Dose-response of cisplatin (CS) with honokiol 
(HK) 
Table 3.7 presents the dose-response values (fa) at three different concentrations of CS 
and HK administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant 
A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.10 displays the corresponding 
dose-effect logarithmic line graphs. 
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Table 3.7: Fractions of the affected cell (fa) at three different concentrations of CS and 
HK administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
CS (µM) Effect CS (µM) Effect CS (µM) Effect CS (µM) Effect 
0.24 0.27±0.02 0.80 0.08±0.01 1.25 0.23±0.02 1.80 0.01±0.00 
0.94 0.60±0.04 3.20 0.37±0.03 4.98 0.38±0.02 7.21 0.43±0.04 
3.78 0.73±0.05 12.80 0.66±0.03 19.94 0.69±0.06 28.83 0.92±0.06 
HK (µM) Effect HK (µM) Effect HK (µM) Effect HK (µM) Effect 
5.00 0.01±0.00 4.40 0.05±0.00 6.00 0.05±0.00 8.00 0.05±0.00 
20.00 0.20±0.02 17.60 0.28±0.01 24.00 0.44±0.03 32.00 0.53±0.11 
80.00 0.93±0.10 70.40 0.93±0.11 96.00 0.88±0.08 128.00 0.90±0.04 
Drug concentrations (µM) treated in combination, effect means the percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 CS HK Effect Effect Effect 
0.12 2.50 0.17±0.00 0.18±0.01 0.09±0.01 
0.47 10.00 0.24±0.02 0.37±0.04 0.36±0.03 
1.89 40.00 0.92±0.12 0.93±0.05 0.92±0.11 
A2780
cisR
 CS HK Effect Effect Effect 
0.40 2.20 0.18±0.01 0.13±0.01 0.01±0.00 
1.60 8.80 0.22±0.02 0.23±0.01 0.32±0.00 
6.40 35.20 0.79±0.02 0.71±0.03 0.77±0.05 
A2780
ZD0473R
 
 
CS HK Effect Effect Effect 
0.62 3.00 0.07±0.01 0.15±0.01 0.04±0.00 
2.49 12.00 0.30±0.01 0.37±0.03 0.34±0.03 
9.97 48.00 0.86±0.08 0.83±0.14 0.86±0.14 
SKOV-3 CS HK Effect Effect Effect 
0.90 4.00 0.05±0.00 0.06±0.00 0.01±0.00 
3.60 16.00 0.21±0.02 0.30±0.01 0.29±0.02 
14.42 64.00 0.92±0.09 0.91±0.06 0.91±0.07 
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Figure 3.10: Dose-response curves applying to CS and HK alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between CS and HK, it was found that the 0/4 h 
combination (meaning cisplatin added first then honokiol four hours later) produced 
the greatest number of cell kill (as compared to the two other sequences) against 
parent, picoplatin-resistant and p53 null ovarian cancer cell lines while the bolus 0/0 h 
combination of CS and HK showed highest number of cell kill against cisplatin-
resistant cell line.   
3.3.1.7 Dose-response of oxaliplatin (OX) with honokiol 
(HK) 
Table 3.8 presents the dose-response values (fa) at three different concentrations of 
OX and HK administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-
resistant A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.11 displays the 
corresponding dose-effect logarithmic line graphs. 
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Table 3.8: Fractions of the affected cell (fa) at three different concentrations of OX 
and HK administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
OX (µM) Effect OX (µM) Effect OX (µM) Effect OX (µM) Effect 
0.02 0.08±0.00 0.03 0.10±0.01 0.03 0.14±0.01 3.49 0.23±0.02 
0.16 0.35±0.02 0.29 0.45±0.04 0.33 0.48±0.04 34.88 0.62±0.02 
1.60 0.61±0.05 2.88 0.58±0.03 3.28 0.61±0.05 348.80 0.89±0.05 
HK (µM) Effect HK (µM) Effect HK (µM) Effect HK (µM) Effect 
1.77 0.01±0.00 1.46 0.04±0.00 2.36 0.04±0.00 3.13 0.04±0.00 
17.68 0.02±0.00 14.57 0.08±0.01 23.61 0.30±0.03 31.33 0.46±0.02 
176.80 0.85±0.01 145.68 0.81±0.03 236.08 0.75±0.10 313.28 0.89±0.05 
Drug concentrations (µM) treated in combination, effect means the percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 OX HK Effect Effect Effect 
0.01 0.88 0.01±0.00 0.01±0.00 0.01±0.00 
0.08 8.84 0.02±0.00 0.05±0.00 0.02±0.00 
0.80 88.40 0.87±0.02 0.86±0.03 0.84±0.03 
A2780
cisR
 OX HK Effect Effect Effect 
0.02 0.73 0.01±0.00 0.01±0.00 0.01±0.00 
0.15 7.24 0.02±0.00 0.05±0.00 0.09±0.00 
1.44 72.84 0.83±0.03 0.83±0.04 0.80±0.04 
A2780
ZD0473R
 
 
OX HK Effect Effect Effect 
0.02 1.18 0.01±0.00 0.01±0.00 0.00±0.00 
0.17 11.81 0.22±0.02 0.24±0.01 0.19±0.01 
1.64 118.04 0.78±0.10 0.78±0.11 0.74±0.10 
SKOV-3 OX HK Effect Effect Effect 
1.75 1.57 0.08±0.00 0.02±0.00 0.08±0.01 
17.44 15.67 0.28±0.02 0.24±0.02 0.24±0.03 
174.40 156.64 0.91±0.08 0.91±0.07 0.89±0.05 
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Figure 3.11: Dose-response curves applying to OX and HK alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between OX and HK, it was found that the 0/4 h 
combination (meaning oxaliplatin added first followed by honokiol four hours later) 
produced the highest number of cell kill (as compared to the two other sequences) 
against parent A2780 and picoplatin-resistant A2780
ZD0473R
 cell lines while 4/0 h and 
0/0 h combinations produced the greatest cell kill against cisplatin-resistant A2780
cisR 
and p53 null SKOV-3 ovarian cancer cell lines respectively.  
3.3.1.8 Dose-response of carboplatin (CB) with honokiol 
(HK) 
Table 3.9 presents the dose-response values (fa) at three different concentrations of CS 
and 6-SG administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-
resistant A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.12 displays the 
corresponding dose-effect logarithmic line graphs. 
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Table 3.9: Fractions of the affected cell (fa) at three different concentrations of CB 
and HK administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
CB (µM) Effect CB (µM) Effect CB (µM) Effect CB (µM) Effect 
1.56 0.14± 0.01 3.30 0.12±0.01 4.33 0.16±0.02 5.48 0.17±0.01 
15.62 0.42±0.05 32.96 0.44±0.04 43.30 0.39±0.03 54.85 0.44±0.01 
156.16 0.86±0.06 329.60 0.84±0.08 432.96 0.80±0.05 548.48 0.89±0.06 
HK (µM) Effect HK 
(µM) 
Effect HK (µM) Effect HK (µM) Effect 
1.77 0.01±0.00 1.46 0.01±0.00 2.36 0.05±0.00 3.13 0.08±0.00 
17.68 0.02±0.00 14.57 0.02±0.00 23.61 0.38±0.04 31.33 0.22±0.01 
176.80 0.86±0.05 145.68 0.88±0.11 236.08 0.80±0.06 313.28 0.90±0.06 
Drug concentrations (µM) treated in combination, effect means the percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 CB HK Effect Effect Effect 
0.78 0.088 0.04±0.01 0.02±0.00 0.05±0.01 
7.81 8.81 0.32±0.02 0.35±0.01 0.20±0.01 
78.08 88.4 0.89±0.09 0.89±0.08 0.86±0.08 
A2780
cisR
 CB HK Effect Effect Effect 
1.65 0.73 0.01±0.00 0.01±0.00 0.04±0.00 
16.48 7.28 0.25±0.01 0.27±0.01 0.25±0.01 
164.80 72.84 0.90±0.10 0.90±0.09 0.88±0.08 
A2780
ZD0473R
 
 
CB HK Effect Effect Effect 
2.17 1.18 0.01±0.00 0.02±0.00 0.09±0.01 
21.65 11.8 0.35±0.03 0.23±0.02 0.25±0.02 
216.48 118.04 0.83±0.06 0.83±0.04 0.80±0.05 
SKOV-3 CB HK Effect Effect Effect 
2.74 1.56 0.07±0.00 0.06±0.00 0.08±0.00 
27.43 15.66 0.31±0.01 0.26±0.01 0.30±0.02 
274.24 156.64 0.91±0.07 0.91±0.05 0.90±0.03 
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a) A2780 
 
b) A2780cisR 
 
c) A2780ZD0473R 
 
d) SKOV-3 
 
Figure 3.12: Dose-response curves applying to CB and HK alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between CB and HK, it was that the bolus 0/0 h 
combination (meaning concurrent administration of both drugs) showed the greatest 
number of cell kill as compared to the other sequences against parent A2780 and p53 
null SKOV-3 ovarian cancer cell lines. Moreover, 4/0 h combination of CB with HK 
meaning (honokiol added first followed by carboplatin four hours later) produced the 
highest number of cell kill against cisplatin-resistant A2780
cisR
 and picoplatin-
resistant A2780
ZD0473R
 ovarian cancer tumour models. 
3.3.1.9 Dose-response of cisplatin (CS) with 
cholecalciferol (CC) 
Table 3.10 presents the dose-response values (fa) at three different concentrations of 
CS and CC administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-
resistant A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.13 displays the 
corresponding dose-effect logarithmic line graphs. 
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Table 3.10: Fractions of the affected cell (fa) at three different concentrations of CS 
and CC administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
CS (µM) Effect CS (µM) Effect CS (µM) Effect CS (µM) Effect 
0.24 0.27±0.02 0.80 0.08±0.01 1.25 0.23±0.02 1.80 0.01±0.00 
0.94 0.60±0.04 3.20 0.37±0.03 4.98 0.38±0.02 7.21 0.43±0.04 
3.78 0.73±0.05 12.80 0.66±0.03 19.94 0.69±0.06 28.83 0.92±0.06 
CC (µM) Effect CC (µM) Effect CC (µM) Effect CC (µM) Effect 
3.51 0.12±0.01 4.40 0.12±0.01 2.65 0.01±0.00 10.00 0.05±0.00 
14.06 0.26±0.02 17.60 0.34±0.03 10.59 0.13±0.01 40.00 0.35±0.03 
56.25 0.93±0.09 70.40 0.92±0.11 42.37 0.89±0.06 160.00 0.92±0.07 
Drug concentrations (µM) treated in combination, effect means the percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 CS CC Effect Effect Effect 
0.12 1.75 0.10±0.01 0.16±0.01 0.19±0.01 
0.47 7.03 0.45±0.01 0.41±0.01 0.38±0.03 
1.89 28.13 0.84±0.08 0.78±0.09 0.82±0.02 
A2780
cisR
 CS CC Effect Effect Effect 
0.40 2.20 0.24±0.02 0.24±0.02 0.12±0.01 
1.60 8.80 0.36±0.03 0.34±0.01 0.31±0.02 
6.40 35.20 0.78±0.07 0.74±0.04 0.78±0.08 
A2780
ZD0473R
 
 
CS CC Effect Effect Effect 
0.62 1.33 0.12±0.01 0.13±0.01 0.09±0.01 
2.49 5.30 0.21±0.02 0.36±0.03 0.32±0.02 
9.97 21.19 0.48±0.03 0.48±0.03 0.42±0.04 
SKOV-3 CS CC Effect Effect Effect 
0.90 5.00 0.09±0.01 0.08±0.00 0.06±0.00 
3.60 20.00 0.34±0.01 0.41±0.03 0.34±0.01 
14.42 80.00 0.92±0.09 0.93±0.05 0.93±0.08 
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b) A2780
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Figure 3.13: Dose-response curves applying to CS and CC alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines  
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As applied to the combination between CS and CC, it was found that the 4/0 h 
combination (meaning cholecalciferol added first followed by cisplatin four hours 
later) produced the highest number of cell kill in compare to the other sequences 
against parent ovarian cancer cell line. Besides, bolus 0/0 h combination (meaning CS 
and CC added at the same time) produced the greatest cell kill against cisplatin-
resistant cell line while 0/4 h combination (meaning CS added first then CC four 
hours later) showed greatest cell kill against picoplatin-resistant A2780
ZD0473R 
and p53 
null SKOV-3 ovarian cancer cell lines in comparison to the other combinations.  
3.3.1.10 Dose-response of oxaliplatin (OX) with 
cholecalciferol (CC) 
Table 3.11 presents the dose-response values (fa) at three different concentrations of 
OX and CC administered alone and in combination using 0/0 h, 0/4 h and 4/0 h 
sequences applied to ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-
resistant A2780
ZD0473R
 and p53 null SKOV-3 cell lines. Figure 3.14 displays the 
corresponding dose-effect logarithmic line graphs. 
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Table 3.11: Fractions of the affected cell (fa) at three different concentrations of OX 
and CC administered alone and in combination using 0/0 h, 0/4 h and 4/0 h sequences 
applied to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines 
Drug concentrations (µM) treated alone 
A2780 A2780
cisR
 A2780
ZD0473R
 SKOV-3 
OX (µM) Effect OX (µM) Effect OX (µM) Effect OX (µM) Effect 
0.05 0.20±0.01 0.10 0.35±0.03 0.08 0.23±0.02 6.00 0.19±0.01 
0.20 0.63±0.06 0.40 0.66±0.05 0.32 0.58±0.04 24.00 0.38±0.02 
0.80 0.73±0.08 1.60 0.75±0.04 1.28 0.70±0.06 96.00 0.79±0.01 
CC (µM) Effect CC (µM) Effect CC (µM) Effect CC (µM) Effect 
3.51 0.07±0.00 4.40 0.15±0.01 2.65 0.10±0.01 10.00 0.01±0.00 
14.06 0.26±0.02 17.60 0.36±0.03 10.59 0.31±0.01 40.00 0.34±0.02 
56.22 0.94±0.03 70.40 0.92±0.10 42.37 0.87±0.08 160.00 0.95±0.05 
Drug concentrations (µM) treated in combination, effect means the percentage of cell kill 
Cell line Drug concentration 
(µM) 
Time schedule 
0/0 h 0/4 h 4/0 h 
A2780 OX CC Effect Effect Effect 
0.03 1.75 0.10±0.01 0.14±0.01 0.01±0.00 
0.10 7.03 0.31±0.03 0.18±0.01 0.37±0.01 
0.40 28.11 0.81±0.12 0.73±0.02 0.73±0.00 
A2780
cisR
 OX CC Effect Effect Effect 
0.05 2.20 0.21±0.01 0.25±0.01 0.21±0.01 
0.20 8.80 0.56±0.03 0.53±0.05 0.52±0.03 
0.80 35.40 0.81±0.03 0.80±0.07 0.78±0.07 
A2780
ZD0473R
 
 
OX CC Effect Effect Effect 
0.04 1.33 0.25±0.02 0.19±0.01 0.15±0.01 
0.16 5.30 0.53±0.04 0.40±0.03 0.41±0.04 
0.64 21.18 0.75±0.03 0.72±0.04 0.71±0.06 
SKOV-3 OX CC Effect Effect Effect 
3.00 5.00 0.17±0.02 0.09±0.01 0.14±0.01 
12.00 20.00 0.21±0.02 0.27±0.01 0.32±0.02 
48.00 160.00 0.95±0.11 0.95±0.15 0.94±0.02 
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b) A2780
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Figure 3.14: Dose-response curves applying to OX and CC alone and in combination 
using 0/0 h, 0/4 h and 4/0 sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 cell lines 
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As applied to the combination between OX and CC, it was found that the bolus 0/0 h 
combination produced the greatest cell kill (as compared to the two other sequences) 
against A2780 parent and A2780
ZD0473R
 picoplatin-resistant cell lines while 0/4 h and 
4/0 h combinations of oxaliplatin and cholecalciferol showed the greatest number of 
cell kill against A2780
cisR
 cisplatin-resistant and SKOV-3 p53 null cell lines 
respectively.  
3.3.2 Combination indices (CI) 
Combination indices (CI) provide a quantitative measure of the nature of the 
combined drug action. It is defined as the sum of the concentration ratios of the 
component drugs present in combination and when acting alone to produce 50% cell 
kill. In addition, CI less than 1 means the combination is synergistic, a value equal to 
1 means it is additive and a value greater than 1 means that the combination is 
antagonistic.    
3.3.2.1 The combination between cisplatin (CS) and 6-
shogaol (6-SG) 
Table 3.12 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of CS and 6-SG using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Note: Median effective dose (Dm), exponent 
defining the shape of the dose-response curve (m) and reliability coefficient (r). 
Figure 3.15 shows the corresponding bar diagram at ED50.  
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Table 3.12: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
CS and 6-SG administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug Sequence 
Molar 
ratio 
CI values at 
Dm m r 
ED50 ED75 ED90 
A2780 
CS N/A N/A N/A 1.09 0.67 1.00 
6-SG N/A N/A N/A 4.71 0.92 0.98 
CS + 6-SG  0/0h 
1:8.44 
0.75 0.75 0.78 0.28 0.83 1.00 
CS + 6-SG  0/4h 0.92 0.92 0.95 0.34 0.83 0.99 
CS + 6-SG  4/0h 1.23 1.07 0.97 0.45 0.92 1.00 
A2780
cisR
 
CS N/A N/A N/A 19.77 0.53 0.99 
6-SG N/A N/A N/A 7.09 1.01 0.99 
CS + 6-SG  0/0h 
1:1.65 
0.54 0.55 0.59 1.92 0.91 0.93 
CS + 6-SG  0/4h 0.87 0.71 0.62 3.08 1.09 0.96 
CS + 6-SG  4/0h 0.67 0.58 0.54 2.38 1.03 0.98 
A2780
ZD0473R
 
CS N/A N/A N/A 5.47 0.87 1.00 
6-SG N/A N/A N/A 4.30 0.74 1.00 
CS + 6-SG  0/0h 
1:1.64 
0.48 0.78 1.27 0.86 0.58 0.96 
CS + 6-SG  0/4h 1.30 1.03 0.83 2.30 0.93 1.00 
CS + 6-SG  4/0h 1.46 1.13 0.88 2.58 0.96 1.00 
SKOV-3 
CS N/A N/A N/A 10.94 1.28 1.00 
6-SG N/A N/A N/A 14.03 1.50 0.96 
CS + 6-SG  0/0h 
1:1.33 
1.36 1.27 1.19 7.33 1.53 1.00 
CS + 6-SG  0/4h 1.29 1.18 1.09 6.93 1.56 1.00 
CS + 6-SG  4/0h 1.03 1.12 1.22 5.52 1.26 1.00 
 
 
Figure 3.15: CI values at ED50 applying to the binary combinations of CS and 6-SG 
using 0/0 h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 tumour models 
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Combinations of CS and 6-SG as applied to the A2780 cell line, 0/0 h and 0/4 h found 
to be weakly synergistic at all added concentrations. Whereas 4/0 h combination of 
CS with 6-SG was antagonistic at ED50 but additive at ED90.  
As applied to the combinations of CS and 6-SG in A2780
cisR
cell line, 0/0 h and 4/0 h 
sequences of administration found to be moderately synergistic and 0/4 h sequence is 
mild synergistic. However, the degree of synergism increases with the increase of 
concentrations in 4/0 h and 0/4 h sequences of administration.  
In A2780
ZD0473R
 cell line, the combination of CS and 6-SG with the 0/0 h sequence of 
administration found to be moderately synergistic at ED50 and ED75 levels but 
antagonistic at ED90 level. Besides, 0/4 h sequence of administration showed 
antagonistic activity at the ED50 level, additiveness at ED75 but slightly synergistic at 
ED90. Moreover, 4/0 h sequence of administration was antagonistic at ED50 and ED75 
levels but synergistic at ED90.  
The combination of CS and 6-SG as applied to the SKOV-3 cell line, all of the 
sequences of administration found to display antagonism at all added concentrations 
except 4/0 h sequence at ED50 which showed additiveness. 
3.3.2.2 Combination between oxaliplatin (OX) and 6-
shogaol (6-SG) 
Table 3.13 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of OX and 6-SG using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.16 shows the corresponding bar 
diagram at ED50. 
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Table3.13: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
OX and 6-SG administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug Sequence 
Molar 
ratio 
CI values at 
Dm m r 
ED50 ED75 ED90 
A2780 
OX N/A N/A N/A 0.19 0.86 0.94 
6-SG N/A N/A N/A 4.75 1.56 0.97 
OX + 6-SG  0/0h 
1:37.8 
0.96 0.82 0.76 0.07 1.47 1.00 
OX + 6-SG  0/4h 1.31 1.00 0.81 0.10 1.75 1.00 
OX + 6-SG  4/0h 1.02 0.81 0.68 0.08 1.66 0.99 
A2780
cisR
 
OX N/A N/A N/A 0.22 0.62 0.96 
6-SG N/A N/A N/A 3.51 1.07 0.96 
OX + 6-SG  0/0h 
1:15.0 
0.76 0.84 1.04 0.09 0.76 0.91 
OX + 6-SG  0/4h 1.04 1.26 1.73 0.12 0.71 0.99 
OX + 6-SG  4/0h 1.03 0.81 0.73 0.12 0.99 0.98 
A2780
ZD0473R
 
OX N/A N/A N/A 0.33 0.74 0.96 
6-SG N/A N/A N/A 4.79 1.35 0.99 
OX + 6-SG  0/0h 
1:32.5 
0.85 0.74 0.69 0.09 1.32 0.99 
OX + 6-SG  0/4h 0.93 0.79 0.72 0.09 1.35 0.99 
OX + 6-SG  4/0h 0.86 0.73 0.66 0.09 1.35 1.00 
SKOV-3 
OX N/A N/A N/A 29.45 1.00 0.98 
6-SG N/A N/A N/A 14.15 2.65 0.97 
OX + 6-SG  0/0h 
1:0.5 
0.77 0.72 0.74 11.14 1.77 1.00 
OX + 6-SG  0/4h 0.68 0.71 0.82 9.80 1.49 1.00 
OX + 6-SG  4/0h 1.01 0.77 0.65 14.59 2.59 0.97 
 
 
Figure 3.16: CI values at ED50 applying to the binary combinations of OX and 6-SG 
using 0/0 h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 tumour models  
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The combination of OX and 6-SG as applied to A2780 cell line, 0/0 h and 4/0 h 
sequences of administration were found to be additive at ED50 but slightly synergistic 
at ED75 and ED90. However, 0/4 h sequence of administration showed antagonism at 
ED50, additiveness at ED75 and weakly synergism at ED90.  
As applied to the combination of OX and 6-SG in cisplatin-resistant cell line, 0/0 h 
sequence of administration found to be slightly synergistic at ED50 and ED75 but 
additive at ED90. In addition, 0/4 h sequence showed additiveness at ED50 but 
antagonistic at ED75 and ED90. Besides, this combination with the 4/0 h sequence of 
administration was shown to be additive at ED50 and slightly synergistic at ED75 and 
ED90.  
In picoplatin resistant cell line, combination of OX with 6-SG showed weak to 
moderate synergism at all three modes of administration. However, the degree of 
synergism increases with the increase in concentration.  
Combination of OX with 6-SG as applied to the p53 null cell line, 0/0 h and 0/4 h 
sequences of administration were found to be weak to moderate synergistic at all 
concentrations. Besides, 4/0 h modes of administration showed additiveness at ED50 
but displayed weakly synergism at higher concentrations.  
3.3.2.3 Combination between cisplatin (CS) and 
mycophenolic acid (MA)  
Table 3.14 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of CS and MA using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.17 shows the corresponding bar 
diagram at ED50. 
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Table 3.14: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
CS and MA administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug Sequence 
Molar 
ratio 
CI values at 
Dm m R 
ED50 ED75 ED90 
A2780 
CS N/A N/A N/A 1.09 0.67 1.00 
MA N/A N/A N/A 1.84 0.74 0.95 
CS + MA  0/0h 
1:1.67 
1.73 1.34 1.04 0.95 0.84 0.97 
CS + MA  0/4h 1.70 1.24 0.90 0.93 0.89 0.96 
CS + MA  4/0h 1.46 1.78 2.19 0.80 0.62 0.98 
A2780
cisR
 
CS N/A N/A N/A 19.77 0.53 0.99 
MA N/A N/A N/A 0.84 0.72 0.91 
CS + MA  0/0h 
1:0.275 
0.66 0.59 0.55 1.75 0.75 0.94 
CS + MA  0/4h 1.86 1.57 1.35 4.91 0.78 0.97 
CS + MA  4/0h 0.74 0.62 0.54 1.96 0.78 0.96 
A2780
ZD0473R
 
CS N/A N/A N/A 5.47 0.87 1.00 
MA N/A N/A N/A 0.46 0.47 0.99 
CS + MA  0/0h 
1:0.22 
2.64 1.38 0.95 3.96 0.86 0.99 
CS + MA  0/4h 2.55 1.28 0.85 3.83 0.89 1.00 
CS + MA  4/0h 2.59 1.76 1.57 3.90 0.72 0.99 
SKOV-3 
CS N/A N/A N/A 10.94 1.28 1.00 
MA N/A N/A N/A 4.42 0.86 0.99 
CS + MA  0/0h 
1:0.86 
0.89 0.82 0.79 3.12 1.05 0.99 
CS + MA  0/4h 0.93 0.76 0.65 3.26 1.19 1.00 
CS + MA  4/0h 0.99 0.78 0.64 3.46 1.24 1.00 
 
 
Figure 3.17: CI values at ED50 applying to the binary combinations CS and MA using 
0/0 h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 tumour models 
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As applied to the combination of CS and MA in A2780 cell line, 0/0 h and 0/4 h 
sequences of administration were found to be antagonistic at ED50 and ED75 but 
additive at ED90. Likewise, 4/0 h sequence of administration also showed antagonism 
with all concentrations and the degree of antagonism increase with the higher 
concentrations.  
In A2780
cisR
 cell line, combination of CS and MA with the 0/0 h and 4/0 h sequences 
of administration were exhibited moderate synergism and the degree of synergism 
found to be increased with the increasing concentrations. On the other hand, 0/4 h was 
shown antagonism at lower concentration but the degree of antagonism was found to 
be decreased with the increase of the concentration of added drugs. 
As applied to the combination between CS and MA in A2780
ZD0473R
 cell line, all three 
consequences of administration found to be highly antagonistic at ED50 and 
moderately antagonistic at ED75. However, 0/0 h and 0/4 h consequences of 
administration were shown mild synergism at ED90 while 4/0 h was antagonistic.  
All three sequences of administration of combination between CS and MA as applied 
to the SKOV-3 were found to be weakly synergistic at ED50. Also, the degree of 
synergism was increased further at ED75 and ED90 levels.  
3.3.2.4 Combination between oxaliplatin (OX) and 
mycophenolic acid (MA) 
Table 3.15 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of OX and MA using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.18 shows the corresponding bar 
diagram at ED50. 
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Table 3.15: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
OX and MA administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug Sequence 
Molar 
ratio 
CI values at 
Dm m R 
ED50 ED75 ED90 
A2780 
OX N/A N/A N/A 0.65 0.66 0.98 
MA N/A N/A N/A 3.03 0.76 0.90 
OX + MA  0/0h 
1:7.5 
1.18 0.64 0.35 0.29 1.20 0.95 
OX + MA  0/4h 1.01 0.77 0.60 0.25 0.87 0.95 
OX + MA  4/0h 0.92 0.62 0.42 0.23 0.97 0.94 
A2780
cisR
 
OX N/A N/A N/A 1.03 0.55 0.95 
MA N/A N/A N/A 2.14 0.67 0.89 
OX + MA  0/0h 
1:3.67 
1.35 0.57 0.25 0.50 1.22 0.93 
OX + MA  0/4h 1.56 0.69 0.31 0.58 1.17 0.92 
OX + MA  4/0h 1.13 0.77 0.54 0.42 0.80 0.96 
A2780
ZD0473R
 
OX N/A N/A N/A 0.87 0.48 0.96 
MA N/A N/A N/A 2.64 0.91 0.90 
OX + MA  0/0h 
1:3.67 
1.41 0.73 0.45 0.55 1.23 0.95 
OX + MA  0/4h 1.12 1.08 1.26 0.44 0.72 0.98 
OX + MA  4/0h 1.20 1.00 1.01 0.47 0.80 1.00 
SKOV-3 
OX N/A N/A N/A 18.43 0.72 1.00 
MA N/A N/A N/A 2.25 0.62 1.00 
OX + MA  0/0h 
1:0.18 
1.77 1.30 0.96 13.18 0.81 0.99 
OX + MA  0/4h 1.75 1.27 0.93 13.03 0.81 1.00 
OX + MA  4/0h 1.42 1.06 0.81 10.56 0.79 1.00 
 
 
Figure 3.18: CI values at ED50 applying to the binary combinations of OX and MA 
administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3 tumour models 
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The combination of OX with MA as applied to the A2780 parent cell line; all 
sequences of administration were shown additiveness to weak antagonism at ED50 but 
moderate synergism at higher concentrations. However, the degree of synergism 
increases with the increase of added drug concentrations.  
In A2780
cisR
 cell line, all of the sequences of administration from combination of OX 
with MA displayed antagonism at ED50, moderate synergism at ED75 and high 
synergism at ED90.  
As applied to the combination of OX with MA against A2780
ZD0473R
 cell line, all of 
three modes of administration were exhibited antagonism at ED50. However, at higher 
concentrations bolus administration showed slight synergism, 0/4 h sequence of 
administration displayed antagonism, and 4/0 sequence of administration showed 
additiveness.  
The combination of OX and MA as applied to the SKOV-3 cell line, all modes of 
administration displayed antagonism at ED50 and ED75 concentrations but additiveness 
at ED90. 
3.3.2.5 Combination between carboplatin (CB) and 
mycophenolic acid (MA) 
 Table 3.16 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of CB and MA using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.19 shows the corresponding bar 
diagram at ED50. 
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Table 3.16: CI values at ED50, ED75 and ED90 applying to sequenced combinations of CB 
and MA administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 tumour models 
Cell line Drug 
Sequence 
(h) 
Molar 
ratio 
CI values at 
Dm m r 
ED50 ED75 ED90 
A2780 
CB N/A N/A N/A 17.90 0.79 0.99 
MA N/A N/A N/A 2.10 0.73 0.93 
CB + MA  0/0h 
1:0.1 
0.75 0.67 0.60 7.27 0.83 0.98 
CB + MA  0/4h 1.02 1.16 1.33 9.88 0.70 0.99 
CB + MA  4/0h 1.26 0.89 0.64 12.15 1.00 0.99 
A2780
cisR
 
CB N/A N/A N/A 42.00 0.79 1.00 
MA N/A N/A N/A 2.55 0.77 0.95 
CB + MA  0/0h 
1:0.03 
1.32 0.88 0.59 37.02 1.10 0.95 
CB + MA  0/4h 1.27 0.92 0.67 35.58 1.02 0.97 
CB + MA  4/0h 1.16 1.15 1.14 32.70 0.79 0.98 
A2780
ZD0473R
 
CB N/A N/A N/A 62.23 0.66 0.99 
MA N/A N/A N/A 2.08 0.67 0.93 
CB + MA  0/0h 
1:0.03 
1.57 0.70 0.31 51.71 1.31 0.97 
CB + MA  0/4h 1.64 0.73 0.32 53.92 1.31 0.98 
CB + MA  4/0h 1.06 0.66 0.42 34.76 0.93 0.99 
SKOV-3 
CB N/A N/A N/A 49.11 0.80 0.99 
MA N/A N/A N/A 51.64 1.01 0.96 
CB + MA  0/0h 
1:0.11 
0.89 0.72 0.59 20.58 0.85 0.99 
CB + MA  0/4h 0.96 0.73 0.57 22.01 0.88 1.00 
CB + MA  4/0h 0.95 0.75 0.60 21.95 0.86 0.99 
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Figure 3.19: CI values at ED50 applying to the binary combinations of CB and MA using 0/0 
h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R
 and 
SKOV-3 tumour models 
Combination of CB with MA as applied to A2780 cell line has been exhibited weak 
synergism, additiveness, antagonism with 0/0 h, 0/4 h and 4/0 h sequences of 
administration respectively. However, the degree of synergism was found to increase 
with the increase in concentration with the 0/0 h and 4/0 h sequences of 
administration, such concentration-dependent change in combined drug action was 
not observed for 0/4 h sequence of administration.  
As applied to the combination of CB and MA in A2780
cisR
 cell line, 0/0 h and 0/4 h 
sequences of administration were found to be antagonistic at ED50, additive at ED75 
and synergistic at ED90. But 4/0 h sequence of administration remained antagonistic 
with the increasing concentrations.  
The combination of CB and MA as applied to the A2780
ZD0473R 
cell line, 0/0 h and 0/4 
h sequences of administration were shown to be antagonistic but the 4/0 h sequence 
was additive at ED50. However, all three sequences of administration were moderately 
synergistic at ED75 and significantly synergistic at ED90.  
As applied to the combination of CB and MA in SKOV-3 ovarian cancer cell line, all 
three sequences of administration exhibited to be additive at ED50 and synergistic at 
ED75 and ED90. 
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3.3.2.6 Combination between cisplatin (CS) and honokiol 
(HK) 
Table 3.17 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of CS and HK using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.20 shows the corresponding bar 
diagram at ED50. 
Table 3.17: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
CS and HK administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug Sequence 
Molar 
ratio 
CI values at 
Dm m r 
ED50 ED75 ED90 
A2780 
CS N/A N/A N/A 0.79 0.72 0.97 
HK N/A N/A N/A 30.96 2.59 1.00 
CS + HK  0/0h 
1:20.83 
0.99 0.77 0.79 0.51 1.46 0.91 
CS + HK  0/4h 0.82 0.63 0.64 0.42 1.49 0.96 
CS + HK  4/0h 1.01 0.70 0.64 0.52 1.73 0.99 
A2780
cisR
 
CS N/A N/A N/A 6.37 1.12 0.99 
HK N/A N/A N/A 21.88 1.99 0.99 
CS + HK  0/0h 
1:5.5 
1.05 1.53 2.32 2.57 1.02 0.90 
CS + HK  0/4h 1.36 2.01 3.10 3.33 1.01 0.96 
CS + HK  4/0h 1.26 1.07 0.93 3.09 2.09 0.98 
A2780
ZD0473R
 
CS N/A N/A N/A 7.54 0.73 0.99 
HK N/A N/A N/A 30.01 1.78 1.00 
CS + HK  0/0h 
1:4.82 
1.03 0.81 0.74 3.50 1.58 0.99 
CS + HK  0/4h 0.88 0.87 1.01 3.01 1.20 0.99 
CS + HK  4/0h 1.06 0.77 0.65 3.62 1.80 1.00 
SKOV-3 
CS N/A N/A N/A 9.92 2.54 0.99 
HK N/A N/A N/A 35.82 1.85 0.99 
CS + HK  0/0h 
1:4.44 
1.11 1.16 1.23 4.93 1.94 0.97 
CS + HK  0/4h 1.02 1.11 1.22 4.55 1.83 0.99 
CS + HK  4/0h 1.24 1.15 1.07 5.51 2.49 1.00 
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Figure 3.20: CI values at ED50 applying to the binary combinations of CS and HK 
using 0/0 h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 tumour models 
 The combination of CS and HK as applied to the A2780 cell line, slightly synergistic 
to additive at ED50 but showed moderate synergism at higher concentrations.  
As applied to the combination of CS and HK in A2780
cisR
 cell line, all sequences of 
administration were found to be weak to strong antagonistic except 4/0 h showed 
additiveness at ED90.  
In A2780
ZD0473R 
cell line, combinations of CS and HK with the 0/0 h and 4/0 h 
sequences of administration were shown to be additive at ED50 but moderately 
synergistic at ED75 and ED90. Furthermore, 0/4 h sequence of administration found to 
be slightly synergistic at ED50 and ED75 and additive at ED90.  
As applied to the combination of cisplatin and honokiol in SKOV-3 cell line, all 
sequences of administration were exhibited mild antagonism except 0/4 h sequence at 
ED50 (additive).  
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3.3.2.7 Combination between oxaliplatin (OX) and 
honokiol (HK) 
Table 3.18 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of OX and HK using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.21 shows the corresponding bar 
diagram at ED50. 
Table 3.18: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
OX and HK administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug Sequence 
Molar 
ratio 
CI values at 
Dm M r 
ED50 ED75 ED90 
A2780 
OX N/A N/A N/A 0.65 0.66 0.98 
HK N/A N/A N/A 90.91 1.37 0.91 
OX + HK  0/0h 
1:88.5 
0.93 0.56 0.40 0.37 1.50 0.92 
OX + HK  0/4h 0.79 0.48 0.35 0.31 1.47 0.97 
OX + HK  4/0h 1.05 0.65 0.48 0.42 1.44 0.92 
A2780
cisR
 
OX N/A N/A N/A 1.03 0.55 0.95 
HK N/A N/A N/A 58.09 1.01 0.93 
OX + HK  0/0h 
1:48.67 
1.42 0.69 0.39 0.78 1.47 0.93 
OX + HK  0/4h 1.15 0.56 0.32 0.64 1.46 0.97 
OX + HK  4/0h 1.10 0.55 0.33 0.60 1.40 0.99 
A2780
ZD0473R
 
OX N/A N/A N/A 0.87 0.48 0.96 
HK N/A N/A N/A 67.50 0.93 1.00 
OX + HK  0/0h 
1:78.67 
1.30 0.61 0.36 0.56 1.33 1.00 
OX + HK  0/4h 1.27 0.60 0.35 0.55 1.33 0.99 
OX + HK  4/0h 1.52 0.73 0.44 0.65 1.28 1.00 
SKOV-3 
OX N/A N/A N/A 18.43 0.72 1.00 
HK N/A N/A N/A 45.05 1.14 1.00 
OX + HK  0/0h 
1:0.9 
1.83 1.38 1.13 24.68 1.03 0.98 
OX + HK  0/4h 2.55 1.50 0.95 34.29 1.35 1.00 
OX + HK  4/0h 2.16 1.71 1.47 29.05 0.99 0.97 
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Figure 3.21: CI values at ED50 applying to the binary combinations of OX and HK 
using 0/0 h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 tumour models  
As applied to the combination of OX with HK in parent A2780 ovarian cancer cell 
line, all three sequences of administration were shown slightly synergistic activity at 
ED50 concentration but moderate to high synergistic activity at higher concentrations.  
The combination of OX with HK applied to the A2780
cisR 
cell line exhibited 
antagonism at ED50, moderate synergism at ED75 and high synergism at ED90 with all 
three sequences of administration.  
In A2780
ZD0473R
 cell line, combination of OX with HK at the three modes of 
administration found to be antagonistic at ED50 but moderately synergistic at ED75 
and highly synergistic at ED90. 
The combination of OX and HK applied to SKOV-3 cell lines showed antagonism 
with all three sequences of administration at different concentration except 0/4 h 
sequence of administration found to be additive at ED90. 
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3.3.2.8 Combination between carboplatin (CB) and 
honokiol (HK) 
Table 3.19 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of CB and HK using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.22 shows the corresponding bar 
diagram at ED50. 
Table 3.19: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
CB and HK administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug 
Sequence 
(h) 
Molar 
ratio 
CI values at 
Dm m r 
ED50 ED75 ED90 
A2780 
CB N/A N/A N/A 17.90 0.79 0.99 
HK N/A N/A N/A 87.35 1.39 0.91 
CB + HK 0/0h 
1:1.13 
0.92 0.69 0.56 13.35 1.14 1.00 
CB + HK 0/4h 1.00 0.67 0.48 14.53 1.30 1.00 
CB + HK 4/0h 1.21 1.00 0.90 17.57 1.03 0.98 
A2780
cisR
 
CB N/A N/A N/A 42.00 0.79 1.00 
HK N/A N/A N/A 66.16 1.43 0.91 
CB + HK 0/0h 
1:0.44 
1.11 0.69 0.47 36.33 1.48 1.00 
CB + HK 0/4h 1.08 0.68 0.46 35.48 1.48 1.00 
CB + HK 4/0h 0.99 0.78 0.67 32.48 1.12 0.99 
A2780
ZD0473R
 
CB N/A N/A N/A 62.23 0.66 0.99 
HK N/A N/A N/A 48.78 0.94 1.00 
CB + HK 0/0h 
1:0.55 
1.46 0.79 0.46 53.33 1.34 0.99 
CB + HK 0/4h 1.59 0.96 0.61 57.98 1.19 1.00 
CB + HK 4/0h 1.37 1.29 1.29 50.19 0.80 0.98 
SKOV-3 
CB N/A N/A N/A 49.11 0.80 0.99 
HK N/A N/A N/A 51.64 1.01 0.96 
CB + HK 0/0h 
1:0.57 
1.21 0.95 0.77 38.38 1.06 0.99 
CB + HK 0/4h 1.35 1.03 0.81 42.99 1.10 0.98 
CB + HK 4/0h 1.24 1.04 0.89 39.36 1.01 0.98 
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Figure 3.22: CI values at ED50 applying to the binary combinations of CB and HK 
using 0/0 h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 tumour models  
The combination of CB and HK were shown to be additive for 0/0 h and 0/4 h 
sequences of administration in A2780 cell line and antagonistic 4/0 h sequence of 
administration. However, the degree of synergism is found to increase with the 
increasing concentrations irrespective of the sequence of administration.  
As applied to the combination of CB and HK in A2780
cisR
 cell line, all the three 
sequences of administration were found to be additive at different concentrations. 
However, the degree of synergism is found to increase with the increase in 
concentration as in the parent cell line.  
As applied to the combination of CB and HK in A2780
ZD0473R
 cell line, all the three 
sequences of administration were found to be antagonistic at ED50. But as the 
concentration was increased, the nature of combined drug activity was found to be 
synergistic as applied to 0/0 h and 0/4 h sequences of administration (more so at ED90 
than at ED75). Such concentration-dependent change in combined drug action was not 
observed for 4/0 h sequence of administration. As applied to the combination of CB 
and HK in SKOV-3 cell line, all the three sequences of administration were displayed 
antagonism at ED50, additiveness at ED75 and slight synergism at ED90.  
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3.3.2.9 Combination between cisplatin (CS) and 
cholecalciferol (CC) 
Table 3.20 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of CS and CC using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.23 shows the corresponding bar 
diagram at ED50. 
Table 3.20: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
CS and CC administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug Sequence 
Molar 
ratio 
CI values at 
Dm m r 
ED50 ED75 ED90 
A2780 
CS N/A N/A N/A 0.79 0.72 0.97 
CC N/A N/A N/A 15.40 1.65 0.95 
CS + CC  0/0h 
1:14.63 
1.26 0.95 0.85 0.57 1.40 1.00 
CS + CC  0/4h 1.34 1.30 1.48 0.60 1.06 1.00 
CS + CC  4/0h 1.20 1.15 1.29 0.54 1.08 0.98 
A2780
cisR
 
CS N/A N/A N/A 6.37 1.12 0.99 
CC N/A N/A N/A 18.40 1.60 0.97 
CS + CC  0/0h 
1:5.5 
0.87 1.41 2.32 1.91 0.87 0.96 
CS + CC  0/4h 1.01 1.85 3.45 2.21 0.79 0.95 
CS + CC  4/0h 1.13 1.32 1.56 2.47 1.18 0.99 
A2780
ZD0473R
 
CS N/A N/A N/A 7.54 0.73 0.99 
CC N/A N/A N/A 19.47 2.41 0.99 
CS + CC  0/0h 
1:2.13 
3.12 6.26 15.80 12.89 0.69 0.99 
CS + CC  0/4h 2.21 4.80 13.12 9.12 0.66 0.97 
CS + CC  4/0h 2.91 5.49 13.00 12.03 0.72 0.95 
SKOV-3 
CS N/A N/A N/A 9.92 2.54 0.99 
CC N/A N/A N/A 48.48 1.94 1.00 
CS + CC  0/0h 
1:5.55 
0.86 0.99 1.14 4.00 1.71 0.98 
CS + CC  0/4h 0.81 0.90 1.00 3.75 1.81 1.00 
CS + CC  4/0h 0.89 0.96 1.03 4.16 1.92 0.99 
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Figure 3.23: CI values at ED50 applying to the binary combinations of CS and CC 
using 0/0 h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 tumour models  
As applied to the combination of CS and CC in A2780 cell line, 0/0 h sequence was 
shown to be antagonistic at ED50, additive at ED75 and weakly synergistic at ED95 
respectively. However, 0/4 h and 4/0 h sequences of administrations were antagonistic 
at all three different concentrations. 
In A2780
cisR 
ovarian cancer cell line, combination of CS and CC showed weak 
synergism, additiveness and weak antagonism for 0/0 h, 0/4 h and 4/0 h sequences of 
administration respectively at ED50. At higher concentrations, all the three sequences 
of administration were found to be antagonistic and the degree of antagonism 
increasing with the increased concentration.  
As applied to the combination of CS and CC in A2780
ZD0473R
 cell line, all sequences 
of administration were shown high antagonism and the degree of antagonism 
increased with higher concentrations.  
In SKOV-3 cell line, combination of CS and CC showed weak synergism with all the 
three sequences of administration at ED50 but found to be additiveness at higher 
concentrations. 
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3.3.2.10 Combination between oxaliplatin (OX) and 
cholecalciferol (CC) 
Table 3.21 presents the CI values at ED50, ED75 and ED90 meaning effective dose for 
50 percent, 75 percent and 90 percent cell death respectively applying to binary 
combinations of OX and CC using 0/0 h, 0/4 h and 4/0 h sequences administered to 
ovarian parent A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant A2780
ZD0473R 
and p53 null SKOV-3 tumour models. Figure 3.24 shows the corresponding bar 
diagram at ED50. 
Table 3.21: CI values at ED50, ED75 and ED90 applying to sequenced combinations of 
OX and CC administered to ovarian A2780, A2780
cisR
, A2780
ZD0473R 
and SKOV-3 
tumour models 
Cell line Drug Sequence 
Molar 
ratio 
CI values at 
Dm m r 
ED50 ED75 ED90 
A2780 
OX N/A N/A N/A 0.19 0.86 0.94 
CC N/A N/A N/A 16.37 1.92 0.97 
OX + CC  0/0h 
1:70.2 
1.46 1.30 1.29 0.15 1.41 1.00 
OX + CC  0/4h 2.06 2.27 2.81 0.22 1.10 0.93 
OX + CC  4/0h 1.94 1.32 1.01 0.20 2.13 0.96 
A2780
cisR
 
OX N/A N/A N/A 0.22 0.62 0.96 
CC N/A N/A N/A 17.09 1.51 0.97 
OX + CC  0/0h 
1:44.0 
1.27 1.08 1.16 0.18 1.00 1.00 
OX + CC  0/4h 1.24 1.19 1.46 0.17 0.90 1.00 
OX + CC  4/0h 1.43 1.30 1.53 0.20 0.93 1.00 
A2780
ZD0473R
 
OX N/A N/A N/A 0.33 0.74 0.96 
CC N/A N/A N/A 13.56 1.48 0.98 
OX + CC  0/0h 
1:33.13 
0.84 1.13 1.73 0.15 0.79 1.00 
OX + CC  0/4h 1.51 2.19 3.60 0.27 0.75 1.00 
OX + CC  4/0h 1.35 1.45 1.76 0.24 0.95 1.00 
SKOV-3 
OX N/A N/A N/A 29.45 1.00 0.98 
CC N/A N/A N/A 53.12 2.72 1.00 
OX + CC  0/0h 
1:1.67 
0.78 0.75 0.81 11.92 1.63 0.89 
OX + CC  0/4h 0.84 0.74 0.73 12.79 1.90 0.96 
OX + CC  4/0h 0.76 0.73 0.78 11.56 1.65 0.96 
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Figure 3.24: CI values at ED50 applying to the binary combinations of OX and CC 
using 0/0 h, 0/4 h and 4/0 h sequences administered to ovarian A2780, A2780
cisR
, 
A2780
ZD0473R
 and SKOV-3 tumour models 
As applied to the combination of OX with CC in SKOV-3 cell line has been exhibited 
slight synergism with all three modes of administration and different concentrations. 
In addition, 0/0 h sequence applied to picoplatin resistant cell line at ED50 showed 
slight synergism and 4/0 h sequence of administration against A2780 found to be 
additive at ED90. However, the rest of the combinations applied to the parent, 
cisplatin-resistant and picoplatin-resistant cell lines were found to be antagonistic.  
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3.4 Cellular accumulation of platinum 
drugs 
Cellular accumulation of drugs is one of the rate-limiting steps affecting the drug 
effect. It is believed that increased cellular accumulation leads to a higher efficacy of 
the drug. In this study, cisplatin and oxaliplatin alone and their nine synergistic 
combinations were selected for cellular accumulation assay. The aim is to explore the 
ability of compounds from natural sources to potentiate platinum accumulation in 
ovarian cancer parent A2780 and cisplatin-resistant A2780
cisR
 cell lines. 
3.4.1 Cellular accumulation study in parent 
ovarian cancer cell line  
Table 3.22 presents the amount of intracellular platinum concentration expressed as 
nmol Pt per 5 х 106 cells in ovarian parent A2780 cell line applying to CS and OX 
alone and their selected sequenced combinations with compounds from natural 
resources. Figure 3.25 displays the corresponding bar diagrams.  
Table 3.22: The amount of intracellular platinum concentration (nmol Pt per 5 х 106 
cells) in A2780 cell line applying to CS and OX alone and their selected sequenced 
combinations with natural compounds 
Drug/Combination nmol Pt per 5 х 106 cells 
Cisplatin 1.23 ± 0.08 
CS+HK (0/0 h) 0.60 ± 0.15 
CS+6-SG (0/0 h) 1.67 ± 0.12 
Oxaliplatin 0.30 ± 0.03 
OX+HK (0/4 h) 0.13 ± 0.00 
OX+6-SG (0/0 h) 0.26 ± 0.03 
OX+MA (4/0 h) 0.12 ± 0.02 
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Figure 3.25: Intracellular platinum concentration in A2780 cell line as applied to CS 
and OX alone and their selected sequenced combinations with natural compounds 
It can be seen that bolus combination of cisplatin with 6-shogaol resulted in the 
greatest platinum accumulation in the parent A2780 ovarian cancer cell line whereas 
bolus combination of honokiol with cisplatin resulted in lower platinum accumulation 
than that from cisplatin alone. When platinum accumulations from cisplatin and its 
combination with honokiol and 6-shogaol were compared with corresponding values 
from oxaliplatin and its combinations with honokiol and 6-shogaol, it was found the 
values associated with oxaliplatin were much lower. This is to be expected partly 
because concentrations of oxaliplatin were much lower due to its greater activity. The 
results will be further discussed in the next chapter. Besides, bolus combination of 
oxaliplatin and 6-shogaol showed similar cellular accumulation as compared to that 
from oxaliplatin alone. However, combination of OX with HK using 0/0 h sequence 
and that of OX with MA using 4/0 h sequence showed lower cellular accumulation 
than oxaliplatin. 
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3.4.2 Cellular accumulation study in cisplatin-
resistant ovarian cancer cell line 
Table 3.23 presents the amount of intracellular platinum concentration expressed as 
nmol Pt per 5 х 106 cells in ovarian cisplatin-resistant A2780cisR cell line applying to 
CS and OX alone and their selected sequenced combinations with compounds from 
natural resources. Figure 3.26 displays the corresponding bar diagrams.  
Table 3.23: The amount of intracellular platinum concentration (nmol Pt per 5 х 106 
cells) in A2780
cisR
 cell line applying to CS and OX alone and their selected sequenced 
combinations with natural compounds 
Drug/ Combination nmol Pt per 5 х 106 cells 
Cisplatin 2.29 ± 0.48 
CS+CC (0/0 h) 1.59 ± 0.47 
CS+6-SG (4/0 h) 1.95 ± 0.08 
CS+MA (0/0 h) 1.55 ± 0.12 
Oxaliplatin 0.21 ± 0.01 
OX+6-SG (0/0 h) 0.19 ± 0.00 
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Figure 3.26:  Intracellular platinum concentration in A2780
cisR
 cell line as applied to 
CS and OX alone and their selected sequenced combinations with natural compounds 
It is observed that highest amount of platinum accumulated in cisplatin-resistant cells 
when it was treated with cisplatin alone. However, platinum accumulation has been 
slightly reduced when cisplatin-resistant cells treated with selected synergistic 
combinations of cisplatin and natural compounds. Moreover, oxaliplatin alone and its 
combination with 6-shogaol using 0/0 h sequence have shown similar tread of 
platinum accumulation in cisplatin-resistant cells but much lower platinum 
accumulation in comparison to the cisplatin alone treated cells.  
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3.5 Pt-DNA binding 
Platinum drugs exhibit anticancer activity by forming a covalent bond with DNA 
leading to substantial DNA damage which causes cancer cell death. In the present 
study, the extent of PtDNA binding level has been determined when the ovarian 
cancer parent A2780 and cisplatin-resistant A2780
cisR 
cell lines were treated with 
platinum drug alone and their selected synergistic combinations.  
3.5.1 Pt-DNA binding of platinum drugs in parent 
ovarian cancer cell line 
Table 3.24 presents the extent of platinum-DNA binding expressed as nmol Pt per mg 
of DNA as applied to the addition of CS and OX alone and their selected sequenced 
combinations with HK, 6-SG and MA in ovarian parent A2780 cell lines. Figure 3.27 
shows corresponding bar diagrams.  
Table 3.24: The extent of platinum-DNA binding (nmol Pt per mg of DNA) as applied 
to the addition of CS and OX alone and their selected sequenced combinations with 
HK, 6-SG and MA in A2780 cell lines 
Drug/Combination nmol Pt per mg of DNA 
Cisplatin 0.10 ± 0.00 
CS+HK (0/0 h) 0.95 ± 0.04 
CS+6-SG (0/0 h) 0.33 ± 0.04 
Oxaliplatin 0.15 ± 0.02 
OX+HK (0/4 h) 0.10 ± 0.01 
OX+6-SG (0/0 h) 0.09 ± 0.01 
OX+MA (4/0 h) 0.16 ± 0.01 
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Figure 3.27:  Platinum-DNA binding levels in A2780 cell line as applied to the 
addition of  CS and OX alone and their selected sequenced combination with natural 
compounds 
The bolus combination of cisplatin and honokiol showed 9.5 times higher PtDNA 
binding in comparison to cisplatin-alone treated ovarian parent A2780 cell line 
whereas 0/0 h combination of cisplatin and 6-shogaol accounts for 3.3 times. On the 
other hand, oxaliplatin individually and in combination with mycophenolic acid 4/0 h 
sequence showed similar Pt-DNA binding whereas OX with 6-SG 0/0 h sequence and 
OX with HK 0/4 h combination have a lower Pt-DNA binding. Besides, the PtDNA 
binding of oxaliplatin individually in A2780 cell line was found to be 1.5 times more 
than cisplatin alone even though a higher concentration of cisplatin was used in 
cisplatin-treated cells.   The results are discussed in the next chapter.  
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3.5.2 Pt-DNA binding of platinum drugs in 
cisplatin-resistant ovarian cancer cell line 
Table 3.25 presents the extent of platinum-DNA binding expressed as nmol Pt per mg 
of DNA as applied to the addition of CS and OX alone and their selected sequenced 
combinations with HK, 6-SG and MA in ovarian cisplatin-resistant A2780
cisR
 cell 
lines. Figure 3.28 shows corresponding bar diagrams.  
Table 3.25: The extent of platinum-DNA binding (nmol Pt per mg of DNA) as applied 
to the addition of CS and OX alone and their selected sequenced combinations with 
HK, 6-SG and MA in A2780
cisR
 cell lines 
Drug/ Combination nmol Pt per mg of DNA 
Cisplatin 0.50 ± 0.00 
CS+CC (0/0 h) 1.03 ± 0.02 
CS+6-SG (4/0 h) 0.73 ± 0.01 
CS+MA (0/0 h) 0.51 ± 0.01 
Oxaliplatin 0.52 ± 0.05 
OX+6-SG (0/0) 0.30 ± 0.02 
 
 
Figure 3.28: Platinum-DNA binding levels in A2780
cisR
 cell line as applied to the 
addition of  CS and OX alone and their selected sequenced combinations with natural 
compounds 
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PlatinumDNA binding of the 0/0 h sequence combination of cisplatin and 
cholecalciferol was found to be two times higher than cisplatin-alone treated ovarian 
cisplatin-resistant A2780
cisR
 cell lines while 1.5 times more PtDNA binding resulted 
by the combination of cisplatin and 6-shogaol with 4/0 h sequence. Moreover, bolus 
combination of cisplatin and mycophenolic acid have similar Pt-DNA binding when 
compared to cisplatin-alone treated cells. However, combination of oxaliplatin and 6-
shogaol with 0/0 h sequence showed much lower PtDNA binding than oxaliplatin 
alone treated cells. In spite of using a lower concentration of oxaliplatin while treating 
A2780
cisR
 cell lines, PtDNA binding of oxaliplatin alone was found to be similar to 
cisplatin-alone treated cells. The results are discussed in the next chapter.  
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3.6 DNA Damage Study 
DNA damage study was carried out to obtain insight into the mechanism of combined 
drug action. It is thought that platinum drugs bind to DNA, thus altering its 
conformation and may even cause DNA damage. When administered along with the 
compounds from the natural resources, DNA damage may be reduced or further 
enhanced depending on the nature of the natural compound in question. 
3.6.1 Parent ovarian cancer cell line 
Figure 3.29 presents the extent DNA damage as applied to the addition of platinum 
drug and natural compound alone and their selected sequenced combinations in 
ovarian parent A2780 cell lines. Figure 3.30 shows corresponding bar diagrams.  
1       2           3          4           5          6           7          8           9         10         11      
 
Figure 3.29: The extent of DNA damage as applied to the addition of following 1. 
Untreated DNA, 2. CS, 3.CS + HK (0/0 h), 4.CS + 6-SG (0/0 h), 5.OX, 6.OX + HK 
(0/4 h), 7.OX + 6-SG (0/0 h), 8.OX + MA (4/0 h), 9. HK, 10.6-SG, 11.MA in A2780 
cell line 
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Figure 3.30: The extent of DNA damage in A2780 cell line as applied to the addition 
of platinum drug and natural compound alone and their selected sequenced 
combinations 
It can be seen that cisplatin and honokiol alone and in 0/0 h combination showed 
significant DNA damage to ovarian parent A2780 cell line. In addition, 6-shogaol also 
showed slight DNA damaging capability toward same cell line. Moreover, 
mycophenolic acid, oxaliplatin and it's combinations have no effect or protect DNA 
damage in comparison to untreated parent ovarian cancer cell line.  
3.6.2 Cisplatin-resistant ovarian cancer cell line 
Figure 3.31 presents the extent DNA damage as applied to the addition of platinum 
drug and natural compound alone and their selected sequenced combinations in 
ovarian cisplatin-resistant A2780
cisR
 cell lines. Figure 3.32 shows corresponding bar 
diagrams.  
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1         2           3            4            5            6           7           8            9          10 
 
Figure 3.31: The extent of DNA damage as applied to the addition of following 1. 
Untreated DNA, 2. CS, 3.CS + CC (0/0 h), 4.CS + 6-SG (4/0 h), 5.CS + MA (0/0 h), 
6.OX, 7.OX + 6-SG (0/0 h), 8.CC, 9.6-SG, 10.MA in A2780
cisR
 cell lines 
 
 
Figure 3.32: The extent of DNA damage in A2780
cisR
 cell line as applied to the 
addition of platinum drug and natural compound alone and their selected sequenced 
combinations 
It can be seen that 0/0 h combination of cisplatin and cholecalciferol showed 
significant DNA damage towards cisplatin-resistant A2780
cisR
 ovarian cancer cell 
line. Additionally, cholecalciferol alone also caused promising DNA damage to same 
cell line. Moreover, bolus combination of cisplatin and mycophenolic acid caused 
significant DNA damage to A2780
cisR
 cell line. Furthermore, oxaliplatin caused slight 
DNA damage to A2780
cisR
 cell line.  
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However, cisplatin alone and its other combinations, 6-shogaol and mycophenolic 
acid alone as well as combination of oxaliplatin and 6-shogaol have no effect or intact 
DNA of cisplatin-resistant A2780
cisR
 cell line.  
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3.7 Proteomics studies on ovarian 
cancer cell lines 
Ovarian cancer causes the highest number of death among the gynecological 
carcinomas across the globe. It is mainly due to the absence of symptoms at early 
stages of ovarian cancer and relapse after treatment (Schuijer and Berns 2003, Nessa, 
Beale et al. 2011). Recently, proteomic studies have emerged as a new technique to 
discover proteins involved with poor prognosis and drug-resistance in ovarian cancer 
(Posadas, Davidson et al. 2004).  The technique usually involves 2D-gel 
electrophoresis followed by protein identification by mass spectrometry (Posadas, 
Davidson et al. 2004, Meleady 2011).  
In the present study, proteomic studies have been performed with the view to explore 
major proteins involved with chemo-resistance in ovarian parent and resistant cell 
lines. In addition, attention has been given to the proteins which significantly up- or 
down-regulated in resistant cell line in comparison to the parent cell line. If any 
protein undergoes up-regulation or down-regulation by 1.5 fold or more in 
comparison to the parent cell line, the change is considered to be significant 
(Maloney, Clarke et al. 2007). And changes in protein expression following treatment 
with drug combinations are also observed. These proteins are specially considered for 
further analysis because they might play a major role in drug-resistance. Specifically, 
the aim of the current study was to determine alterations in protein expression due to 
treatment of cisplatin-resistant cell line A2780
cisR
 with nine significant synergistic 
combinations namely OX+MA (0/0 h), CS+6SG (0/0 h), CS+6SG (4/0 h), CS+CC 
(0/0 h), CS+HK (0/4 h), OX+6SG (0/0 h), OX+6SG (4/0 h), OX+HK (4/0 h) and 
OX+MA (0/0 h) and of against picoplatin-resistant cell line with CS+6SG (0/0 h). 
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After 2D-gel electrophoresis, gel pictures were captured and protein spots images 
were analyzed by using Melanie software. And each spot of protein was specified by a 
common matched ID number and Melanie software automatically identified 308 
proteins spots in parent cell line as well as 107 proteins spots in the cisplatin-resistant 
cell line. Out of these proteins, 23 highly altered protein spots from parent and 
cisplatin-resistant cell line have been selected for MALDI-TOF/TOF MS assay. In 
addition, 2D-gels of untreated A2780 (Figure 3.33) and A2780
cisR 
(Figure 3.34)  have 
been selected for the analysis of 23 spots. The pictures of selected gels with annotated 
protein spots (Figure 3.33 and Figure 3.34) followed by the 2D-gels from selected 
combinations (Figure 3.35)  are given below: 
 
Figure 3.33: Two-dimensional gel protein profile of untreated parent ovarian cancer 
cell line with annotated protein spots.  
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Figure 3.34: Two-dimensional gel protein profile of untreated cisplatin-resistant 
ovarian cancer cell line with annotated protein spots. 
 
a) Untreated A2780 parent ovarian cancer cell line  
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b) Untreated A2780
cisR
 cisplatin-resistant cell line  
 
c) Cisplatin-resistant cell line treated with OX+MA (0/0 h) 
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d) Cisplatin-resistant cell line treated with CS+6SG (0/0 h) 
 
e) Cisplatin-resistant cell line treated with CS+6SG (4/0 h) 
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f) Cisplatin-resistant cell line treated with CS+CC (0/0 h) 
 
g) Cisplatin-resistant cell line treated with CS+HK (0/4 h) 
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h) Cisplatin-resistant cell line treated with OX+6SG (0/0 h) 
 
i) Cisplatin-resistant cell line treated with OX+6SG (4/0 h) 
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j) Cisplatin-resistant cell line treated with OX+HK (4/0 h) 
 
k) Cisplatin-resistant cell line treated with OX+MA (0/0 h) 
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l) Untreated A2780
ZD0473R
 picoplatin-resistant cell line 
 
m) Picoplatin-resistant cell line treated with CS+6SG (0/0 h) 
Figure 3.35: Two dimensional protein expression of a) Untreated A2780 cell line, b) 
Untreated A2780
cisR
 cell line, c) OX+MA (0/0 h)-treated A2780
cisR
 cell line, d) 
CS+6SG (0/0 h)-treated A2780
cisR
 cell line, e) CS+6SG (4/0 h)-treated A2780
cisR
 cell 
line,  f) CS+CC (0/0 h)-treated A2780
cisR
 cell line,  g) CS+HK (0/4 h)-treated 
A2780
cisR
 cell line,  h) OX+6SG (0/0 h)-treated A2780
cisR
 cell line, i) OX+6SG (4/0 
h)-treated A2780
cisR
 cell line,  j) OX+HK (4/0 h)-treated A2780
cisR
 cell line,  k) 
OX+MA (0/0 h)-treated A2780
cisR
 cell line, l) Untreated A2780
ZD0473R
 cell line, m) 
CS+6SG (0/0 h)-treated A2780
ZD0473R
 cell line. 
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Table 3.26 and 3.27 present the transformation of protein expression in ovarian 
cisplatin-resistant A2780
cisR
 and picoplatin-resistant A2780
ZD0473R
 cell lines as applied 
to the administration of selected synergistic drug combinations when ovarian parent 
A2780 tumour model used as a reference.  
Table 3.26: Transformation of protein expression in cisplatin-resistant A2780
cisR
 
tumour model as applied to the administration of selected synergistic drug 
combinations when ovarian A2780 tumour model used as a reference 
Spot 
No. 
Altered protein expression in cisplatin resistant cell line 
Untreated 
A2780
cisR
 
(Fold) 
Drug treatments 
CS+6SG 
(0/0 h) 
CS+6SG 
(4/0 h) 
CS+CC 
(0/0 h) 
CS+HK 
(0/4 h) 
OX+6SG 
(0/0 h) 
OX+6SG 
(4/0 h) 
OX+HK 
(4/0 h) 
OX+MA 
(0/0 h) 
13 ↑ (1.92)  NC OR OR - - OR - 
18 ↑ (1.58) OR - - OR - OR - PR 
45 - OR PR - PR PR PR PR OR 
89 - OR - PR - PR PR FR - 
155 - - - - PR - - - - 
195 - PR - - - - - - - 
196 ↑ (8.14) OR - - - - - - - 
Keys: ↑ = Up regulated;  = Further up-regulated; NC = No change; OR = Over-
restored; PR = Partially restored; FR = Fully restored; - = Not found.  
Table 3.27: Transformation of protein expression in picoplatin-resistant A2780
ZD0473R
 
tumour model as applied to the administration of selected synergistic drug 
combinations when ovarian A2780 tumour model used as a reference 
Spot 
No.  
Altered protein expression in picoplatin-resistant cell line 
Untreated A2780
ZD0473R
 
(Fold) 
Drug treatments 
CS + 6-SG (0/0 h) 
13 ↑ (5.9) PR 
18 NC OR 
45 ↑ (2.2) - 
89 - - 
155 - - 
195 - - 
196 - - 
Keys: ↑ = Up regulated; NC= No change; OR = Over-restored; PR = Partially 
restored; - = Not found.  
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Table 3.28 and 3.29 present the transformation of protein expression in ovarian 
cisplatin-resistant A2780
cisR
 and picoplatin-resistant A2780
ZD0473R
 cell lines as applied 
to the addition of selected synergistic drug combinations when ovarian cisplatin-
resistant A2780
cisR
 tumour model used as a reference.  
Table 3.28: Transformation of protein expression in cisplatin-resistant A2780
cisR
 
tumour model as applied to the addition of selected synergistic drug combinations 
when ovarian A2780
cisR
 tumour model used as a reference 
Spot 
No. 
Altered protein expression in cisplatin resistant cell line 
Untreated 
A2780
cisR
 
(Fold) 
Drug treatments 
CS+6SG 
(0/0 h) 
CS+6SG 
(4/0 h) 
CS+CC 
(0/0 h) 
CS+HK 
(0/4 h) 
OX+6SG 
(0/0 h) 
OX+6SG 
(4/0 h) 
OX+HK 
(4/0 h) 
OX+MA 
(0/0 h) 
1 ↑ 2.4 PR OR PR OR PR PR PR PR 
2 ↑ 2  OR OR OR OR OR OR OR 
Cn_9 ↑ 4.9 PR PR PR PR  PR PR PR 
Cn_16 ↑ 8.2 PR PR PR PR PR  - PR 
Cn_23 ↑ 1.8 OR OR PR - PR PR NC PR 
Cn_27 ↑ 10 PR PR - PR PR PR - - 
Cn_34 ↑ 3.6 PR PR  OR PR PR FR  
Cn_38 ↑ - - - - - - - - 
Cn_39 ↑ 2.1 OR PR - - OR OR OR - 
Cn_41 ↑ 24 PR PR PR - PR PR PR PR 
Cn_48 ↑ 3.5 PR  PR PR - - PR  
Cn_51 ↑ 23 PR PR PR PR PR PR PR PR 
Cn_55 ↑ 3.7 PR - - PR PR PR PR  
Cn_56 ↑ ↓ - - - ↓ ↓ - ↓ 
Cn_65 ↑ ↓ ↓ - ↓ ↓ ↓ ↓ ↓ 
Cn_69 ↑ 5.4 OR PR - OR PR - PR OR 
Cn_78 ↑ - - - - - - - ↑ 
Cn_79 ↑ 7.5 - - - - OR - - PR 
Cn_89 ↑ 4.7 - - - - - OR OR - 
Cn_90 ↑ - - OR OR - - OR - 
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Keys: ↑ = Up regulated; ↓ = Down regulated;  = Further up-regulated; NC = No 
change; OR = Over-restored; PR = Partially restored; FR = Fully restored; - = Not 
found.  
 
Table 3.29: Transformation of protein expression in picoplatin-resistant A2780
ZD0473R
 
tumour model as applied to the addition of selected synergistic drug combinations 
when ovarian A2780
cisR
 tumour model used as a reference 
 
Spot 
No. 
Altered protein expression in picoplatin-resistant cell line 
Untreated A2780
ZD0473R
 
(Fold) 
Drug treatments 
CS + 6-SG (0/0 h) 
1 ↑ 2.37  
2 ↑ 1.25  
Cn_9 ↑ 5.39 PR 
Cn_16 ↑ 5.44 PR 
Cn_23 ↑ 2.94 - 
Cn_27 ↑ 20.07 - 
Cn_34 ↑ 2.56 - 
Cn_38 - - 
Cn_39 ↓ 1.56 - 
Cn_41 ↑ 42.17 - 
Cn_48 ↑ 1.49 - 
Cn_51 ↑ 18.25 - 
Cn_55 ↑ 2.25 - 
Cn_56 - - 
Cn_65 - - 
Cn_69 - - 
Cn_78 - - 
Cn_79 - - 
Cn_89 - - 
Cn_90 - - 
Keys: ↑ = Up regulated; ↓ = Down regulated;  = Further up-regulated; NC= No 
change; OR= Over-restored; PR= Partially restored; - = Not found.  
 
Table 3.30 displays the list of identified proteins according to their mode of action. 
MALDI TOF/TOF MS assay has been done to detect the proteins. The protein name, 
ID, accession number, mascot search results and subcellular location were mentioned 
in the table 3.30. The description of the proteins such as alternative names, short 
name, gene and molecular functions are discussed in appendix IV.  
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Table 3.30: List of identified proteins according to their mode of action  
Cytoskeleton and associated proteins 
Spot 
No.
a
 
       
 
Protein ID 
(HUMAN) 
Protein name
b
 Mascot Search results Sub-cellular 
location 
1 ACTB Actin, 
cytoplasmic 1 
Mass
c
 (Da): 41710 
pI
d
: 5.29 
Mascot score
e
: 520 
No of matched peptides
f
: 16 
Sequence coverage
g
 (%): 30 
Cytoskeleton 
Cn_39 ACTB Actin, 
cytoplasmic 1 
Mass
c
 (Da): 41710 
pI
d
: 5.29 
Mascot score
e
: 87 
No of matched peptides
f
: 10 
Sequence coverage
g
 (%): 14 
Cytoskeleton 
Cn_79 ACTB Actin, 
cytoplasmic 1 
Mass
c
 (Da): 41710 
pI
d
: 5.29 
Mascot score
e
: 231 
No of matched peptides
f
: 19 
Sequence coverage
g
 (%): 48 
Cytoskeleton 
2 VIME Vimentin Mass
c
 (Da): 53619 
pI
d
: 5.06 
Mascot score
e
: 739 
No of matched peptides
f
: 6 
Sequence coverage
g
 (%): 45 
Cytoplasm 
Cn_48 VIME Vimentin Mass
c
 (Da): 53619 
pI
d
: 5.06 
Mascot score
e
: 285 
No of matched peptides
f
: 26 
Sequence coverage
g
 (%): 30 
Cytoplasm 
Cn_69 COF1 Cofilin-1 Mass
c
 (Da): 18491 
pI
d
: 8.22 
Mascot score
e
: 144 
No of matched peptides
f
: 10 
Sequence coverage
g
 (%): 22 
Cytoskeleton, 
Nucleus matrix, 
plasma 
membrane 
Metabolism enzymes  
 
Cn_41 CISY Citrate synthase, 
mitochondrial 
Mass
c
 (Da): 51680 
pI
d
: 8.45 
Mascot score
e
: 97 
No of matched peptides
f
: 14 
Sequence coverage
g
 (%): 16 
Mitochondrion 
matrix 
Calcium binding, control and apoptosis proteins  
 
195 ANXA1 Annexin A1 Mass
c
 (Da): 38690 
pI
d
: 6.57 
Mascot score
e
: 651 
No of matched peptides
f
: 28 
Sequence coverage
g
 (%): 45 
Nucleus, 
cytoplasm,  
cell membrane   
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89 CALR Calreticulin Mass
c
 (Da): 48112 
pI
d
: 4.29 
Mascot score
e
: 112 
No of matched peptides
f
: 8 
Sequence coverage
g
 (%): 17 
Endoplasmic 
reticulum 
lumen, cytosol, 
cytoplasm  
Stress response and molecular chaperons and cochaperons  
13 CH60 60 kDa heat shock 
protein, 
mitochondrial 
Mass
c
 (Da): 61016 
pI
d
: 5.70 
Mascot score
e
: 518 
No of matched peptides
f
: 19 
Sequence coverage
g
 (%): 24 
Mitochondrion 
matrix 
18 ENPL Endoplasmin Mass
c
 (Da): 92411 
pI
d
: 4.76 
Mascot score
e
: 647 
No of matched peptides
f
: 36 
Sequence coverage
g
 (%): 21 
Endoplasmic 
reticulum 
lumen, 
melanosome 
45 GRP78 78 kDa glucose-
regulated protein 
Mass
c
 (Da): 72288 
pI
d
: 5.07 
Mascot score
e
: 820 
No of matched peptides
f
: 28 
Sequence coverage
g
 (%): 27 
Endoplasmic 
reticulum, 
melanosome, 
cytoplasm 
Cn_16 HSP7C Heat shock cognate 
71 kDa protein 
Mass
c
 (Da): 70854 
pI
d
: 5.37 
Mascot score
e
: 686 
No of matched peptides
f
: 27 
Sequence coverage
g
 (%): 21 
Plasma 
membrane, 
nucleus, 
melanosome 
Cn_51 HSP7C Heat shock cognate 
71 kDa protein 
Mass
c
 (Da): 70854 
pI
d
: 5.37 
Mascot score
e
: 110 
No of matched peptides
f
: 12 
Sequence coverage
g
 (%): 15 
Plasma 
membrane, 
nucleus, 
melanosome 
Cn_90 HSP7C Heat shock cognate 
71 kDa protein 
Mass
c
 (Da): 70854 
pI
d
: 5.37 
Mascot score
e
: 64 
No of matched peptides
f
: 5 
Sequence coverage
g
 (%): 6 
Plasma 
membrane, 
nucleus, 
melanosome 
Cn_65 CH10 10 kDa heat shock 
protein, 
mitochondrial 
Mass
c
 (Da): 10925 
pI
d
: 8.89 
Mascot score
e
: 78 
No of matched peptides
f
: 9 
Sequence coverage
g
 (%): 33 
Mitochondrion 
Cn_78 SERPH Serpin H1 Mass
c
 (Da): 46411 
pI
d
: 8.75 
Mascot score
e
: 75 
No of matched peptides
f
: 12  
Sequence coverage
g
 (%): 24 
Endoplasmic 
reticulum 
Transcription and RNA processing proteins 
155 H33 Histone H3.3 Mass
c
 (Da): 15319 
pI
d
: 11.27 
Mascot score
e
: 120 
Nucleus, 
chromosome 
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No of matched peptides
f
: 11 
Sequence coverage
g
 (%): 27 
196 NACA Nascent polypeptide-
associated complex 
subunit alpha 
Mass
c
 (Da): 23370 
pI
d
: 4.52 
Mascot score
e
: 110 
No of matched peptides
f
: 12 
Sequence coverage
g
 (%):32 
Nucleus, 
cytoplasm 
Protein synthesis and processing proteins 
Cn_9 RSSA 40S ribosomal 
protein SA 
Mass
c
 (Da): 32833 
pI
d
: 4.79 
Mascot score
e
: 130 
No of matched peptides
f
: 10 
Sequence coverage
g
 (%): 17 
Nucleus, cell 
membrane, 
cytoplasm 
Cn_34 EFTU Elongation factor Tu, 
mitochondrial 
Mass
c
 (Da): 49510 
pI
d
: 7.26 
Mascot score
e
: 88 
No of matched peptides
f
: 13 
Sequence coverage
g
 (%): 16 
Mitochondrion 
Cn_23 K2C1 Keratin, type II 
cytoskeletal 1 
Mass
c
 (Da): 65999 
Mascot score
e
: 31 
No of matched peptides
f
: 5 
Cell membrane 
Catalytic proteins 
Cn_56 TERA Transitional 
endoplasmic 
reticulum ATPase 
Mass
c
 (Da): 89266 
pI
d
: 5.14 
Mascot score
e
: 208 
No of matched peptides
f
: 14 
Sequence coverage
g
 (%): 10 
Endoplasmic 
reticulum, 
cytosol, nucleus 
Redox regulation and drug detoxification proteins  
Cn_27 PRDX6 Peroxiredoxin-6 Mass
c
 (Da): 25019 
pI
d
: 6.0 
Mascot score
e
: 60 
No of matched peptides
f
: 6 
Sequence coverage
g
 (%): 19 
Lysosome, 
cytoplasm 
 
Keys: a Spot number belonging to remarks provided in Figure  
b Protein name and identification obtained from Uni-PortKB  
c Molecular weight of protein in Dalton attained from the Mascot database 
d Isoelectric point attained from the Mascot database 
e Mascot score higher than 56 is considered to be significant (p<0.05). Mascot score 
attained from the Mascot database 
f Number of matched peptides from the mass spectral assay.  
g Percentage of matched amino acids sequence in a recognized protein 
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3.7.1 Gel spot and mass spectral analysis  
3.7.1.1 Actin, cytoplasmic 1 (ACTB) 
ACTB_HUMAN standing for the protein named actin, cytoplasmic 1 has protein 
accession number P02570. It appears as three different spots; 1, Cn_39 and Cn_79 in 
untreated cisplatin-resistant ovarian cancer cell line A2780
cisR
. Each of the spots was 
upregulated compared to the level found in untreated parent ovarian cancer cell line 
A2780. The fold factors were 2.4, 2.1 and 7.5 respectively. Spot number 1 was over-
restored compared to the level found in parent cell line due to treatments with CS + 6-
SG (4/0 h) and CS + HK (0/4 h) while it was partially restored due to treatments with 
other synergistic combinations (Table 3.28). Spot number Cn_39, was partially 
restored back due to treatment with CS + 6-SG (4/0 h) but could not be detected 
following treatments with CS + CC (0/0 h), CS + HK (0/4 h) and OX + MA (0/0 h) 
combinations. Treatments with other synergistic combinations also caused over-
restoration of the protein applying to spot Cn_39. Spot number Cn_79 was partially 
and over-restored due to treatment with OX + MA (0/0 h) and OX + 6-SG (0/0 h) 
respectively. The spot could not be detected following treatments with rest of the 
selected combinations (Table 3.28). 
Actin, cytoplasmic 1 has appeared as two spots: 1 and Cn_39 in picoplatin-resistant 
cell lines A2780
ZD0473R
. The protein was found to be up-regulated at spot number 1 by 
2.37 folds while down-regulated at spot number Cn_39 by 1.56 folds as compared to 
the protein expression level observed in parent ovarian cell line A2780. However, the 
protein was further up-regulated in spot number 1 whereas spot Cn_39 could not be 
identified due to the treatment with CS + 6-SG (0/0 h) (Table 3.29). Among the three 
spots, highest mascot score of actin, cytoplasmic 1 has been observed for spot number 
1 in cisplatin-resistant cell line A2780
cisR
 (Table 3.28).  
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The mass spectrum and matched peptides sequence of actin, cytoplasmic 1 in spot 
number 1 are presented in Figure 3.36 and Figure 3.37.  
 
Figure 3.36: The mass spectrum of actin, cytoplasmic 1  
 
Figure 3.37: Sequences of matched peptides for actin, cytoplasmic 1  
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3.7.1.2  Vimentin (VIME) 
VIME_HUMAN stands for the protein named vimentin. It has protein accession 
number P08670. It is observed in two different spots:  2 and Cn_48 in the cisplatin-
resistant A2780
cisR
 cell line. Both spots were up-regulated in comparison to the level 
found in parent A2780 cell line and the fold factors were 2 and 3.5 respectively. 
However, the protein was over-restored as compared to the level found in parent cell 
line at spot number 2 due to the treatments with selected synergistic drug 
combinations except that with CS+6-SG (0/0 h) (further up-regulated). Moreover, the 
protein could not be found at spot number Cn_48 due to the treatments with OX+6-
SG using 0/0 h and 4/0 h sequences. The protein was further up-regulated due to 
treatments with CS+6-SG (4/0 h) and OX+MA (0/0 h) combinations while that with 
other synergistic combinations caused partial-restoration of vimentin as compared to 
the level found in parent A2780 cell line (Table 3.28).  
Vimentin appeared as two different spots 2 and Cn_48 also in the untreated 
picoplatin-resistant cell line. Both spots were up-regulated in comparison to the level 
of protein expression in parent A2780 cell line and had the fold factors of 1.25 and 
1.49 respectively. However, treatment with CS+6-SG (0/0 h) caused further up-
regulation of protein at spot number 2 while the spot could not be detected at spot 
number Cn_48 (Table 3.29).  
The highest mascot score of vimentin applied to spot number Cn_48 in the cisplatin-
resistant ovarian cancer cell line (Table 3.28). The mass spectrum and matched 
peptides sequence of vimentin in spot number Cn_48 are presented in Figure 3.38 and 
Figure 3.39. 
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Figure 3.38: The mass spectrum of vimentin 
 
 
Figure 3.39: Sequences of matched peptides for vimentin  
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3.7.1.3 Cofilin-1 (COF1) 
 
COF1_HUMAN standing for the protein named cofilin-1 has protein accession 
number P23528. The expression of cofilin-1 was significantly up-regulated in the 
cisplatin-resistant A2780
cisR
 cell line by 5.4 folds at spot number Cn_69 compared to 
the level found in untreated parent ovarian cancer A2780 cell line. However, the 
protein spot could not be identified following treatments with CS+CC (0/0 h) and 
OX+6-SG (4/0 h). Cofilin was either over-restored or partially restored back to the 
level found in untreated parent A2780 cell line due to treatment with other synergistic 
drug combinations (Table 3.28). The mass spectrum and matched peptides sequence 
of cofilin-1 in spot number Cn_69 are presented in Figure 3.40 and Figure 3.41. 
 
 
Figure 3.40: The mass spectrum of cofilin 1 
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Figure 3.41: Sequences of matched peptides for cofilin 1.   
3.7.1.4 Citrate synthase, mitochondrial (CISY) 
CISY_HUMAN standing for the protein named citrate synthase, mitochondrial has 
protein accession number Q71UT9. The protein was exceedingly up-regulated in both 
untreated cisplatin-resistant A2780
cisR
 and picoplatin-resistant A2780
ZD0473R
 cell lines 
by 24 and 42.17 folds respectively at spot number Cn_41 in comparison to the level 
detected in the untreated parent A2780 cell line. However, the protein spot could not 
be detected when cisplatin-resistant A2780
cisR
 cell line treated was with CS+HK (0/4 
h) and picoplatin-resistant A2780
ZD0473R
 cell line was treated with CS+6-SG (0/0 h). 
Moreover, citrate synthase, mitochondrial was partially restored back to the level 
found in untreated parent A2780 cell line due to treatments with other synergistic drug 
combinations in the cisplatin-resistant A2780
cisR
 cell line (Table 3.28 and Table 3.29). 
The mass spectrum and matched peptides sequence of citrate synthase, mitochondrial 
in spot number Cn_41 are presented in Figure 3.42 and Figure 3.43.  
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Figure 3.42: The mass spectrum of citrate synthase, mitochondrial 
 
 
Figure 3.43: Sequences of matched peptides for citrate synthase, mitochondrial 
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3.7.1.5 Annexin A1 (ANXA1) 
ANXA1_HUMAN standing for the protein named annexin 1 has protein accession 
number  P04083. It appeared in parent ovarian cancer A2780 cell line at spot number 
195. However, annexin 1 was absent in both treated and untreated cisplatin-resistant 
A2780
cisR
 and picoplatin-resistant A2780
ZD0473R
 cell lines except that the protein was 
partially restored back to the level found in untreated parent ovarian A2780 cell line 
when cisplatin-resistant A2780
cisR
 cell line was treated with CS+6-SG (0/0 h) (Table 
3.26 and Table 3.27). The mass spectrum and matched peptides sequence of annexin 1 
are presented in Figure 3.44 and Figure 3.45.  
 
 Figure 3.44: The mass spectrum of annexin 1 
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Figure 3.45: Sequences of matched peptides for annexin 1. 
3.7.1.6 Calreticulin (CALR) 
 
CALR_HUMAN standing for the protein named calreticulin has protein accession 
number P27797. It was identified at spot number 89 in untreated parent ovarian 
cancer A2780 cell line. But the protein spot could not be detected in untreated 
cisplatin-resistant, untreated and treated picoplatin-resistant cell lines. In addition, the 
protein could not be detected following treatments with  CS+6-SG (4/0 h), CS+HK 
(0/4 h) and OX+MA (0/0 h) in the cisplatin-resistant A2780
cisR
 cell line. However, 
calreticulin was partially restored back to the level of expression observed in 
untreated parent A2780
 
cell line when the cisplatin-resistant A2780
cisR
 cell line treated 
with CS+CC (0/0 h) and OX+6-SG using 0/0 h and 0/4 sequences. Likewise, the 
protein was fully restored and overrestored due to the treatments of OX+ HK (4/0 h) 
and CS+6-SG (0/0 h) respectively in the cisplatin-resistant A2780
cisR
 cell line (Table 
3.26). The mass spectrum and matched peptides sequence of calreticulin are presented 
in Figure 3.46 and Figure 3.47. 
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Figure 3.46: The mass spectrum of calreticulin 
 
Figure 3.47: Sequences of matched peptides for calreticulin.  
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3.7.1.7 60 kDa heat shock protein, mitochondrial  (CH60) 
 
CH60_HUMAN standing for the protein named 60 kDa heat shock protein, 
mitochondrial has protein accession number is P10809. It was detected at spot number 
13 in untreated parent A2780, cisplatin-resistant A2780
cisR
 and picoplatin-resistant 
A2780
ZD0473R
 ovarian cancer cell lines.  
In cisplatin-resistant A2780
cisR
 cell line, the protein expression was observed to be up-
regulated by 1.92 folds in comparison to its level of expression in the untreated parent 
A2780 cell line. However, the expression of the protein was further up-regulated due 
to treatment with CS+6-SG 0/0 h. But expression level remained unchanged following 
treatment with CS+6-SG (4/0 h). The protein was overrestored as compared to its 
level of expression in parent A2780 cell line due to the treatments with CS+CC (0/0 
h), CS+HK (0/4 h) and OX+HK (4/0 h). Though the expression of 60 kDa heat shock 
protein, mitochondrial could not be identified with rest of the synergistic drug 
combinations (Table 3.26). 60 kDa heat shock protein, mitochondrial was highly 
upregulated in untreated picoplatin-resistant A2780
ZD0473R
 cell line by 5.9 folds in 
comparison to the level expressed in the untreated parent A2780 cell line. However, 
the protein was partially restored back due to the treatment with CS+6-SG (0/0 h) 
(Table 3.27). The mass spectrum and matched peptides sequence of 60 kDa heat 
shock protein, mitochondrial are presented in Figure 3.48 and Figure 3.49. 
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 Figure 3.48: The mass spectrum of 60 kDa heat shock protein, mitochondrial 
 
Figure 3.49: Sequences of matched peptides for 60 kDa heat shock protein, 
mitochondrial.  
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3.7.1.8 Endoplasmin  (ENPL) 
ENPL_HUMAN standing for the protein named endoplasmin has protein accession 
number P14625. It appeared at spot number 18 in untreated parent ovarian cancer 
A2780 cell lines. The expression of endoplasmin was shown to be upregulated by 
1.58 folds in the untreated cisplatin-resistant A2780
cisR
 cell line in comparison to the 
level found in the untreated parent A2780 cell line. However, the protein was over-
restored in comparison to its level in A2780 cell line due to treatments with CS+6-SG 
(0/0 h), CS+HK (0/4 h) and OX+6-SG (4/0 h). Likewise, its expression was partially 
restored back due to the treatment with OX+MA (0/0 h) (Table 3.26).  
Endoplasmin expression in untreated picoplatin-resistant A2780
ZD0473R
 cell line stayed 
the same level as expressed in parent A2780 cell line. However, the protein was 
overrestored due to the treatment with CS+6-SG (0/0 h) (Table 3.27). The mass 
spectrum and matched peptides sequence of endoplasmin are presented in Figure 3.50 
and Figure 3.51. 
 
Figure 3.50: The mass spectrum of endoplasmin 
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Figure 3.51: Sequences of matched peptides for endoplasmin 
3.7.1.9 78 kDa glucose-regulated protein (GRP78) 
GRP78_HUMAN standing for the protein named 78 kDa glucose-regulated protein 
has protein accession number P11021. It was detected at spot number 45 in untreated 
parent ovarian cancer A2780 cell line (Table 3.26).  
The protein spot was absent in untreated cisplatin-resistant cell line and the spot could 
not be detected following treatment of A2780
cisR
 with CS+CC (0/0 h). However, the 
expression of 78 kDa glucose-regulated protein was overrestored due to the treatments 
with CS + 6-SG (0/0 h) and OX + MA (0/0 h). In addition, expression of the protein 
was partially restored due to the treatments with other selected synergistic 
combinations (Table 3.26).  
78 kDa glucose-regulated protein expression was shown to be highly up-regulated by 
2.2 folds in the untreated picoplatin-resistant A2780
ZD0473R
 cell line in comparison to 
its level in A2780 cell line. However, the protein spot could not be detected following 
treatment with CS+6-SG (0/0 h) (Table 3.27).  
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The mass spectrum and matched peptides sequence of 78 kDa glucose-regulated 
protein are presented in Figure 3.52 and Figure 3.53. 
 
 Figure 3.52: The mass spectrum of 78 kDa glucose-regulated protein 
 
 
Figure 3.53: Sequences of matched peptides for 78 kDa glucose-regulated protein 
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3.7.1.10 Heat shock cognate 71 kDa protein (HSP7C) 
HRP7C_HUMAN standing for the protein named heat shock cognate 71 kDa protein 
has protein accession number P11142. It appears as three different spots: Cn16, Cn51 
and Cn90 in the untreated cisplatin-resistant A2780
cisR
 cell line. The protein was 
highly upregulated in all three spots in untreated cisplatin-resistant A2780
cisR
 cell line 
as compared to the level found in the untreated parent A2780 cell line. Spot number 
Cn_16 was further up-regulated due to the treatment with OX+6-SG (4/0 h) while the 
spot could not be detected following treatment with OX+HK (4/0 h). Treatment with 
other synergistic combinations caused partial restoration of protein in cisplatin-
resistant A2780
cisR
 cell line as compared to the level observed in parent A2780 cell 
line. For spot number Cn_51, the protein was partially restored back due to treatments 
with all the synergistic combinations. For spot number Cn_90, over-restoration was 
observed as compared to the level found in parent A2780 cell line due to the 
treatments with CS+CC (0/0 h), CS+HK (0/4 h) and OX+HK (4/0 h). But the protein 
could not be detected due to the application of rest of the synergistic drug 
combinations (Table 3.28).  
Heat shock cognate 71 kDa protein also appears in picoplatin-resistant A2780
ZD0473R
 
cell line at two different spots: Cn_16 and Cn_51. Both spots were highly up-
regulated as compared to the level observed in untreated parent A2780 cell line and 
the fold factors were 5.44 and 18.25 respectively. Due to the treatment with CS+6-SG 
(0/0 h) synergistic combinations, the protein partially was restored back at spot 
number Cn_16 whereas the protein could not be detected at spot number Cn_51 
(Table 3.29). Amongst the three spots, highest mascot score of heat shock cognate 71 
kDa protein has been detected at spot number Cn_16 in the cisplatin-resistant cell line 
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A2780
cisR
. The mass spectrum and matched peptides sequence of heat shock cognate 
71 kDa protein at spot number Cn_16 are presented in Figure 3.54 and Figure 3.55. 
 
Figure 3.54: The mass spectrum of heat shock cognate 71 kDa protein 
 
Figure 3.55: Sequences of matched peptides for heat shock cognate 71 kDa protein.  
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3.7.1.11 10 kDa heat shock protein, mitochondrial (CH10) 
CH10_HUMAN standing for a protein named 10 kDa heat shock protein, 
mitochondrial has protein accession number P61604. It was detected in cisplatin-
resistant A2780
cisR
 cell line at spot number Cn_65. The protein spot was absent in 
untreated parent A2780, treated and untreated picoplatin-resistant A2780
ZD0473R
 cell 
line. However, the protein was highly upregulated in the untreated cisplatin-resistant 
A2780
cisR
 cell line. The protein spot could not be detected following treatment with 
CS+CC (0/0 h). Treatments with other selected synergistic combinations caused 
significant down-regulation of 10 kDa heat shock protein, mitochondrial (Table 3.28). 
The mass spectrum and matched peptides sequence of 10 kDa heat shock protein, 
mitochondrial at spot number Cn_65 are presented in Figures 3.56 and Figure 3.57. 
 
Figure 3.56: The mass spectrum of 10 kDa heat shock protein, mitochondrial 
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Figure 3.57: Sequences of matched peptides for 10 kDa heat shock protein, 
mitochondrial. 
3.7.1.12 Serpin H1 (SERPH) 
SERPH_HUMAN standing for a protein named serpin H1 has protein accession 
number P50454. It appears in the cisplatin-resistant A2780
cisR
 cell line at spot number 
Cn_78. The protein spot could not be detected in the untreated parent A2780, treated 
and untreated picoplatin-resistant A2780
ZD0473R
 cell lines. The protein was found to be 
up-regulated in cisplatin-resistant A2780
cisR
 cell line due to treatment with OX+MA 
(0/0 h). But the protein spot was absent following treatment with other synergistic 
combinations (Table 3.28).  The mass spectrum and matched peptides sequence of 
serpin H1 at spot number Cn_78 are presented in Figure 3.58 and Figure 3.59. 
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Figure 3.58: The mass spectrum of serpin H1 
 
Figure 3.59: Sequences of matched peptides for serpin H1 
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3.7.1.13 Histone H3.3 (H33) 
H33_HUMAN standing for the protein named histone H3.3 has protein accession 
number P06351. It is detected in parent ovarian A2780 cell line at spot number 155. 
The protein spot was not observed in the untreated cisplatin-resistant A2780
cisR
, 
treated and untreated picoplatin-resistant A2780
ZD0473R
 cell lines. However, histone 
H3.3 was partially restored back as compared to the level detected in untreated parent 
A2780 cell line due to treatment CS+HK (0/4 h). The protein expression could not be 
observed in cisplatin-resistant A2780
cisR
 cell line following treatments with rest of the 
synergistic combinations (Table 3.26 and Table 3.27). The mass spectrum and 
matched peptides sequence of histone H3.3 at spot number 155 are presented in 
Figure 3.60 and Figure 3.61. 
 
Figure 3.60: The mass spectrum of histone H3.3 
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Figure 3.61: Sequences of matched peptides for histone H3.3. 
3.7.1.14 Nascent polypeptide-associated complex subunit 
alpha (NACA) 
NACA_HUMAN standing for the protein named nascent polypeptide-associated 
complex subunit alpha has protein accession number Q13765. It was detected as spot 
number 196 in the parent ovarian A2780 cell line. The protein was found to be highly 
upregulated in cisplatin-resistant cell line by 8.14 folds as compared to its level of 
expression in the untreated parent ovarian A2780 cell line. Treatment of cisplatin-
resistant A2780
cisR
 cell line with CS+6-SG (0/0 h) caused over-restoration of protein 
in comparison to the level observed in A2780 cell line. However, the protein spot 
could not be detected following treatment with other synergistic drug combinations. 
The protein was absent in untreated and treated picoplatin-resistant A2780
ZD0473R
 cell 
line (Table 3.26 and Table 3.27). The mass spectrum and matched peptides sequence 
of nascent polypeptide-associated complex subunit alpha at spot number 196 are 
presented in Figure 3.62 and Figure 3.63. 
 162 
 
Figure 3.62: The mass spectrum of nascent polypeptide-associated complex subunit 
alpha 
 
Figure 3.63: Sequences of matched peptides for nascent polypeptide-associated 
complex subunit alpha 
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3.7.1.15 40S ribosomal protein SA (RSSA) 
RSSA_HUMAN standing for the protein named 40S ribosomal protein SA has protein 
accession number P08865. It was observed as spot number Cn_9 in the cisplatin-
resistant A2780
cisR
 cell line. The protein was appeared to be significantly upregulated 
in cisplatin-resistant A2780
cisR
 cell line by 4.9 folds as compared to its level observed 
in the untreated A2780 cell line. The protein was further up-regulated due to treatment 
with OX+6-SG (0/0 h) but was partially restored back due to the treatment with other 
selected synergistic drug combinations (Table 3.28). The protein was also identified to 
be highly upregulated in picoplatin-resistant A2780
ZD0473R
 cell line by 5.39 folds as 
compared to its level of expression detected in untreated parent ovarian A2780 cell 
line. However, the protein was partially restored back due to treatment with CS+6-SG 
(0/0 h) (Table 3.29). The mass spectrum and matched peptides sequence of 40S 
ribosomal protein SA at spot number Cn_9 are presented in Figure 3.64 and Figure 
3.65. 
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Figure 3.64: The mass spectrum of 40S ribosomal protein SA 
 
Figure 3.65: Sequences of matched peptides for 40S ribosomal protein SA 
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3.7.1.16 Elongation factor Tu, mitochondrial (EFTU) 
EFTU_HUMAN standing for the protein named elongation factor Tu, mitochondrial 
has protein accession number P49411. It appeared as spot number Cn_34 in the 
cisplatin-resistant A2780
cisR
 cell line. The protein was upregulated in cisplatin-
resistant A2780
cisR
 cell line in comparison to its level of expression detected in parent 
A2780 cell line. The protein was further upregulated due to treatment with OX+MA 
(0/0 h). The protein could not be detected due to treatment with CS+CC (0/0 h). 
Elongation factor Tu, mitochondrial expression was fully and over-restored as 
compared to the level found in A2780 cell line due to the treatments with OX+HK 
(0/0 h) and CS+HK (0/4 h) respectively. However, treatments with other synergistic 
combinations caused partial restoration of protein expression in the cisplatin-resistant 
A2780
cisR
 cell line (Table 3.28). Elongation factor Tu, mitochondrial also appeared to 
be upregulated by 2.56 folds in picoplatin-resistant A2780
ZD0473R
 cell line as 
compared to its level of expression detected in parent A2780 cell line. However, 
protein spot could not be detected following treatment with CS+6-SG (0/0 h) (Table 
3.29). The mass spectrum and matched peptides sequence of elongation factor Tu, 
mitochondrial at spot number Cn_34 are presented in Figure 3.66 and Figure 3.67. 
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Figure 3.66: The mass spectrum of elongation factor Tu, mitochondrial 
 
Figure 3.67: Sequences of matched peptides for elongation factor Tu, mitochondrial 
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3.7.1.17 Transitional endoplasmic reticulum ATPase 
(TERA) 
TERA_HUMAN stands for the protein named transitional endoplasmic reticulum 
ATPase has protein accession number P55072. It observed as spot number Cn_56 in 
the cisplatin-resistant A2780
cisR
 cell line. However, the protein spot couldn’t be 
detected in untreated parent A2780, treated and untreated picoplatin resistant 
A2780
ZD0473R
 cell lines. The protein found to be upregulated in the cisplatin-resistant 
A2780
cisR
 cell line. The application of CS+6-SG (0/0 h), OX+6-SG (0/0 h), OX+6-SG 
(4/0 h) and OX+MA (0/0 h) were observed to cause down-regulation of transitional 
endoplasmic reticulum ATPase protein expression in the A2780
cisR
 cell line. 
However, the protein spot could not be identified following treatment with other 
synergistic combinations (Table 3.28 and Table 3.29). The mass spectrum and 
matched peptides sequence of transitional endoplasmic reticulum ATPase at spot 
number Cn_56 are presented in Figure 3.68 and Figure 3.69.  
 
 
 
Figure 3.68: The mass spectrum of transitional endoplasmic reticulum ATPase.  
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Figure 3.69: Sequences of matched peptides for transitional endoplasmic reticulum 
ATPase 
3.7.1.18 Peroxiredoxin-6 (PRDX6) 
PRDX6_HUMAN stands for the protein named peroxiredoxin-6 has protein accession 
number P30041. It appeared as spot number Cn_27 in the cisplatin-resistant A2780
cisR
 
cell line. The protein was exceedingly upregulated in cisplatin-resistant A2780
cisR
 cell 
line by 10 folds as compared to its level of expression observed in the untreated parent 
A2780 cell line. The protein spot could not be identified following treatment with 
CS+CC (0/0 h), OX+HK (4/0) and OX+MA (0/0 h). But the protein expression was 
partially restored back to the level detected in untreated parent A2780 cell line due to 
the application of other selected synergistic combinations (Table 3.28). The protein 
also observed to be extremely upregulated in picoplatin-resistant A2780
ZD0473R
 cell 
line by 20.07 folds in comparison to its expression level found in the untreated parent 
A2780 cell line.  
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However, the protein spot could not be detected following treatment with CS+6-SG 
(0/0 h) (Table 3.29). The mass spectrum and matched peptides sequence of 
peroxiredoxin-6 at spot number Cn_27 are presented in Figure 3.70 and Figure 3.71. 
 
Figure 3.70: The mass spectrum of peroxiredoxin-6 
 
 
Figure 3.71: Sequences of matched peptides for peroxiredoxin-6 
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4 Chapter Four: 
Discussion 
4.1 Preamble 
As stated earlier, the objective of the present study was to determine combined effects 
of binary combinations between platinum drugs and compounds from natural sources 
administered to human ovarian cancer cell lines. The results of the study were 
presented in chapter three. This chapter provides a detailed discussion of results 
including IC50 values, dose-response curves and combination indices. The mechanistic 
insight of the combined drug actions obtained from studies on DNA damage, cellular 
accumulation of platinum, level of platinumDNA binding and proteomics are also 
discussed.  
4.2 IC50 values 
4.2.1 Cisplatin 
The IC50 values would indicate that cisplatin has much higher activity against parent 
ovarian A2780 cell line than the cisplatin-resistant A2780
cisR
, picoplatin-resistant 
A2780
ZD0473R
 and p53 null SKOV-3 ovarian cancer cell lines (Table 3.1). The 
resistant factors of cisplatin are 7.64, 5.27 and 7.64 against A2780
cisR
, A2780
ZD0473R
 
and SKOV-3 cell lines respectively. The lower activity of cisplatin against A2780
cisR 
and A2780
ZD0473R
 cell lines is expected. Because A2780
cisR
 cell line was developed 
from the parent cell line A2780 by continual exposure of the cell to cisplatin 
(Behrens, Hamilton et al. 1987) while A2780
ZD0473R
 cell line was also developed from 
the A2780 cell line by continuous exposure of the parent cells to ZD0473 (Holford, 
Beale et al. 2000).  
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As p53 apoptotic protein plays a key role in cisplatin-induced apoptotic cell death, the 
absence of p53 as in SKOV-3 cell line would markedly reduce the capability of 
cisplatin to make cell death in SKOV-3 cell line (Akeshima, Kigawa et al. 2001). 
Previous studies carried out in the host laboratory also found the same trend in the 
activity of cisplatin activity against ovarian cancer cell lines (Yunos, Beale et al. 
2011, Al-Eisawi 2013, Mazumder 2013, Nessa 2013).   
4.2.2 Oxaliplatin 
The IC50 values would indicate that oxaliplatin has greater activity than cisplatin 
against parent ovarian A2780, cisplatin-resistant A2780
cisR
, picoplatin-resistant 
A2780
ZD0473R
 whereas it has lower activity against SKOV-3 cell line (Table 3.1). It is 
believed that the bulky diaminocyclohexane-DNA (DACH) ligand in oxaliplatin 
would allow form intrastrand crosslink with 3 guanine nucleobase of DNA while 
cisplatin would form intrastrand crosslink with 5 guanine nucleobase of DNA. And 
the intrastrand crosslink of oxaliplatin is much stronger and stable than those formed 
by cisplatin. Mismatch repair proteins would not recognize oxaliplatin-DNA adducts. 
Hence it shows greater activity than cisplatin against ovarian parent, cisplatin-resistant 
and picoplatin-resistant cell lines (Sharma, Gong et al. 2007, Ray-Coquard, Weber et 
al. 2009).  As stated earlier, the lower activity of oxaliplatin against SKOV-3 cell line 
is expected because its anticancer activity is highly dependent on p53 pro-apoptotic 
protein induced apoptotic pathway (Hayward, Macpherson et al. 2004). The absence 
of p53 protein in SKOV-3 cell line significantly reduces the activity of oxaliplatin as 
well. Altered p53 protein in colon cancer cell lines is found to cause remarkable 
resistance against oxaliplatin (Toscano, Parmentier et al. 2007).   
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The findings are in agreement with the results of previous research in the host 
laboratory and elsewhere (Yunos, Beale et al. 2011, Al-Eisawi 2013, Nessa 2013, 
Sheng, Jiang et al. 2013).  
4.2.3 Carboplatin 
The IC50 values would indicate that carboplatin has lower activity than cisplatin and 
oxaliplatin against ovarian cancer cell lines (Table 3.1). Despite carboplatin and 
cisplatin having a similar mechanism of action and the spectrum of antitumour 
activity, higher doses of carboplatin are required for carboplatin than those for 
cisplatin to attain equivalent effects (Neidle, Ismail et al. 1980, Kuduk-Jaworska, 
Jański et al. 2017). This is may be due to the presence of bidentate dicarboxylate 
ligand in carboplatin making it less susceptible to hydrolysis associated with the need 
for ring opening (Go and Adjei 1999). For this reason, a longer time is needed for 
activation of carboplatin followed by the formation of carboplatinDNA adducts 
((Kuduk-Jaworska, Jański et al. 2017)). Previous studies carried out in the host 
laboratory also reported that carboplatin is less active than cisplatin and oxaliplatin 
against various ovarian cancer cell lines (Al-Eisawi 2013). 
4.2.4 Mycophenolic acid 
The IC50 values would indicate that mycophenolic acid exhibits comparable activity to 
cisplatin against A2780 cell line but has 6.3, 4.6 and 1.2 times greater activity than 
cisplatin against A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines. It is important to 
note that mycophenolic acid has greater activity against resistant cell lines than parent 
cell line (Table 3.1). It is thought that nuclear factor kappa beta (NF-κB) and  protein 
kinase (AKT/mTOR) pathways are the prime contributors of platinum-based chemo-
resistance  (Li, Ahmed et al. 2005) while mycophenolic acid is the potent inhibitor of 
AKT/mTOR (Dun, Sharma et al. 2014) and NF-κB pathways (He, Smeets et al. 
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2011). Hence it would have better ability to overcome resistance found in the resistant 
cell lines. Mycophenolic acid triggers anticancer activity via inhibition of VEGF-α 
secretion (Monguilhott Dalmarco, Mendes de Córdova et al. 2011), cell cycle arrest 
and p53-mediated programmed cell death (Sun, Dai et al. 2008). Therefore, the 
absence of p53 protein as in SKOV-3 cell line would result in an increase of IC50 
values of mycophenolic acid against SKOV-3 cell line.  
4.2.5 6-Shogaol 
The IC50 values would indicate that 6-shogaol shows significant anticancer activity 
against ovarian cancer cell lines having IC50 values in the range 6.79-10.20 µM. In 
addition, it is the most active compound against SKOV-3 cell line (1.32 and 2.52 
times more active than cisplatin and oxaliplatin respectively) (Table 3.1). It has been 
reported that 6-shogaol significantly prevents cell proliferation against ovarian parent 
A2780 cell line (Rhode, Fogoros et al. 2007). 6-shogaol found to be associated with 
trigger autophagy in breast and colorectal cancers (Ray, Vasudevan et al. 2015, Li and 
Chiang 2017). It also induces autophagy in non-small lung cancer cell line by 
blocking AKT/mTOR transduction pathway (Hung, Hsu et al. 2009). It initiates 
mitotic arrest and decreases the viability of gastrointestinal tumour cells (Ishiguro, 
Ando et al. 2007). It prevents the transition of G2/M phase in the cell cycle to prevent 
colorectal carcinoma (Li and Chiang 2017). 6-shogaol highly down-regulates NF-κB 
genes such as surviving, cyclin D1 and c-MYC to resist prostate cancer (Saha, Blando 
et al. 2014). 6-shogaol decreases expression of matrix metalloproteinase-9 (MMP-9) 
by inhibiting  NF-κB pathway towards prevention of metastasis in breast cancer 
(Ling, Yang et al. 2010).  
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As stated earlier, NF-κB induces chemo-resistance in ovarian cancer while 6-shogaol 
has the ability to dampen the NF-κB expression. Hence it shows comparable activity 
against resistant cell lines. 6-shogaol induces PPAR-γ dependent programmed cell 
death (apoptosis) in breast cancer MCF-7 and colorectal HT-29 cells lines (Tan, Kang 
et al. 2013). It also causes apoptotic cell death through caspase-dependent oxidative 
stress pathway in p53-mutant hepatic mahlavu cells (Chen, Liu et al. 2007). 6-shogaol 
induces caspase-dependent programmed cell death in leukemic cancer (Liu, Peng et 
al. 2013) and triggers up-regulation of pro-apoptotic factors such as interleukin-7, 
BAX and p27 to facilitate apoptotic cell death in prostate cancer (Saha, Blando et al. 
2014). Hence it may show greater activity against p53 null ovarian SKOV-3 cell line.  
4.2.6 Cholecalciferol 
The IC50 values would indicate that cholecalciferol has higher activity than 
carboplatin against all tested ovarian cancer cell lines. It shows higher activity against 
resistant cell lines than the parent cell line (Table 3.1). This may be due to its ability 
to down-regulate the expression of nuclear factor kappa beta (NF-κB) (Wu and Sun 
2011). Pre-clinical studies have shown that cholecalciferol exhibits anticancer effect 
against ovarian, lung, breast and prostate cancers by blocking transition of G0/G1 
phase in the cell cycle, prevents new blood vessel formation during cancer 
progression and triggers apoptotic cell death (Deeb, Trump et al. 2007, Fleet, DeSmet 
et al. 2012). It also causes cell kill by inhibiting interferon-γ to trigger autophagy (Wu 
and Sun 2011). Cholecalciferol was found to be associated with up-regulation of pro-
apoptotic BAX protein expression and would prevent expression of anti-apoptotic 
cyclin D1, Bcl-2  protein (Yang, Lamprecht et al. 2008).  
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Mutation in p53 protein would prevent cholecalciferol induced apoptosis in SKBR3 
breast cancer cell line (Stambolsky, Tabach et al. 2010). Thus, cholecalciferol would 
lower activity against p53 null SKOV-3 cell line.  
4.2.7 Honokiol 
The IC50 values show that honokiol is more active than carboplatin against ovarian 
A2780
cisR
, A2780
ZD0473R
 and SKOV-3 cell lines (by factors of 2.26, 1.84 and 1.75 
respectively). It shows greater activity against the resistant A2780
cisR
  than the parent 
A2780 cell line (Table 3.1). This might be due to the fact that honokiol induces down-
regulation of NF-κB, EFGR, mTOR and STAT3 pathways to produce high 
antitumour activity against ovarian, pancreatic, prostate, skin and gastrointestinal 
cancers (Arora, Bhardwaj et al. 2011, Arora, Singh et al. 2012). Liposomal honokiol 
exhibits significant activity against ovarian parent and cisplatin-resistant cell line in 
vivo (Luo, Zhong et al. 2008). Honokiol has been associated with prevention of 
angiogenesis and induction of caspase-dependent programmed cell death towards 
promoting anticancer activity against chronic lymphocytic leukemia, myeloma and 
leukemia (Fried and Arbiser 2009). Honokiol suppresses cancer progression and 
triggers programmed cell death in lung and colon carcinomas. It also blocks 
expression of human epidermal growth receptor 2 to inhibit breast cancer progression 
(Liu, Zang et al. 2008). Honokiol blocks G1 phase in the cell cycle, trigger the activity 
of pro-apoptotic protein Bax to express anticancer activity against pancreatic cancer 
(Arora, Bhardwaj et al. 2011). Honokiol causes apoptotic cell death via p53 dependent 
(Guo, Bao et al. 2015) as well as p53 independent manner (Wang, Chen et al. 2004).  
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4.2.8 Kaempferol 
The IC50 values would indicate that kaempferol is more active than carboplatin 
against cisplatin-resistant A2780
cisR
 and p53 null SKOV-3 cell lines (by factors of 3.0 
and 1.2 respectively). It shows greater activity against cisplatin-resistant A2780
cisR
 
cell line than parent cell line (Table 3.1). Kaempferol inhibits the proliferation of 
ovarian OVCAR-3, A2780/wt, and A2780/CP70 cells at 40 µM or higher 
concentration after incubation for 24 h (Luo, Rankin et al. 2011). As 72 h incubation 
period applied in our studies, so it is to be expected that the IC50 values would be 
much lower against ovarian cancer cell lines. Kaempferol prevents angiogenesis and 
VEGF expression, induces apoptosis by activating caspase-3, caspase-7, upregulates 
the expression of pro-apoptotic p53, Bax proteins and downregulated anti-apoptotic 
Bcl-XL protein in ovarian OVCAR-3, A2780/wt, and A2780/CP70 cells (Luo, Rankin 
et al. 2009, Luo, Rankin et al. 2011). Kaempferol inhibits Bcl-xL expression while it 
increases the expression of caspase-3, caspase-7 and caspase-9 in HT29 colon cancer 
cell line (Lee, Cho et al. 2014) and induces p53 dependent growth inhibition and 
apoptotic cell death in HCT116 colon cancer cell line (Li, Du et al. 2009). Kaempferol 
is associated with downregulation of NF-κB and AKT expression in different cancer 
cell lines. It inhibits G2/M phase transition in the cell cycle by inhibiting cyclin-
dependent kinase 1 and cyclin B. Moreover, kaempferol inhibits ERKp38- JNK and 
AP-1 signaling pathways to prevent invasion of the cancer cell (Kim and Choi 2013).  
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4.3 Drug Combinations 
4.3.1 Combination of platinum drugs with 6-
Shogaol  
Combination indices (Table 3.13) indicate that bolus addition of 6-shogaol with 
oxaliplatin (0/0 h) manifested moderate synergism against all the four ovarian cancer 
cell lines: A2780, A2780
cisR
, A2780
ZD0473R
 and SKOV-3. In contrast, sequenced 
administrations (0/4 h and 4/0 h) generally produced additive to antagonistic effects at 
lower concentration although slight synergism was observed in A2780
ZD0473R
 and 
SKOV-3 cell lines. At higher concentrations, the nature of combined drug action 
became more synergistic especially for 0/0 h and 4/0 h sequences of administration 
(Table 3.13).  
As applied to combinations of 6-shogaol and cisplatin (Table 3.12), 0/0 h and 0/4 h 
sequences of administration showed mild synergism against A2780 cell line, whereas 
4/0 h sequence of administration was found to be antagonistic at lower concentrations 
(ED50 and ED75) and additive at ED90. However, all three sequences of administration 
displayed mild to moderate synergism against A2780
cisR
 cell line and degree of 
synergism increased with the increase in concentration. Bolus administration (0/0 h 
sequence) showed moderate synergism at lower concentration but antagonism at a 
higher concentration in A2780
ZD0473R
 cell line. The converse was true as applied to 
0/4 h and 4/0 h sequences of administration. In SKOV-3 cell line, all three sequences 
of administration showed antagonism except for 4/0 h at the ED50 (Table 3.12).  In 
summary, 6-shogaol in combination with cisplatin and oxaliplatin was observed to be 
synergistic with bolus administration (0/0 h sequence) at lower concentration (ED50) 
against A2780, A2780
cisR
 and A2780
ZD0473R
 cell lines (Table 3.21 and Table 3.13).   
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And in SKOV-3 cell line, 6-shogaol in combination with cisplatin and oxaliplatin 
showed additiveness at lower concentration (ED50) with 4/0 h sequence meaning 6-
shogaol added first then cisplatin or oxaliplatin added four hours later (Table 3.21 and 
Table 3.13).  
From the above discussion, it can be stated that 6-shogaol showed sequence and 
concentration-dependent synergism with platinums in most of the cases. Current 
literature indicates that NF-B acts as a significant player in about fifteen percent of 
solid tumours including ovarian cancer (Pacifico and Leonardi 2006, Banerjee, Zhang 
et al. 2007, Xia, Shen et al. 2014, Wu, Wu et al. 2015). AKT or protein kinase B also 
contributes significantly to cancer progression and chemo-resistance. In contrast, most 
cancer preventive agents are believed to inhibit NF-B and AKT pathways 
(Yamamoto and Gaynor 2001, Nguyen-Hai 2006, Karunaweera, Raju et al. 2015, 
Luettig, Rosenthal et al. 2016). Whereas aberrant activation of NF-B and AKT 
would provide protection against programmed cell death and enhance proliferation of 
cancerous cells, inactivation of them would enhance apoptosis. In contrast, 6-shogaol 
has the ability to attenuate NF-κB expression in different cancer cell lines (Ling, Yang 
et al. 2010, Hong, Huang et al. 2013, Saha, Blando et al. 2014, Wang, Zhou et al. 
2016, Han, Yuan et al. 2017). 6-shogaol is also observed to be associated with 
reduced AKT expression in different cancer cell lines (Hung, Hsu et al. 2009, Kim, 
Lee et al. 2014, Luettig, Rosenthal et al. 2016). 6-shogaol was found to inhibit 
expression of anti-apoptotic protein Bcl-2 (Wang, Hong et al. 2013) and triggered 
PPAR-γ dependent apoptotic pathways (Tan, Kang et al. 2013, Han, Yuan et al. 2017) 
to facilitate programmed cell death. Platinum resistance in ovarian cancer is believed 
to be associated with the upregulation of NF-B and AKT at the molecular level (Li, 
Ahmed et al. 2005, Vilma Maldonado and Jorge 2008, Godwin, Baird et al. 2013), 
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whereas 6-shogaol has shown the ability to downregulate their expression. Therefore, 
6-shogaol would act synergistically with platinum drugs against ovarian cancer. 
Recently prooxidant activity of 6-shogaol has been identified especially at lower 
concentrations (Annamalai, Kathiresan et al. 2016). Due to this activity, it can 
generate oxidative stress inside the cell which can further lead to apoptotic cell death. 
Oxidative stress could cause increased depletion of glutathione. Reduction of 
glutathione concentration inside the cell may make more platinum drugs being 
available to bind with DNA to kill cancer cells. The exact mechanism could not be 
identified due to the limitation of the scope of the present study. 6-shogaol increases 
gemcitabine activity against pancreatic cancer by inhibiting expression of TLR4/NF-
κB genes such as survivin, XIAP, cyclinD1, COX-2 and cIAP-1 (Zhou, Qi et al. 
2014). To the best of our knowledge, the present study is the first to apply 
combinations of platinum drugs and 6-shogaol against ovarian cancer cell lines. 
4.3.2 Combination of platinum drugs with 
honokiol 
Combination indices (Table 3.17) show that combinations of cisplatin with honokiol 
was mildly synergistic to additive at ED50 but moderately synergistic at higher added 
concentrations (ED75 and ED90) against A2780 cell line irrespective of the sequence 
of administration. In A2780
ZD0473R 
cell line, 0/0 h and 4/0 h sequences of drug 
administration were shown to be additive at ED50 but moderately synergistic at higher 
concentrations (ED75 and ED90). 0/4 h sequence of administration produced weak 
synergism at lower concentrations (ED50 and ED75) and additiveness at ED90.  
In SKOV-3 cell line, 0/4 h mode of addition was found to be additive at ED50 (Table 
3.17).  
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When A2780 cells were treated with a combination of oxaliplatin and honokiol (Table 
3.18), all three sequence combinations were slightly synergistic at ED50 and moderate 
to strongly synergistic at higher concentrations (ED75 and ED90). However, the same 
combinations applied to the A2780
cisR 
cell line presented antagonism at ED50 but 
moderate to high synergism at higher concentrations (ED75 and ED90) with all three 
sequences of drug administration. The same effect was found to be true in 
A2780
ZD0473R
 cell line. In SKOV-3 cell line, 0/4 h sequence of drug administration 
observed to be additive at ED90 (Table 3.18).  
As applied to the combination of carboplatin and honokiol (Table 3.19), 0/0 h and 0/4 
h sequences of drug administration were observed to be additive at lower 
concentration (ED50) against A2780 cell line. However, the nature of combined drug 
action became more synergistic at higher concentrations irrespective of the sequences 
of drug administration. In A2780
cisR
 cell line, all the three sequences of drug 
administration displayed additiveness at all added drug concentrations and degree of 
synergism was increased with the increase in drug concentration as in A2780. In 
A2780
ZD0473R
 cell line, all the three modes of drug administration produced 
antagonism at lower concentration (ED50). But as the concentration was increased, the 
nature of combined drug action was observed to be synergistic as applied to 0/0 h and 
0/4 h sequences of drug administration (more so at ED90 than at ED75). In the SKOV-
3 cell, all the three sequences of drug administration were found to be antagonistic at 
lower concentration (ED50) but additive and mildly synergistic at higher 
concentrations ED75 and ED90 respectively (Table 3.19).  
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In summary, honokiol in combination with cisplatin, oxaliplatin and carboplatin was 
synergistic with bolus administration (0/0 h sequence) at ED50 against A2780 cell line 
and degree of synergism increased with increase in added drug concentration. 
Honokiol showed synergism with platinum drugs at higher concentrations in most of 
the cases, especially for the 4/0 h sequence.  
Honokiol is the key component of magnolia tree and commonly used as a Chinese 
herbal medicine. It can be act as an antioxidant, anticancer, antiplatelet, anti-
inflammatory, antiarrhythmic, anxiolytic, antiviral agent (Liou, Shen et al. 2003, 
Chen, Lu et al. 2011, Lan, Wang et al. 2012, Woodbury, Yu et al. 2013) and more 
importantly, it can act as a mediator of overcoming drug-resistance in conventional 
anticancer therapy (Ishitsuka, Hideshima et al. 2005). For example, it has been stated 
that liposomal honokiol in combination with cisplatin significantly increases apoptotic 
cell death in in-vitro and in-vivo colon CT26 and in vitro ovarian SKOV-3 cancer 
models (Liu, Chen et al. 2008, Cheng, Xia et al. 2011). The same combination 
strongly inhibited new blood vessel formation (angiogenesis) and induced 
programmed cell death (apoptosis) against human A549 lung cancer xenograft model 
(Jiang, Fan et al. 2008). Honokiol in combination with oxaliplatin greatly increases 
programmed cell death (apoptosis) by increasing expression of the pro-apoptotic 
factor caspase-3 against human colorectal HT-29 tumour model. The combination 
also found to significantly inhibit expression of the pro-carcinogenic factors such as 
NF-κB, P65, AKT, VEGF protein, ERK1/2, PGE2 and COX-2 to prevent cancer 
progression of the human colon HT-29 tumour model (Hua, Chen et al. 2013). 
Honokiol in combination with lapatinib was reported to significantly inhibit cell 
proliferation and triggered apoptotic cell death in HER-2 breast cancer tumour model.  
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mTOR inhibitor rapamycin markedly increased honokiol-induced programmed cell 
death in MCF-7 and drug-resistant MCF-7 breast cancer tumour models (Liu, Zang et 
al. 2008). Honokiol in combination with 5-fluorouracil synergistically induced 
apoptosis in oral squamous cell carcinoma by intrinsic pathways (Ji, Jiang et al. 
2017). 
Synergistic effects were more pronounced at higher doses of honokiol and platinum 
drugs in combination. This might be due to the antioxidant effect of honokiol which 
would neutralize reactive oxygen species at lower concentration (Liou, Shen et al. 
2003) whereas platinum drugs could show anticancer activity by inducing oxidative 
stress (Carozzi, Marmiroli et al. 2010, Mazumder 2013). Therefore, honokiol exhibits 
antagonistic or additive effects at a lower concentration in most of the cases. But at 
higher concentration, honokiol showed anticancer activity and therefore act 
synergistically with a platinum drug.  
As stated earlier, platinum chemo-resistance is mainly due to overexpression of NF-
B and AKT mediated transduction pathways whereas honokiol has the enormous 
potential to inhibit NF-B and AKT pathways (Crane, Panner et al. 2009, Kumar, 
Kumar Singh et al. 2013, Qiu, Xu et al. 2015). Honokiol can inhibit angiogenesis 
(Bai, Cerimele et al. 2003), induces G1 phase cell cycle arrest (Singh, Prasad et al. 
2013), triggers autophagy and apoptosis (Battle, Arbiser et al. 2005, Luo, Li et al. 
2017) to express anticancer activity. Hence, honokiol can act synergistically with 
platinum drugs.  However, the particular mechanism could not be identified due to the 
limitation of the scope of the present study. 
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4.3.3 Combination of platinum drugs with 
mycophenolic acid 
Combination indices (Table 3.14) indicate that combination of cisplatin with 
mycophenolic acid administered with 0/0 h and 0/4 h sequences manifested 
antagonism at lower concentrations (ED50 and ED75) but slightly synergistic to 
additive at ED90 in A2780 and A2780
ZD0473R
 cell lines. In A2780
cisR
 cell lines, 0/0 h 
and 4/0 h sequences of administration displayed moderate synergism at all applied 
concentrations where the degree of synergism increases with the increase of applied 
concentrations. Generally, all three sequences of administration exhibited mild 
synergism to additive effect at lower concentrations (ED50 and ED75) but moderately 
synergistic at high concentration (ED90) against SKOV-3 cell line (Table 3.14).  
When A2780 cells were treated with a combination of oxaliplatin and mycophenolic 
acid (Table 3.15), all sequence combinations were additives to weak antagonistic at 
ED50 but the moderate synergistic at higher concentrations (ED75 and ED90) against 
A2780 cell line. However, the degree of synergism was found to increase with the 
increase of added drug concentrations. In A2780
cisR
 cell line, all three sequence 
combinations were manifested antagonism at ED50 but moderately synergistic at ED75 
and highly synergistic at ED90.  In A2780
ZD0473R
 cell line, all of three modes of 
administration were antagonistic at ED50. However, 0/0 h sequence of administration 
was found to be slightly synergistic at the higher concentrations (ED75 and ED90) 
whereas 4/0 sequence of administration showed additiveness at the same 
concentrations. As applied to the SKOV-3 cell line, all sequences of administration 
were found to be antagonistic at lower concentrations (ED50 and ED75) but additive at 
ED90 (Table 3.15). From above discussion, combinations of oxaliplatin and 
mycophenolic acid were exhibited synergism at higher concentration.  
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Mycophenolic acid is a marine compound isolated from fungus Penicillium 
brevicompactum. It’s prodrug mycophenolate mofetil widely used as an 
immunosuppressant during kidney transplantation. It also can be used in the treatment 
of viral, fungal and psoriasis infections and more importantly against cancer 
(Silverman Kitchin, Pomeranz et al. 1997). Mycophenolic acid showed synergism 
with platinum at a higher concentration in most of the cases. Mycophenolic acid acts 
as an antioxidant by reducing reactive oxygen species (ROS) level at the cell (Saad, 
Arafah et al. 2007, Dalmarco, Budni et al. 2009) whereas platinum drugs can exhibit 
cytotoxicity by producing ROS (Marullo, Werner et al. 2013, Choi, Kim et al. 2015). 
Thus, mycophenolic acid might act as an antioxidant at a lower concentration, but 
mediate cytotoxicity at higher concentration. For this reason, synergistic effect has 
been observed at higher concentration. It is assumed that higher expression of NF-B 
and AKT are the main reasons for platinum-resistance in ovarian cancer. 
Mycophenolic acid significantly reduces NF-B (Hauser, Johnson et al. 1997, 
Andreucci, Faga et al. 2010, Hai-Dong, Zhi-Hong et al. 2016) and AKT (He, Smeets 
et al. 2011, Zeng, Qin et al. 2016) expressions in human endothelial cancer cell lines. 
Therefore, it displayed synergistic effects in combination with platinum drugs. 
Mycophenolic acid in combination with cisplatin and carboplatin was observed to be 
synergistic at lower concentration (ED50) irrespective of sequence of administration 
against p53 null SKOV-3 cell line and degree of synergism increased with increase in 
concentration.  
From the IC50 values (Table 3.1), approximately 4.3 times greater doses of 
mycophenolic acid were needed to get cytotoxicity against SKOV-3 cell line in 
comparison to the other three ovarian cancer cell lines.  
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Mycophenolic acid induces necrosis to promote apoptotic cell death in apoptosis-
resistant Dab-1 (lymphoblastoid B-cell line), CEM (leukemic T-cell line) and jurkat 
(doxorubicin-resistant) cancer cell lines (Guidicelli, Chaigne-Delalande et al. 2009). 
The mycophenolic acid in combination with imatinib was observed to synergistically 
trigger apoptosis to K562 parental and K562R leukemic cancer cell lines whereas 
imatinib alone fails to induce apoptosis in those cells (Gu, Santiago et al. 2005, 
Drullion, Lagarde et al. 2012). As stated earlier, cisplatin and carboplatin have a 
similar mode of action and the spectrum of anticancer effects (Neidle, Ismail et al. 
1980, Kuduk-Jaworska, Jański et al. 2017). For this reason, mycophenolic acid may 
show synergistic effect with both cisplatin and carboplatin in SKOV-3 cell line. 
However, the particular mechanism could not be identified due to the limitation of the 
scope of the present study. To the best of our knowledge, the present study was the 
first to apply combinations of platinum drugs and mycophenolic acid against ovarian 
cancer cell lines. 
4.3.4 Combination between cholecalciferol and 
platinum drugs 
Combination indices (Table 3.20) show that bolus addition (0/0 h sequence) of 
cisplatin and cholecalciferol was found to be additive and weakly synergistic at ED75 
and ED95 respectively in the A2780 cell line. In A2780
cisR 
cell line, 0/0 h and 0/4 h 
sequences of drug administration exhibited weak synergism and additiveness 
respectively at lower concentration (ED50). In A2780
ZD0473R
 cell line, high antagonism 
observed with all sequences of administration irrespective of applied drug 
concentrations and degree of antagonism increased with increase in drug 
concentrations.  
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In SKOV-3 cell line, all the three sequences of drug administration were found to be 
weakly synergistic at ED50 but additive at higher concentrations (ED75 and ED90). 
When SKOV-3 cells were treated with a combination of oxaliplatin and 
cholecalciferol, all three sequence combinations were slightly synergistic. Likewise, 
bolus administration (0/0 h sequence) applied to A2780
ZD0473R
 cell line was found to 
be slightly synergistic at ED50. Besides, 4/0 h sequence of administration displayed 
additiveness at higher concentration (ED90) in A2780 cell line. However, the rest of 
the combinations applied to A2780, A2780
cisR
 and A2780
ZD0473R
 cell lines were 
observed to be antagonistic.  
Cholecalciferol in combination with cisplatin and oxaliplatin was synergistic at ED50 
irrespective of a sequence of addition to the SKOV-3 cell line. Cholecalciferol 
potentiated cisplatin and carboplatin anticancer activity against LNCaP and DU145 
prostate cancer (Moffatt, Johannes et al. 1999) and  MCF-7 breast cancer cell lines 
(Cho, Christensen et al. 1991, Ma, Trump et al. 2010). Cholecalciferol enhances 
cisplatin-induced cell kill against human retinoblastoma Y-79 xenograft model 
(Kulkarni, van Ginkel et al. 2009). Cholecalciferol in combination with cisplatin 
highly upregulated mitogen-activated protein kinase-1 (MEKK-1) expression to 
induced apoptotic cell death in murine squamous cell carcinoma (SCC) (Hershberger, 
McGuire et al. 2002, Ma, Trump et al. 2010). In contrast, mutation in p53 was 
reported to inhibit cisplatin-mediated apoptosis in SKBR3 breast cancer cell line 
(Stambolsky, Tabach et al. 2010).  
However, cholecalciferol in combination with cisplatin-associated with potentiation of 
caspase-dependent apoptotic cell kills and synergistically delivered anticancer effect 
against T24 and UMUC3 human bladder cancer cell lines (Ma, Yu et al. 2010).  
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Cholecalciferol in combination with microtubuline inhibitors docetaxel or paclitaxel 
triggered programmed cell death and inhibited cell proliferation in prostate cancer cell 
line  (Ting, Hsu et al. , Hershberger, Yu et al. 2001). It can be assumed that by 
interfering with the above mechanisms cholecalciferol showed synergistic activity 
against ovarian SKOV-3 cell line. However, the particular mechanism could not be 
identified due to the limitation of the scope of the present study. To the best of our 
knowledge, the present study is the first report to apply combinations of platinum 
drugs and cholecalciferol against ovarian cancer cell lines. 
4.4 Cellular accumulation and 
platinumDNA binding 
Cellular accumulations from cisplatin alone and its selected combinations (Table 3.22 
and Table 3.23) indicate that highest amount of platinum resulted when A2780 cells 
were treated with the combination of cisplatin and 6-shogaol administered as a bolus. 
Passive diffusion and active transport via copper transporter receptor 1 (CTR1) are the 
two major pathways involved with cisplatin influx (Al-Eisawi 2013). However, 
cisplatin is involved with proteasomal degradation and down-regulation of CTR1 
expression (Al-Eisawi 2013, Nessa 2013, Kilari, Guancial et al. 2016) thus reducing 
its own influx. In contrast, a recent study reported that 6-shogaol can act as a 
proteasomal inhibitor (Nedungadi, Binoy et al. 2018). Therefore, 6-shogaol could 
prevent cisplatin-induced CTR1 down-regulation. Hence in the presence of 6-shogaol, 
cellular accumulation of platinum would be higher and subsequently higher platinum-
DNA binding could result.  
Combination of cisplatin with honokiol using 0/0 sequence showed half of the 
platinum accumulation compared to that of cisplatin alone against the same cell line. 
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In contrast, cisplatin alone treatment caused the greatest extent of platinum 
accumulation in A2780
cisR
 cell line among all the treated groups.   
Cellular accumulations from oxaliplatin alone and its selected combinations (Table 
3.22 and Table 3.23) indicate that highest amount of platinum resulted from 
oxaliplatin alone whereas treatment with combination of oxaliplatin and 6-shogaol 
using bolus administration produced slightly lower platinum accumulation compared 
to that from oxaliplatin alone in both A2780 and A2780
cisR
 ovarian cell lines. Other 
combinations of oxaliplatin presented less than half of the platinum accumulation in 
comparison to that from oxaliplatin alone in A2780 cell line. Although the platinum 
accumulation from oxaliplatin was much less than that from cisplatin in both the 
parent and the resistant cell lines reflecting differences in the nature of the carrier 
ligands and leaving groups. In particular, the bulky nature of oxaliplatin may make it 
less amenable to be carried across the cell by the copper transporter. 
Platinum-DNA binding study on cisplatin and its selected combinations (Table 3.24 
and Table 3.25) indicate that the bolus administration (0/0 h sequence) of cisplatin 
and honokiol resulted in 9.5 times higher platinum-DNA binding than that from 
cisplatin alone in A2780 cell line whereas combination of cisplatin with 6-shogaol 
using the same sequence resulted in 3.3 times greater level of platinum-DNA binding.  
Combination of cisplatin with cholecalciferol using bolus administration also 
produced higher platinum-DNA binding (about two times greater) than from cisplatin 
in A2780
cisR
 cell line whereas the combination of cisplatin with 6-shogaol using 4/0 h 
sequence resulted in 1.5 times more platinum-DNA binding.  
Combination of cisplatin with mycophenolic acid (0/0 h) was found to show similar 
platinum-DNA binding as compared to that from cisplatin alone. 
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Platinum-DNA binding study of oxaliplatin alone and its selected combinations 
(Table 3.24 and Table 3.25) indicate that oxaliplatin alone and in combination with 
mycophenolic acid using 4/0 sequence revealed similar platinum-DNA binding in 
A2780 cell line. However, other combinations showed lower platinum-DNA binding 
in the same cell line. As applied to the platinum-DNA binding of oxaliplatin in the 
A2780
cisR 
cell line, higher platinum-DNA binding was observed from oxaliplatin 
alone rather than combination of oxaliplatin with 6-shogaol using bolus 
administration. It was observed that 6-shogaol in combination with cisplatin 
significantly increased platinum binding with DNA in both A2780 and A2780
cisR
 cell 
lines (Table 3.24 and Table 3.25).  
Increase in platinum binding can be explained by the prooxidant activity of 6-shogaol 
(Annamalai, Kathiresan et al. 2016). Due to the generation of excessive reactive 
oxygen species (ROS) (Han, Woo et al. 2015, Annamalai, Kathiresan et al. 2016), 
more glutathione will be used up to neutralize the oxidative stress. As a result, an 
increased amount of cisplatin will be available to bind with DNA. It has been 
observed that honokiol facilitated cisplatin binding with DNA in A2780 cell line 
whereas cholecalciferol did the same in the A2780
cisR
 cell line. Honokiol too was also 
reported to be associated with increased formation of reactive oxygen species (Sun, 
Liao et al. 2017, Huang, Chen et al. 2018). Hence intracellular glutathione 
concentration will be reduced in presence of honokiol and higher amount of cisplatin 
will be able to bind with DNA. And it has been reported that in presence of 
cholecalciferol, glutathione depletion might occur (de Talamoni, Marchionatti et al. 
1996), hence it could allow higher cisplatin-DNA binding. Decreased DNA repair 
might also contribute to higher platinum-DNA binding. 
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Despite using lower concentration of oxaliplatin applied in A2780 and A2780
cisR
 cell 
lines than cisplatin, platinum-DNA binding of oxaliplatin was found to be 1.5 times 
higher in A2780 cell line and similar in the A2780
cisR
 cell line. This may be one of the 
reasons why oxaliplatin is found to be the most active compound against A2780 and 
A2780
cisR
 cell lines.  
Generally, it is assumed that higher intracellular platinum accumulation would 
produce higher cytotoxic effects of platinums towards cancer cells. However, in 
presence of intracellular platinophiles namely glutathione (Chen and Kuo 2010, 
Traverso, Ricciarelli et al. 2013, Cadoni, Valletta et al. 2017) and metallothionein 
(Ruttkay-Nedecky, Nejdl et al. 2013), a large number of platinums could be 
deactivated. Also increased DNA damage repair could significantly limited activity of 
platinum against cancer cell lines (Johnson, Laub et al. 1997, Martin, Hamilton et al. 
2008, Shen, Pouliot et al. 2012, Bonanno, Favaretto et al. 2014, Stefanou, Bamias et 
al. 2015). Downstream protein activation from binding with DNA plays key roles in 
determining death of cancer cells (Ohndorf, Rould et al. 1999, Kartalou and 
Essigmann 2001, Zorbas and Keppler 2005, Ang, Myint et al. 2010, Zhu, Chang et al. 
2010).  Therefore, free intracellular platinum concentration at the site of action, DNA 
damage repair, activity pattern of pro-apoptotic and or anti-apoptotic proteins are the 
rate limiting factors for cancer cell death.  
4.5 DNA damage study 
DNA damage study applying to platinum drugs, natural compounds and their selected 
combinations (Figure 3.29 and Figure 3.31) showed that cisplatin caused significant 
DNA damage in A2780 cell line. It is to be expected because the anticancer activity of 
cisplatin is mainly due to DNA damage (Siddik 2003, Shen, Pouliot et al. 2012, 
Dasari and Bernard Tchounwou 2014).  
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Among compounds from the natural sources, honokiol alone and in combination with 
cisplatin produced significant DNA damage in A2780 cell line. Honokiol potentiates 
bleomycin activity against human cancer cell lines by inhibiting DNA repair pathways 
in different cancer cell lines. Honokiol blocked DNA polymerases  and  action to 
prevent base excision repair and nonhomologous end joining pathways respectively 
(Gowda, Suo et al. 2017).  Honokiol in combination with radiotherapy facilitated 
radiotherapy induced DNA damage by suppressing the expression of survivin (potent 
DNA damage repair protein) in head and neck squamous cell carcinoma (Wang, 
Beitler et al. 2017). To be the best of our knowledge, this is the first study to report on 
DNA damage due to honokiol.  
6-shogaol alone and in combination with cisplatin caused only slight DNA damage in 
A2780 cell line. It also has the ability to cause DNA damage in Hep-2 laryngeal 
(Annamalai, Kathiresan et al. 2016), COLO 205 colorectal (Pan, Hsieh et al. 2008) 
and mahlavu liver (Chen, Liu et al. 2007) cancer cell lines. Thus 6-shogaol alone and 
in combination with platinum drugs is found to cause DNA damage in the A2780 cell 
line. Although IC50 values (Table 3.1) indicate that 6-shogaol has the higher activity 
than honokiol against A2780 cell line, honokiol is found to cause greater DNA 
damage than 6-shogaol. Hence DNA damage is not the key indicator for compounds 
activity against ovarian cancer cell line. To be the best of our knowledge, this is the 
first study to report on DNA damage due to 6-shogaol in combination with platinum 
against any tumour models. In contrast to cisplatin, oxaliplatin and its selected 
combinations did not show any effect to DNA in A2780 cell line.  
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Cholecalciferol alone and in combination with cisplatin is found to cause much DNA 
damage in the A2780
cisR
 cell line. But the major role of cholecalciferol is believed to 
prevent DNA damage by activating DNA repair pathways (Kansara and Sen Gupta 
2018). This may be more significant at lower concentrations. However, higher 
concentrations needed to cause cell death by cholecalciferol against the ovarian cancer 
cell line means that the protective role against DNA damage may not be in play 
(Table 3.1). Thus, cholecalciferol has displayed higher DNA damage at higher 
concentrations. Calcitriol, the activated form of cholecalciferol has been shown to 
cause DNA damage in lymphocytes (Rizvi, Hasan et al. 2013).  
Mycophenolic acid alone did not show any DNA damage, but in combination with 
cisplatin showed much DNA damage. It is thought although mycophenolic acid might 
not cause DNA damage; in combination it would facilitate DNA damage due to 
cisplatin.  
4.6 Proteomics studies  
4.6.1 Actin, Cytoplasmic 1 (ACTB) 
The protein is coded as ACTB and also known as beta-actin. Three types of actin are 
found in humans including alpha (α), beta () and gamma (γ) actin. Among these 
three categories α actin is primarily found in muscles e.g. skeletal and smooth. In 
contrast  actin is ubiquitous as meshwork in non-muscles whereas γ actin is 
considered as both muscle and non-muscle variant. The main functions of actin 
proteins are regulating the shape, motility and mechanics of the cell (Bunnell, 
Burbach et al. 2011, Dominguez and Holmes 2011, Artman, Dormoy-Raclet et al. 
2014, Xu, Huff et al. 2017). The history of using  actin as a reference gene dates 
back to a long time. But such use has now been challenged.  
 193 
The elevated expression of   actin has been observed in many cancers including skin 
cancer, stomach cancer, hepatoma, lung carcinoma, breast and ovarian carcinoma 
(Waxman and Wurmbach 2007, Li, Ye et al. 2009, Suzuki, Akira et al. 2010, Guo, 
Liu et al. 2013, Xu, Huff et al. 2017). 
In the present study, expression of ACTB was identified to be significantly 
upregulated in untreated A2780
cisR
 cell line at three different spots; 1, Cn_39 and 
Cn_79 in comparison to the level of its expression in the untreated A2780 cell line. 
ACTB was over-restored at spot number 1 in comparison to the level observed in 
untreated A2780 due to treatments with CS + 6-SG (4/0 h) and CS + HK (0/4 h) while 
it was partially restored back following administration with other synergistic 
combinations (Table 3.28). The protein was over-restored compared to the level found 
in untreated A2780 cell line at spot number Cn_39 due to the treatments with CS+6-
SG (0/0 h), OX+6-SG (0/0 h), OX+6-SG (4/0 h) and OX+HK (4/0 h). The protein 
spot could not be detected when treated with CS + CC (0/0 h), CS + HK (0/4 h) and 
OX + MA (0/0 h) meaning the protein was highly over-restored due to the treatments. 
Though the protein was found to be highly upregulated at spot number Cn_79, the 
protein spot could not be identified due to the treatments with most of the synergistic 
combinations meaning the protein was highly over-restored on these occasions (Table 
3.28).  
Previous studies in the host laboratory also reported that actin, cytoplasmic 1 was 
significantly over-expressed in the A2780
cisR
 cell line (Al-Eisawi 2013, Mazumder 
2013, Nessa 2013). From the above discussion, it could be stated that ACTB is anti-
apoptotic in nature and contribute significantly towards chemo-resistance in ovarian 
cancer. Thus the synergistic combinations have the ability to suppress the expression 
of ACTB to overcome drug-resistance.    
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4.6.2 Cofilin-1 (COF1)  
The protein is coded as COF1 and belongs to ADF (actin depolymerizing family) 
proteins. Till today three different types of ADF proteins have been discovered 
namely: COF1 (Cofilin-1), COF2 (Cofilin-2) and destrin. Among these three 
categories, the most abundant protein is Cofilin-1 with 95% and the other two 
constitutes the rest 5%. The primary function of Cofilin-1 is to control actin dynamics 
to bind with monomeric G actin and filamentous F actin (Wang, Eddy et al. 2007, 
Yamaguchi and Condeelis 2007). Moreover, the protein has been reported to have the 
capability to activate phospholipase D1 and cytochrome-c associated apoptotic cell 
death (Han, Stope et al. 2007, Bamburg and Bernstein 2010). Increased expression of 
the protein has been noticed in breast carcinoma, ovarian carcinoma, oesophageal 
cancer, lung and pancreatic cancer (Sinha, Hütter et al. 1999, Martoglio, Tom et al. 
2000, Keshamouni, Michailidis et al. 2006, Turhani, Krapfenbauer et al. 2006, 
Dowling, Meleady et al. 2007). 
In the current study, COF1 was detected to be significantly upregulated in untreated 
A2780
cisR
 cell line as compared to the level of expression observed in the untreated 
A2780 cell line. The COF1 was over-restored compared to the level detected in 
untreated A2780 cell line following treatments with CS+6-SG (0/0 h), CS+HK (0/4 h) 
and OX+MA (0/0 h). The protein spot could not be identified due to the treatments 
with CS+CC (0/0 h) and OX+6-SG (4/0 h) indicating the protein was highly over-
restored in these occasions (Table 3.28).  
From the above discussion, it can be said that cofilin-1 is an anti-apoptotic protein that 
plays a significant role towards drug-resistance in ovarian cancer while expression of 
cofilin-1 could be changed by the selected combinations of platinums and natural 
compounds towards overcoming drug-resistance.  
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4.6.3 Vimentin (VIME) 
The protein is encoded as VIME and belongs to intermediate filament category of 
cytoskeleton proteins. It is universally located in mesenchymal cells and recognized 
as type III intermediate filaments. The main function of vimentin is to maintain 
cellular integrity, adhesion and motility (Lundkvist, Reichenbach et al. 2004, Satelli 
and Li 2011). The protein has also been reported to perform a significant role in 
epithelial to mesenchymal transition (EMT) and cell survival mechanisms. Vimentin 
is considered to be the marker protein to distinguish breast cancer from metastasized 
one to the nonmetastasized counterparts (Ngan, Yamamoto et al. 2007, Lahat, Zhu et 
al. 2010, Satelli and Li 2011). Overexpression of VIME is evidenced in ovarian 
carcinoma, bronchial carcinoma, prostate and stomach cancers (Al-Saad, Al-Shibli et 
al. 2008, Wei, Xu et al. 2008, Otsuki, Inokuchi et al. 2011, Al-Eisawi 2013).   
In the present study, VIME was observed to highly up-regulated in untreated 
A2780
cisR
 and A2780
ZD0473R
 cell line at spot number 2 and Cn_48 in comparison to 
the level of expression identified in the untreated A2780 cell line. It was over-restored 
as compared to the level observed in untreated A2780 cell line following treatment 
with all selected synergistic combinations except CS+6-SG (0/0 h) at spot number 2 
(Table 3.28). In contrast, the protein spot could not be detected due to treatment with 
CS+6-SG (0/0 h) in A2780
ZD0473R
 cell line meaning the protein was highly over-
restored at spot number Cn_48. The result of this study can be seen to be in agreement 
with the earlier report from host laboratory where VIME protein was considered as an 
anti-apoptotic protein and was found to be highly up-regulated in the A2780
cisR
 cell 
line (Al-Eisawi 2013). From the above discussion, it can be observed that chemo-
resistance in ovarian cancer could be linked with vimentin expression due to its anti-
apoptotic in nature and that the selected combinations of platinum drugs and 
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compounds from the natural sources have been able to alter the expression of VIME 
towards overcoming drug resistance.  
4.6.4 Endoplasmin (ENPL) 
The protein is encoded as ENPL and also recognized as GRP94 (glucose-regulated 
protein-94). ENPL is mainly located in endoplasmic reticulum and functions during 
ATP hydrolysis. The protein is responsible for controlling the folding and unfolding 
of numerous proteins (Stebbins, Russo et al. 1997). This master immune chaperone 
has been reported to show a vital role in many inflammatory conditions as well as 
cancer. Increased proliferation of cells has been evidenced by overexpression of 
ENPL through the LRP6-Wnt pathway. Moreover, ENPL modulates EMT and 
promote metastasis (Wanderling, Simen et al. 2007, Otsuki, Inokuchi et al. 2011, Wu, 
Hong et al. 2016). Upregulation of ENPL has been observed in oral cancer, prostate 
carcinoma, pancreatic adenocarcinoma and lung cancer (Chen, Ding et al. 2002, 
Wang, He et al. 2005, Pan, Erkan et al. 2009, O'Connell, Prencipe et al. 2012). 
In the current study, the expression of ENPL was found to be upregulated in untreated 
A2780
cisR
 cell line as compared to the level of expression detected in the untreated 
A2780 cell line. The expression of ENPL in A2780
cisR
 cell line was over-restored 
following treatment with CS+6-SG (0/0h), CS+HK (0/4 h) and OX+6-SG (4/0 h). The 
spot could not be detected following administration of CS+6-SG (4/0h), CS+CC (0/0 
h) and OX+6-SG (0/0 h) meaning the protein was highly over-restored as compared to 
its level found in the untreated A2780 cell line (Table 3.26). Also, the protein was 
partially restored back to the level observed in A2780 cell line due to the 
administration of OX+MA (0/0 h). Though, ENPL expression in A2780
ZD0473R
 cell 
line was observed to be identical in comparison to its expression level found in the 
untreated A2780 cell line, treatment with CS+6-SG (0/0 h) caused over-restoration of 
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the protein (Table 3.27). Thus it can be seen that endoplasmin is an anti-apoptotic 
protein and could be associated with chemoresistance in ovarian cancer and that 
treatment with synergistic combinations of platinum and natural compounds could 
reduce the expression of endoplasmin towards overcoming drug-resistance.   
4.6.5 78 kDa glucose regulated protein (GRP78) 
The protein is encoded as GRP78 and also recognized as Bip (binding 
immunoglobulin protein). In contrast to other heat shock proteins of HSP70 family, 
GRP78 is mainly located in the endoplasmic reticulum. GRP78 serves all chaperon 
functions in the cell by activating the folding of emerging proteins, eliminating 
wrongly folded proteins and creating unfolded protein response (Lee 2001, Lee 2007, 
Park, Kim et al. 2017). The protein has been reported to contribute significantly in the 
progression of cancer through creating endoplasmic reticulum stress necessary for 
maintaining tumour microenvironment (Kaufman 2002, Li, Lee et al. 2006, Wang, 
Wey et al. 2009). Upregulation of GRP78 has also found to be associated with 
mediating resistance to tumour cells against chemotherapy, anti-angiogenesis therapy 
and anti-hormonal therapy especially in ovarian cancer (Liu, Opipari et al. 2002, 
Landriscina, Laudiero et al. 2010). Overexpression of the protein has been noticed in 
prostate, liver, lung and breast cancers (Shuda, Kondoh et al. 2003, Uramoto, Sugio et 
al. 2005, Lee, Nichols et al. 2006, Daneshmand, Quek et al. 2007, Lee 2007).  
In the present study, elevated expression of GRP78 was detected in untreated 
picoplatin-resistant A2780
ZD0473R
 cell line as compared to the level observed in the 
untreated A2780 cell line. But the spot could not be detected following treatment with 
CS+6-SG (0/0 h) meaning the protein was significantly over-restored (Table 3.27). 
The result of the present study is in agreement with the earlier report from host 
laboratory where the GRP78 protein was suggested as an antiapoptotic protein and 
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was found to be highly up-regulated in the A2780
cisR
 cell line (Al-Eisawi 2013, 
Mazumder 2013, Nessa 2013). Therefore, it can be stated that 78 kDa glucose-
regulated protein is an anti-apoptotic protein and significantly contribute to the drug-
resistance in ovarian cancer. And the selected synergistic combinations of platinum 
drug and natural compounds showed the ability to significantly alter the expression of 
GRP78 to overcome drug resistance.   
4.6.6 60 kDa heat shock protein (CH60) 
The protein is encoded as CH60 (HSP60) and also recognized as a chaperonin. The 
main locations of HSP60 are mitochondria, cell membrane and intermediate spaces 
between cells. In most of the cases, HSP60 acts simultaneously with CH10 and serves 
chaperonin like activities. HSP60 can modulate cell growth and apoptosis required to 
sustain tumorigenesis progression (Richardson, Landry et al. 1998, Cappello, Conway 
de Macario et al. 2008). Elevated expression of HSP60 has been reported in liver, 
oral, colon, ovarian, prostate and breast cancers (Kawahara, Yokota et al. 1999, 
Cappello, Bellafiore et al. 2003, Cappello, Di Stefano et al. 2005, Kuramitsu and 
Nakamura 2005, Desmetz, Bibeau et al. 2008, Castilla, Congregado et al. 2010, 
Hjerpe, Egyhazi et al. 2013). In contrast, downregulation of the protein has also been 
observed in lung and bladder cancer (Ito, Kawabe et al. 1998, Desmetz, Bibeau et al. 
2008). 
In the current study, CH60 was found to be upregulated in both untreated A2780
cisR
 
and A2780
ZD0473R
 cell lines in comparison to the expression level observed in the 
untreated A2780 cell line. The protein was over-restored when A2780
cisR
 cell line was 
treated with CC (0/0 h), CS+HK (0/4 h) and OX+HK (4/0 h).  The protein spot could 
not be detected following administration of OX+6-SG (0/0 h), OX+6-SG (4/0 h) and 
OX+MA (0/0 h) meaning the protein was highly over-restored in these occasions 
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(Table: 3.26). CH60 was partially restored back to the level observed in A2780 due to 
the administration of CS+6-SG (0/0 h) in A2780
ZD0473R 
cell line (Table: 3.27). 
Previous research performed in the host laboratory also reported that CH60 was 
upregulated in A2780
ZD0473R 
cell line (Al-Eisawi 2013, Mazumder 2013, Nessa 2013). 
From the above discussion, it could be concluded that 60 kDa heat shock protein is 
anti-apoptotic in nature and heavily linked with chemoresistance in ovarian cancer 
and that synergistic combinations suppress the expression of CH60 towards 
overcoming drug resistance in ovarian cancer.  
4.6.7 10 kDa heat shock protein (CH10) 
The protein is encoded as CH10 (HSP10) and serves as the function of co-chaperone 
of CH60. Since the protein has been identified in the non-cancerous bone marrow, it 
has been assumed that HSP10 also contribute in cellular proliferation and 
differentiation (Cappello, David et al. 2005, David, Bucchieri et al. 2013). 
Upregulation of HSP10 has been reported in many cancers including ovarian, colon, 
prostate and uterine carcinoma (Cappello, Bellafiore et al. 2003, Cappello, Rappa et 
al. 2003, Akyol, Gercel-Taylor et al. 2006). On the other hand, downregulation of 
HSP10 has also been noticed in lung cancer (Cappello, Di Stefano et al. 2006). 
In the present study, the CH10 expression was observed to be overexpressed in 
untreated A2780
cisR
 cell line whereas the protein spot could not be detected in 
untreated A2780 and A2780
ZD0473R
 cell lines. However, the protein was significantly 
downregulated following administration of selected synergistic combinations (Table 
3.28). Therefore, it could be stated that 10 kDa heat shock protein is anti-apoptotic in 
nature and may contribute towards drug-resistance in ovarian cancer and that selected 
combinations of platinum drugs and natural compounds have the ability to alter the 
expression of CH10 towards overcoming drug resistance.  
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4.6.8 Heat shock cognate 71 kDa protein (HSC70) 
The protein is encoded as HSP7C and also recognized as HSC70. It belongs to HSP70 
family but only expressed in response to stress. HSP7C shows ATPase dependent 
chaperonian activity. The protein remains inactive unless the hydrolysis of ATP has 
been taken place. Additionally, it has been associated with the development of the 
embryo, aging and apoptosis (Liu, Daniels et al. 2012). HSP7C is also associated with 
regulation of the cellular signals; facilitate lysosome-mediated misfolded protein 
degradation; protein folding and translocation (Sheffield, Shore et al. 1990, Siegers, 
Bölter et al. 2003, Lu, Huang et al. 2010, Shiota, Kusakabe et al. 2010). Upregulation 
of HSP7C is evident in many cancers including breast carcinoma, stomach, pancreatic 
and colon cancers (Maeda, Ohguro et al. 2000, Kubota, Yamamoto et al. 2010).  
In the current study, HSP7C was found to be upregulated in both untreated A2780
cisR
 
and A2780
ZD0473R
 cell lines in comparison to the expression level observed in the 
untreated A2780 cell line. The protein appears in three different spots: Cn_16, Cn_51 
and Cn_90 in the untreated cisplatin-resistant A2780
cisR
 cell line (3.28) while the 
protein was expressed in two spots: Cn16 and Cn51 in untreated A2780 and 
A2780
ZD0473R
 cell lines Cn16, Cn51 (3.29). HSP7C was found to be highly over-
expressed in spot number Cn_16 in both untreated A2780
cisR
 and A2780
ZD0473R
 cell 
lines as compared to the expression level observed in the untreated A2780 cell line. 
The protein was partially restored back to the level observed in A2780 due to the 
treatment with most of the synergistic combinations in A2780
cisR
 and A2780
ZD0473R
 
cell lines. HSP7C was shown to be exceedingly upregulated in untreated A2780
cisR
 
and A2780
ZD0473R
 cell lines at spot number Cn_51 in comparison to the level observed 
in A2780 cell line.  
 201 
The protein spot could not be identified following administration of CS+6-SG (0/0 h) 
in A2780
ZD0473R
 cell line meaning the protein was highly over-restored (Table 3.29). 
In A2780
cisR
 cell line, the protein was partially restored back to the level found in 
A2780 due to the treatment with all synergistic combinations (Table 3.28). At spot 
number Cn_90, elevated expression of the HSP7C was detected and the protein either 
over-restored or spot could not be detected (highly over-restored) due to the treatment 
with synergistic combinations (Table 3.28). From above discussion, it could be 
assumed that heat shock cognate 71 kDa protein is an anti-apoptotic in nature and is 
heavily involved with chemo-resistance in ovarian carcinoma and that the natural 
compounds specially 6-shogaol in combination with cisplatin significantly 
downregulate HSP7C expression in both A2780
cisR
 and A2780
ZD0473R
 cell lines. 
Therefore, it can be stated that 6-shogaol in combination with cisplatin plays a 
significant role to overcome drug resistance in ovarian cancer.   
4.6.9 Citrate synthase (CISY) 
The protein is encoded as CISY, which is ubiquitously expressed in heart, fat and 
other tissues. The protein serves as an essential enzyme in the oxidative metabolic 
process, Krebs cycle. Citrate synthase catalyzes the first step of Krebs cycle where 
citrate is formed from oxaloacetate and acetyl coenzyme A (Wiegand and Remington 
1986). The protein has been reported to control cell growth via STAT-3 pathway 
(MacPherson 2016, MacPherson, Horkoff et al. 2017). Upregulation of citrate 
synthase has been found in ovarian and pancreatic carcinomas (Chen, Liu et al. 2014). 
In the current study, the expression of CISY was found to be upregulated in both 
untreated A2780
cisR
 and A2780
ZD0473R
 cell lines as compared to the expression level 
detected in the untreated A2780 cell line.  
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The protein spot could not be detected following administration of CS+HK (0/4 h) 
meaning the protein was highly over-restored while the protein partially restored back 
to the level observed in A2780 due to the treatment with rest of the combinations in 
the A2780
cisR
 cell line (Table 3.28). The protein spot could not be detected following 
treatments with CS+6-SG (0/0 h) meaning the protein was highly over-restored in 
A2780
ZD0473R
 cell line (Table 3.29). From the above discussion, citrate synthase is 
suggested as an anti-apoptotic protein and heavily linked with drug-resistance in 
ovarian cancer and that selected combinations of platinums and natural compounds 
could alter the expression of citrate synthase to overcome drug resistance in ovarian 
cancer.  
4.6.10 Annexin A1 (ANXA1) 
The protein is encoded as ANXA1 and also known as lipocortin-1. It belongs to 
annexin family and functions as phospholipase A2 blocker. Annexin A1 has also been 
linked with the modulation of cell growth and cell death pathways (D'acquisto, 
Perretti et al. 2008). Contradictory reports have been found in the literature regarding 
the expression of Annexin A1 in various cancers. For example, downregulation of the 
protein has been demonstrated in oesophageal, gastric, breast and prostate carcinomas 
(Shen, Nooraie et al. 2006, Moraes, Kar et al. 2017). Others report overexpression of 
Annexin A1 in colon cancer (Su, Xu et al. 2010), stomach carcinoma (Cheng, Wu et 
al. 2012), breast cancer, pancreatic cancer, hepatic cancer and prostate cancer (Lim 
and Pervaiz 2007).   
In the current study, ANXA1 protein appeared in the ovarian parent A2780 cell line. 
The protein spot could not be identified in both untreated cisplatin-resistant A2780
cisR
 
and picoplatin-resistant A2780
ZD0473R
 cell lines.  
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However, the protein partially restored back to the level observed in A2780 cell line 
following treatments with CS+6-SG (0/0 h) in the A2780
cisR
 cell line (Table 3.26 and 
Table 3.27). Other researchers from the host laboratory reported that ANXA1 
expression was down-regulated in A2780
cisR
 cell line and that ANXA1 is a pro-
apoptotic protein (Al-Eisawi 2013, Nessa 2013). The results of the current study show 
that 6-shogaol in combination with cisplatin has the ability to alter the expression of 
ANXA1.  
4.6.11 Calreticulin (CALR) 
The protein is encoded as CALR and mainly located in the endoplasmic reticulum. 
The principal function of calreticulin is to maintain calcium homeostasis in the cell. It 
can also serve chaperonian activities by controlling the protein folding and cellular 
adhesion. Moreover, calreticulin has been associated with the modulation of gene 
transcription and immune response. Involvement of the protein in carcinogenesis has 
also been noticed. Elevated expression of calreticulin is evident in various 
malignancies e.g. oesophageal, prostate, bladder, ovarian and colorectal carcinomas 
(Lu, Weng et al. 2015, Zamanian, Hamadneh et al. 2016).  
In the present study, CALR protein spot was detected in the ovarian parent A2780 cell 
line. The protein spot could not be observed in both untreated cisplatin-resistant 
A2780
cisR
 and picoplatin-resistant A2780
ZD0473R
 cell lines. The protein was over-
restored or fully restored compared to the level found in untreated A2780 cell line 
following treatment with CS+6-SG (0/0 h) and OX+HK (4/0 h) respectively in the 
cisplatin-resistant A2780
cisR
 cell line. Moreover, the protein spot could not be 
identified following treatments with CS+6-SG (4/0 h), CS+HK (0/4 h) and OX+MA 
(0/0 h) while other combinations caused partial restoration of protein in the same cell 
line (Table 3.26, Table 3.27).  
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Previous studies from the host laboratory reported that CALR was elevated in 
expression in A2780
cisR
 cell line and suggested that CALR would be anti-apoptotic in 
function (Al-Eisawi 2013, Nessa 2013).  
4.6.12 Serpin H1 (SERPH) 
The protein is encoded as SERPH and also recognized as HSP47 (colligin). Primary 
location of Serpin H1 is endoplasmic reticulum and predominantly responsible for 
assembly of collagen fibers and their crosslinking. The chaperonin like activities of 
Serpin H1 is not linked with endoplasmic reticulum stress (Sauk, Nikitakis et al. 2005, 
Ito and Nagata 2017). Higher expression of the protein has been found in many 
diseases e.g. arthritis, arteriosclerosis and liver cirrhosis (Razzaque and Taguchi 1997, 
Razzaque, Hossain et al. 1998, Kubota 2001). In multiple cancers (pancreatic, breast 
and gastric carcinomas), the expression of serpin H1 has been found to be 
significantly elevated compared to non-cancerous cells (Xu, Mikami et al. 2013, Zhu, 
Xiong et al. 2015).  
In the present study, SERPH protein was identified to be over-expressed in the 
ovarian cisplatin-resistant A2780
cisR
 cell line. The protein spot could not be observed 
in both untreated parent A2780 and picoplatin-resistant A2780
ZD0473R
 cell lines. 
Following treatments with most of the synergistic combinations, the protein spot 
could not be detected meaning the protein was over-expressed. From the above 
discussion, it could be stated serpin H1 acts as an anti-apoptotic protein and may be 
involved with drug-resistance in ovarian carcinoma and that selected combinations of 
platinum drugs and natural compounds were able to reduce the expression of SERPH 
in ovarian cancer towards overcoming drug resistance.  
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4.6.13 Histone H3.3 (H33) 
The protein is encoded as H33 and also known as replacement histone which is an 
essential structural component of the nucleosome (the basic unit of chromatin). 
Histone H3.3 is expressed in all phases of cell cycle and contributes to stem cell 
growth, fertilization and transcription process (Ahmad and Henikoff 2002, Reddy and 
Gupta 2017). Mutation of the protein has been reported in various malignancies e.g. 
brain tumour, codman tumour and bone tumours (Kallappagoudar, Yadav et al. 2015). 
In the present study, histone H3.3 was observed in the untreated ovarian A2780 cell 
line. However, the protein could not be identified in the untreated A2780
cisR
, treated 
and untreated A2780
ZD0473R
 cell lines. The protein was partially restored to the level 
found in untreated A2780 cell line following treatment with CS+HK (0/4 h) in the 
A2780
cisR
 cell line. From the above discussion, it may be suggested that histone H3.3 
is anti-apoptotic in nature.   
4.6.14 Nascent polypeptide-associated complex 
subunit alpha (NACA) 
The protein is encoded as NACA and represents the alpha subunit of the heterodimer 
nascent polypeptide-associated complex. NACA is mainly located in the cytoplasm 
and shows transcriptional activity via a c-Jun pathway. The protein has the capability 
to bind with both DNA and RNA. Elevated expression of NACA is evidenced in liver 
cancer through triggering ERK pathway (Karan and Subudhi 2012, Lee, Yu et al. 
2015).  
In the current study, NACA was found to be exceedingly upregulated in untreated 
A2780
cisR
 cell line as compared to the expression level detected in the untreated 
A2780 cell line. However, the protein was over-restored compared to the level found 
in untreated A2780 cell line following treatments with CS+6-SG (0/0 h) in the 
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A2780
cisR
 cell line (Table 3.26 and Table 3.27). From the above discussion, it may be 
suggested that nascent polypeptide-associated complex subunit alpha (NACA) is an 
anti-apoptotic protein associated with ovarian cancer chemo-resistance and that 
treatment with selected combinations of platinums and compounds from the natural 
resources have the ability to alter the expression of NACA towards overcoming drug 
resistance in ovarian cancer.  
4.6.15 40S ribosomal protein SA (RSSA) 
The protein is encoded as RSSA and also recognized as 37 kDa laminin receptor 
precursor (37LRP). The primary location of the protein is cytoplasm, however 
available in the nucleus as well. RSSA plays a significant role in RNA translation and 
endocytosis process (Rea, Rossi et al. 2012). Upregulation of the protein has been 
found in breast cancer, lung cancer, pancreatic cancer, ovarian carcinoma and 
stomach cancer. The protein has also been reported to confer resistance to 
chemotherapy (Ménard, Tagliabue et al. 1998, Rea, Rossi et al. 2012, Sun, Liu et al. 
2014). 
In the present study, RSSA expression was found to be highly upregulated in 
untreated A2780
cisR
 and A2780
ZD0473R
 cell lines compared to the level detected in the 
untreated A2780 cell line. The protein was partially restored back to the level found in 
untreated A2780 cell line following treatment with most of the synergistic 
combinations in the A2780
cisR
 cell line. Likewise, the protein was also partially 
restored due to the treatment with CS+6-SG (0/0 h) in A2780
ZD0473R
 cell line. Thus, it 
may be suggested that the 40S ribosomal protein SA (RSSA) is anti-apoptotic in 
nature and plays a significant role in ovarian cancer chemoresistance. It can be seen 
that the natural compounds specially 6-shogaol in combination with cisplatin can 
significantly downregulate RSSA expression in both A2780
cisR
 and A2780
ZD0473R
 cell 
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lines. Therefore, it can be assumed that 6-shogaol in combination with cisplatin can 
overcome drug resistance in ovarian cancer. 
4.6.16 Elongation factor Tu (EFTU) 
The protein is encoded as EFTU and also recognized as Tu translational elongation 
factor. EFTU belongs to guanosine triphosphatase protein family and contributes 
significantly in protein biosynthesis. The role of EFTU has also been correlated with 
the formation of the cytoskeleton, cellular growth and various signaling pathways 
(Zheng, Peng et al. 2010, Hamrita, Nasr et al. 2011). Elevated expression of the 
protein has been observed in pancreatic, stomach and skin cancers (Forgber, Trefzer 
et al. 2009). 
In the present study, EFTU was found to over-expressed in untreated A2780
cisR
 and 
A2780
ZD0473R
 cell lines compared to the level observed in the untreated A2780 cell 
line. The protein was over-restored and fully-restored as compared to the level 
detected in untreated A2780 cell line following treatment with CS+HK (0/4 h) and 
OX+HK (0/0 h) respectively in the A2780
cisR
 cell line (Table 3.28). The protein spot 
could not be identified following treatment with CS+CC (0/0 h) in the same cell line 
meaning the protein was highly over-restored in this occasion. In addition, the protein 
was partially restored back following treatments with all sequenced combinations of 
6-shogaol with cisplatin and oxaliplatin, meaning that 6-shogaol would play a 
significant role to suppress the expression of EFTU in the A2780
cisR
 cell line (Table 
3.28). Additionally, the protein spot could not be identified following treatment with 
CS+6-SG (0/0 h) in A2780
ZD0473R
 cell line (Table 3.29). Thus it can be seen that 6-
shogaol in combination with platinum drugs has the ability to significantly 
downregulate the expression of EFTU in ovarian cancer cell line. Hence it can be 
suggested that elongation factor Tu (EFTU) is an anti-apoptotic protein and is 
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significantly involved with platinum drug-resistance in ovarian cancer and that 
synergistic combinations have the ability to overcome it.  
4.6.17 Transitional endoplasmic reticulum ATPase 
(TERA) 
The protein is encoded as TERA and also recognized as vasolin containing protein 
(VCP) or p97. TERA belongs to adenosine triphosphatase protein family and involved 
in a wide range of cellular activities e.g. control of cell cycle; prevention of apoptosis 
and DNA damage recognition (Asai, Tomita et al. 2002, Wang, Song et al. 2004, Vij 
2008). Upregulation of TERA has been associated with pancreatic adenocarcinoma 
and prostate carcinoma (Tsujimoto, Tomita et al. 2004, Kaistha, Schimanski et al. 
2017). 
In the current study, higher expression of TERA was detected in A2780
cisR
 cell line 
whereas the protein spot could not be identified in untreated A2780 and A2780
ZD0473R
 
cell lines. The protein expression was significantly downregulated following 
treatments with CS+6-SG (0/0 h), OX+6-SG (0/0 h), OX+6-SG (4/0 h) and OX+MA 
(0/0 h) in the A2780
cisR
 cell line (Table 3.28 and 3.29). The protein spot could not be 
detected following treatments with other synergistic combinations in the same cell 
line. The elevated expression level of TERA in A2780
cisR
 cell line suggests that the 
protein contributes towards platinum-resistance in ovarian cancer and that it is an anti-
apoptotic protein. It can be seen that the natural compounds specially 6-shogaol in 
combination with platinums have the ability to inhibit expression of TERA towards 
overcoming drug resistance in ovarian cancer cell line. 
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4.6.18 Peroxiredoxin-6 (PRDX6) 
The protein is encoded as PRDX6 and considered as the sixth isozyme discovered in 
nonseleno peroxidases (peroxiredoxins). The distinctive feature of PRDX6 is the 
presence of only one cysteine residue in its structure and the catalytic activity is not 
dependent on thioredoxin. Whereas, other members of peroxiredoxins have two 
cysteine residues in their structure (Fisher 2011, Park, Jo et al. 2016). Upregulation of 
PRDX6 has been reported in mesothelial, lung, bladder, breast and oesophageal 
cancers (Kinnula, Lehtonen et al. 2002, Chang, Li et al. 2007, Shukla, Pranay et al. 
2009, Park, Jo et al. 2016).  
In the current study, PRDX6 was seen to be extremely upregulated in untreated 
A2780
cisR
 and A2780
ZD0473R
 cell lines. The protein spot could not be detected 
following treatment with CS+CC (0/0 h), OX+HK (4/0 h) and OX+MA (0/0 h) in 
A2780
cisR
 cell line meaning the protein was highly over-expressed in these cases. The 
protein was partially restored back to the level observed in untreated A2780 cell line 
due to the treatment with other combinations in the same cell line. The protein could 
not be identified following treatment with CS+6-SG (0/0 h) in A2780
ZD0473R
 cell line 
meaning the protein was extremely over-expressed (Table 3.28 and Table 3.29). From 
above discussion, it can be seen that PRDX6 is an anti-apoptotic protein and highly 
linked with platinum drug-resistance in ovarian cancer and that compounds from the 
natural sources have the ability to significantly suppress the expression of PRDX6 in 
ovarian resistant cell lines towards overcoming drug-resistance.  
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5 Conclusion 
 
Ovarian cancer is considered as one of the most dreaded gynecologic neoplasms 
around the globe. Epidemiological data shows that it is an eighth most diagnosed 
cancer for females in Australia. Although five years’ survival rate among diagnosed 
ovarian cancer patients has increased recently throughout the world, relapse is very 
common. Platinum drugs are considered to be the primary drug of choice to manage 
solid neoplasms including ovarian cancer. Due to the heterogeneous nature of ovarian 
cancer, the occurrence of platinum resistance is seen in most cases. Tumour active 
compounds obtained from natural sources having different mechanisms of cell killing 
than platinum drugs have shown potentiality when administered in combination with 
platinums to overcome drug resistance and reduce side effects. In the present study a 
few compounds from natural sources (mycophenolic acid, 6-shogaol, honokiol, 
kaempferol and cholecalciferol) have been combined with platinum drugs (cisplatin, 
oxaliplatin and carboplatin) against four ovarian cancer cell lines (A2780, A2780
cisR
, 
A2780
ZDO473R
 and SKOV-3). Mechanistic studies (cellular accumulation, PtDNA 
binding, DNA damage and proteomic) were conducted to reveal the mechanism 
underpinning the combined drug action.  
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MTT reduction assay was conducted to determine the cytotoxicity of the compounds 
alone or in combination. Among the platinum drugs, oxaliplatin was found to be the 
most active compound in all tested cell lines except for SKOV-3, where cisplatin 
displayed lower IC50 value than oxaliplatin. Carboplatin was the least active 
compound among all platinum drugs.  Among the studied compounds from natural 
sources, mycophenolic acid showed the greatest anticancer activity than other 
compounds in all tested cell lines except for SKOV, where 6-shogaol gave the lowest 
IC50 values. Anticancer activity of mycophenolic acid was even better than clinical 
drug cisplatin against the investigated ovarian cancer models. Kaempferol showed 
least anticancer activity among all studied compounds. 
Combined drug effect was analyzed by using dose-response curves and combination 
indices at three different sequences of administration (0/0 h, 0/4 h and 4/0 h) and 
concentrations (ED50, ED75 and ED90). Cisplatin in combination with 6-shogaol has 
been produced synergism with bolus administration (0/0 h) in A2780, A2780
cisR
 and 
A2780
ZD0473R
 cell lines. In addition, all sequences of administration and added 
concentrations of the combination of cisplatin and 6-shogaol produced synergism in 
A2780
cisR
 cell line only among the four tested cell lines. In contrast, concurrent 
administration of oxaliplatin with 6-shogaol displayed synergism against all tested 
ovarian cell lines whereas all sequences of administration and added concentration 
produced synergism in SKOV-3 cell line only. The mycophenolic acid in combination 
with cisplatin showed synergism for all sequences of administration and added 
concentrations in SKOV-3 cell line only. When mycophenolic acid was combined 
with oxaliplatin, antagonism was predominant in all tested cell lines irrespective of 
sequences of administration.  
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But synergism was observed at higher concentrations against A2780 and A2780
cisR
 
cell lines for the combination of mycophenolic acid with oxaliplatin. However, for 
combination of carboplatin with mycophenolic acid, synergism was found in SKOV-3 
cell line for all sequences of administration and added concentrations.  
Cholecalciferol in combination with either cisplatin or oxaliplatin showed significant 
synergism only against SKOV-3 cell line for all sequences of administration and 
concentrations. The combined effect was mostly antagonistic to other cell lines. In 
general, honokiol in combination with platinum drugs 
(cisplatin/oxaliplatin/carboplatin) displayed antagonism at lower concentrations for all 
sequences of administration against all tested cell lines. However, synergism was 
predominant at higher added concentrations for all sequences of administrations.     
The platinum cellular accumulation study did not provide a clear trend on the 
relationship between a compound’s cellular potency versus accumulated platinum in 
the cells. There was also no correlation between synergistic treatments and platinum 
accumulation. However, platinum-DNA binding study showed a clear correlation 
between synergism in cell kills and increase in platinumDNA binding level. Detailed 
analysis of the DNA revealed that when drug treatments were cytotoxic, they caused 
damage to DNA, but highly damaged DNA did not always mean the treatment was 
cytotoxic.   
Proteomic studies have been performed to explore the proteins involved with drug-
resistance in ovarian cancer cisplatin-resistant A2780
cisR
 and picoplatin-resistant 
A2780
ZD0473R
 cell lines. Nineteen proteins were found to be significantly expressed 
protein in 23 different spots in untreated A2780
cisR
 and A2780
ZD0473R
 cell lines in 
comparison to the level of expression identified in the untreated A2780 cell line.  
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In contrast, the administration of nine selected synergistic combinations of platinum 
drugs and natural compounds have shown the ability to alter the expression of ACTB, 
VIME, COF1, CISY, ANXA1, CALR, CH60, CH10, GRP78, ENPL, HSP7C, 
SERPH, H33, NACA, RSSA, EFTU, TERA, PRDX6 in A2780
cisR
 and A2780
ZD0473R
 
cell lines towards overcoming drug resistance.  
Especially, 6-shogaol in combination with cisplatin and oxaliplatin exhibited the 
ability to combat against platinum chemo-resistance by attenuating the expression of 
the anti-apoptotic protein and potentiate the expression of the pro-apoptotic protein in 
ovarian A2780
cisR
 and A2780
ZD0473R
 cell lines.  
Finally, it should be noted that from 6-shogaol alone and in combination with 
platinum drugs displayed significant activity against ovarian cancer cell lines. Hence, 
6-shogaol could a potential candidate for combination therapy to treat ovarian cancer.  
Future directions  
In vivo studies could be carried out on the combination of 6-shogaol with platinum 
drugs using suitable animal models towards the development of combination therapy 
to treat ovarian cancer. 
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